Characterising Red Cell-Derived Vesicles in Sickle Cell Disease and Investigating Potential to Induce Tolerance to Human Red Cell Antigens by Drizou, Despoina
                          
This electronic thesis or dissertation has been





Characterising Red Cell-Derived Vesicles in Sickle Cell Disease and Investigating
Potential to Induce Tolerance to Human Red Cell Antigens
General rights
Access to the thesis is subject to the Creative Commons Attribution - NonCommercial-No Derivatives 4.0 International Public License.   A
copy of this may be found at https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode  This license sets out your rights and the
restrictions that apply to your access to the thesis so it is important you read this before proceeding.
Take down policy
Some pages of this thesis may have been removed for copyright restrictions prior to having it been deposited in Explore Bristol Research.
However, if you have discovered material within the thesis that you consider to be unlawful e.g. breaches of copyright (either yours or that of
a third party) or any other law, including but not limited to those relating to patent, trademark, confidentiality, data protection, obscenity,
defamation, libel, then please contact collections-metadata@bristol.ac.uk and include the following information in your message:
•	Your contact details
•	Bibliographic details for the item, including a URL
•	An outline nature of the complaint






Characterising Red Cell-Derived Vesicles in Sickle 
Cell Disease and Investigating Potential to Induce 







A dissertation submitted to the University of Bristol in accordance with the 
requirements for award of the degree of Doctor of Philosophy in the Faculty of 
Biomedical Sciences  
 
 
School of Cellular and Molecular Medicine 
August 2020 
 
Word count: 47,960 





Patients with sickle cell disease (SCD) receive regular blood transfusions, which can lead to 
alloimmunisation due to exposure to different red blood cell (RBC) antigens. The spleen is frequently 
damaged in these patients, resulting in higher numbers of red cell-derived particles (RCDP) and 
autophagic vesicles (AV). Most RCDP, produced through membrane budding, are right-side out and 
expose the external domains of RBC proteins, whereas AV are inside-out, exposing cytoplasmic 
domains. Since SCD patients have higher numbers of RCDP and AV, we aimed to characterise 
these particles and compare with healthy donor plasma and with storage vesicles (SV) from outdated 
blood. We also investigated the use of these particles to induce tolerance to RBC antigens, in a 
murine model. RCDP and AV from SCD and healthy plasma were isolated using immunomagnetic 
separation. Results using imaging flow cytometry (IS) showed that RBC markers like glycophorins A 
and C, band 3, glucose transporter1 and phosphatidylserine, were detected in all particles, 
confirming they originated from RBC. RCDP were more prevalent and generally larger than AV but 
both particle types were more abundant in SCD than healthy plasma. IS was more sensitive for small 
particle detection than flow cytometry. The latter detected large ghost membranes. All particle types 
were detected by transmission electron microscopy (TEM) and immunogold staining against 
extracellular or cytoplasmic GPA domains further confirmed their RBC origin. TEM, IS and dynamic 
light scattering showed that RCDP were larger than AV. A model system was developed to 
investigate tolerance induction in vivo and indicated that both SV and ghosts could be used to prime 
host animals. In conclusion, small RCDP and AV from SCD and healthy plasma have been 
characterised for first time, using IS. It may be possible to use particles from blood cells induce 
tolerance to RBC antigens and thereby reduce alloimmunisation.   
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1.1.1 Production of haemopoietic stem cells 
Haemopoiesis (from Ancient Greek haema (αἷμα) "blood" and poiein (ποιεῖν) "to make") is the 
process by which blood cells are formed. It starts in the embryo of mammalian and non-mammalian 
vertebrates and occurs throughout life. Blood components are synthesised by two different 
pathways: the primitive wave and the definitive wave (1). The primitive wave leads to macrophages 
and erythrocytes (from Ancient Greek erythrós (ἐρυθρός), “red” and kytos, cell) or red blood cell 
(RBC) formation through blood islands (2). It occurs in the embryonic yolk sac in early development 
(3, 4). Blood production is similar for mammals and zebrafish: early in the development during the 
primitive wave, the embryo differentiates from a single layer of epithelial cells called the blastula to 
form the multi-layered gastrula, composed of ectoderm, mesoderm and endoderm, which 
differentiate to form other tissues (5). One of these is the intermediate cell mass, which originates 
from the ventral mesoderm and from which the primitive erythroid progenitors arise. These 
progenitors contain foetal haemoglobin (Hb) and facilitate the oxygen transport during the rapid 
development of the embryo. Macrophage and megakaryocyte progenitors are formed as well (6, 7). 
Blood islands are also derived from the mesoderm and lead to the production of erythroid-myeloid 
progenitors (EMP) in the yolk sac, through a temporary wave of the definitive pathway, resulting in 
the production of myeloid lineage progenitors (8-11). 
Definitive haemopoiesis begins later through the precursors of other blood cells, called pluripotent 
haemopoietic stem cells (HSC) (7). HSC have self renewal and differentiation capacity. In contrast, 
proliferation and differentiation of progenitor cells derived from HSC, is more strictly controlled (12). 
HSC in humans and other vertebrates rise in the aorta-gonad-mesonephros area of the mid-
gestation embryo (13, 14), then relocate to the foetal liver to expand and finally colonise the bone 
marrow (BM) and thymus (15). Definitive erythroid progenitors containing adult Hb are produced in 
the foetal liver and give rise to enucleated foetal red cells, which are then released in the circulation 
(16). The micro-environment of the BM where HSC are renewed and maintained in an 
undifferentiated state is known as the niche (17). From there, HSC produce cells from all blood 





1.1.2  Haemopoietic Hierarchy  
Original perceptions of the haemopoiesis were usually depicted as a hierarchical pyramid or a 
branching tree (Figure 1.1 left). At the top were multipotent HSC, which were losing their self-renewal 
ability while differentiating into multipotent, oligopotent and finally unipotent progenitors of blood 
lineages. Oligopotent common myeloid progenitors were thought to give rise to bipotent granulocyte-
monocyte progenitors and megakaryocyte-erythroid progenitors, which further gave rise to 
granulocytes, monocytes, platelets and RBC respectively. Common lymphoid progenitors were 
thought to differentiate to T, B and Natural Killer (NK) cells (18-20) .  
Advances in genomics and single-cell transcriptomic analysis revealed a new haemopoietic model, 
in which HSC pool showed to consist of molecularly heterogenous populations, rather than 
homogenous (Figure 1.1 right). HSC continually differentiate through multiple branches, to give 
distinct cell types which can “omit” intermediate subcategories (21-26). For example, it was shown 
that unipotent progenitors can arise directly from HSC, skipping differentiation to oligopotent 
progenitors (22). Stem and progenitor cells cannot be easily distinguished and progenitors are not 
strictly unipotent or oligopotent during their maturation to distinct cells (27, 28). Additionally, despite 
the existence of multipotent HSC, most progenitors seem to be unipotent (29, 30). The new model 
suggests that cell differentiation is difficult to represent by a diagram such as those preferred in the 
past publications, showing HSC differentiation in multiple stages (Figure 1.1). Instead, cell 
localisation throughout the HSC development is suggested and new approaches need to be 
investigated (27). 
  
Figure 1.1 Models of haemopoiesis. Older (left) and a newer (right) models of haemopoiesis. In 
the old model, multipotent HSC gave rise to oligopotent common myeloid progenitor (CMP), which 
then differentiated to bipotent megakaryocyte/ erythrocyte progenitors (MEP) or to granulocyte/ 
macrophage progenitors (GMP). Oligopotent common lymphoid progenitors (CLP) were thought to 
produce T, B and Natural Killer cells directly. One of the newest models is based on transcriptomics 
analyses and suggests that the HSC pool is highly heterogenous and cell location represents 
continuous cell differentiation. Image modified from Laurenti 2018 (27). 
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1.1.3 Transcription factors 
Two transcription factors mainly regulate the primitive wave of haemopoiesis; Gata1 and Pu.1 that 
cross-inhibit each other’s function to regulate primitive erythroid and myeloid fates, respectively. For 
instance, pro-erythroblasts in mice lacking Gata1 (Gata1−/−) could not mature into RBC during 
gestation and mice fail to survive in utero. Gata1-expressing cells in zebrafish are thought to encode 
alpha and beta embryonic globin, synthesising erythrocyte specific Hb (6). On the other hand, Pu.1 
is a major regulator for the myeloid lineage giving rise to macrophages and granulocytes (31). This 
is believed to occur through the direct competition of the transcription factors, regulators for the target 
genes (32). In definitive wave of haemopoiesis, Runx1 is a transcription factor which greatly affects 
erythroid, myeloid and lymphoid lineages, as its absence can diminish or even eliminate the 
corresponding cells (3). Primitive erythroid progenitors originate from the hemangioblast, which in 
development is regulated by a panel of transcription factors (6, 33, 34).  
Some other important transcription factors for haemopoiesis include Gata2, Tal1, Lmo2, Etspr and 
Fli1, which were found to support HSC differentiation (34-38). Gata2 is involved in maintenance and 
proliferation of haemopoietic progenitors, since absence of Gata2 (Gata2−/−) is fatal for the embryo, 
which dies from severe anaemia (39). Tal1 affects endothelial differentiation, as tal1 knock down in 
zebrafish and mice inhibits the primitive erythropoiesis and myelopoiesis (40). In addition, Lmo2−/− 
mice lack erythropoiesis in the yolk sac and die, while Fli1 has been suggested to support Tal1 and 
Lmo2 activation through enhancer Flil+12 (41). Etsrp is important for the vascular endothelial and 
primitive myeloid cells in zebrafish (42), as it has been shown that knockout of Etsrp in mice 
eliminates endothelium and blood cells, suggesting that it is involved in the stimulation of progenitors. 
These progenitors co-express etsrp, gata2, tal1, lmo2 and fli1 and can develop into either HSC or 
endothelial progenitors called angioblasts (43). 
 
 
1.1.4 Haemopoietic stem cell regulation by other cells  
Different BM stromal cells and other cells are involved in the HSC regulation. Some of them are 
osteolineage cells, which were the first cells reported to be implicated in the regulation of HSC 
activity, as their depletion affects haemopoiesis by decrease of erythroid, lymphoid and myeloid 
progenitors (44). Mesenchymal stem cells (MSCs) are stromal cells that assist haemopoiesis in the 
BM. They have self-renewal ability and are pluripotent, giving rise to fibroblasts, fat, bone and 
cartilage. MSC form colony-forming unit fibroblasts (CFU-F) and are involved in the organisation of 
niche, as well as generation of other BM stromal cells like osteoblasts, chondrocytes, myocytes and 
adipocytes (45). Adipocytes are involved in BM aging, in which active haemopoietic areas are 
substituted by adipose (yellow marrow) with limited cell differentiation ability in long bones (46). 
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Endothelial cells express several ligands in the BM such as Notch ligands and CXC chemokine 
ligand (CXCL) 12 and produce stem cell factor (SCF) and pleiotrophin. Notch receptors on HSC 
interact with ligands on BM stromal cells to control haemopoiesis (47, 48). 
 
 
1.2 The red blood cell 
1.2.1 Function and characteristics  
Human erythrocytes are one of the most well characterised cells. Their main function is to transfer 
oxygen to tissues by the protein Hb. It is estimated that a human adult produces 2-3x1011 RBC every 
day, comprising almost 70% of the total cells (49). RBC are approximately 7–8μm in size and their 
life span is around 120 days (50). In contrast to leukocytes that can leave the blood to contribute to 
organism’s immune defence, RBC remain in the blood stream. Their shape is biconcave which 
results in a greater membrane surface than being spherical, enabling efficient gas exchange. 
Additionally, the RBC high surface-to-volume ratio allows reversible deformation during repeated 
passage through the narrow capillaries of the microcirculation. RBC can pass through sections as 
small as one third of the cell diameter. RBC deformability is crucial for gas transportation. The 
greatest alteration of RBC shape is during its passage from the splenic cords to the splenic sinus. 
Abnormal RBC shapes with decreased deformability were reported in different haemolytic disorders 
even back in the 1940s, to lead to splenic sequestration (51). Such a disorder is sickle cell disease 
(SCD), in which discoid RBC turn to sickle shape, which will be further discussed in section 1.4.3. In 
the microvasculature, narrow capillaries allow RBC to pass slowly, so that gas exchange can take 
place efficiently. RBC are surprisingly flexible; they can fold and bend themselves in order to pass 
through very narrow capillaries. Bending and unfolding is facilitated by structural proteins, such as 
spectrin, actin, protein 4.1R and ankyrin (51). 
 
1.2.2 Formation and maturation  
RBC originate from multipotent HSC in BM that follow the erythroid lineage and give rise to 
committed erythroid precursors, such as proerythroblasts. Then, they further develop into 
polychromatic and orthochromatic normoblasts (erythroblasts, Figure 1.2) (52). Macrophages 
participate in the regulation of RBC generation at different stages; initially they retain HSCs in the 
hematopoietic niche, then, granulocyte-macrophage colony-stimulating factor (GM-CSF) along with 
other growth factors and cytokines such as interleukin (IL) 3, stimulate the differentiation into early 
erythroid progenitor cells, called burst-forming unit-erythroid cells (BFU-e) (53). Erythropoietin 
(EPO), produced in the kidney, induces the differentiation into rapidly dividing colony-forming unit-
erythroid cells (CFU-e) (54), which then further differentiate in erythroblastic islands. In them, a 
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central macrophage can interface with up to 30 erythroblasts by using adhesion molecules present 
on both types of cells and assists in increasing the number or proerythroblasts up to three times (55, 
56).  
During later stages of RBC maturation, resulting normoblasts expel their nuclei and other organelles, 
like mitochondria, ribosomes and endoplasmic reticula, to form multi-lobular reticulocytes (Figure 
1.2). The nuclei and organelles are phagocytosed by macrophages. Newly formed R1 reticulocytes 
are motile and normally remain in the BM 24 hours after enucleation. R2 reticulocytes are formed 
after maturation is complete, whereby approximately 20% of the surface area is removed along with 
unwanted organelles in red cell derived particles (RCDP). R2 are less motile, more mechanically 
stable and are found in the circulation. They need approximately 24 hours to mature to RBC (57, 
58). Reticulocytes comprise 1-2% of the total erythrocyte number. Membrane remodelling can last 
2-3 days, resulting in non-adherent, flexible and biconcave RBC which can circulate in the 
bloodstream. Senescent and deformed RBC, as well us unwanted organelles, are cleared by 
macrophages in the spleen and liver (52, 56). 
 
Figure 1.2 The maturation stages of erythrocytes. In the bone marrow haemopoietic stem cells 
differentiate to proerythroblasts, which further develop into basophilic, polychromatic and 
orthochromatic normoblasts (erythroblasts). After enucleation immature reticulocytes R1 in the bone 




1.2.3 Metabolic pathways in red cells 
Mature RBC have reduced metabolic ability in contrast to other human cells. However, it is adequate 
for their function, including oxygen binding and transport by Hb (60). The main metabolic pathways 
in RBC are the anaerobic glycolysis (Embden–Meyerhof pathway), the pentose phosphate pathway 
and nucleotide metabolic pathways (61, 62). The anaerobic glycolysis pathway provides energy to 
the cell, through adenosine triphosphate (ATP) production by conversion of intracellular glucose into 
pyruvate or lactate. Among other functions, ATP is a major contributor in crucial functions of the cell, 
like its integrity and deformability through protein phosphorylation via kinases in the cytoskeleton 
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(63) and in membrane phospholipid asymmetry through ATP- dependant phospholipid transporters 
(64). Apart from ATP, reduced nicotinamide adenine dinucleotide (NADH) that facilitates the 
reduction of methaemoglobin to Hb is also produced by the anaerobic glycolysis pathway. 
Furthermore, this pathway plays an important role during oxygen delivery to the tissues by producing 
a shunt called Rapoport - Luebering shunt (65). This generates the production of 2,3-
bisphosphoglycerate (2,3-BPG), which decreases the Hb affinity for O2 by binding to Hb, enabling 
oxygen delivery to the tissues (66). 
Membrane lipids, cytoskeletal proteins and other important cell components are produced by 
oxidation. A contributor to this is nicotinamide adenine dinucleotide phosphate (NADPH), which 
converts oxidised glutathione to its reduced form (GSH) that is important for combating oxidative 
stress. In physiology, NADPH is produced by glucose through the hexose monophosphate pathway. 
During oxidative stress, NADPH levels are maintained through additional consumption of glycose by 
the pentose phosphate pathway (67). Activation of the pathway takes place through the enzyme 
glucose-6-phosphate dehydrogenase. Its deficiency along with pyruvate kinase, which catalyses the 
transfer of a phosphoryl group to adenosine diphosphate (ADP) to generate ATP at the anaerobic 
pathway, are amongst the most common hereditary enzymopathies (65). On the other hand, 
nucleotide metabolic pathways recycle the existing adenine nucleotides required for the ATP 
production in mature RBC, since they lack the machinery for de novo synthesis. Therefore, although 
reduced, metabolic pathways are crucial for erythrocyte survival (60).  
 
1.2.4 Red cell components 
1.2.4.1 Haemoglobin  
In adults, Hb is a globular protein that forms a tetramer consisting of two pairs of alpha (α1, α2) and 
two beta (β1, β2) globin chains, known as HbA (α2/β2). Each globin binds a heme molecule which 
contains an iron complex called porphyrin. The iron ion (Fe2+) allows the reversible binding to one 
molecule of oxygen (O2) or carbon dioxide (CO2). Thus, one Hb molecule can transport four gas 
molecules (Figure 1.3) (52, 68). In the foetus, gamma chains substitute the two beta chains resulting 
in a stronger bond between oxygen and Hb than that in the adults. This allows efficient oxygen 
transfer to the developing foetus. Foetal Hb (HbF, α2/γ2) is replaced by HbA three to six months after 
birth (69). A single erythrocyte may contain about 3x106 Hb molecules that allow the transfer of 




Figure 1.3 Structure of haemoglobin. Left: The tetramer of haemoglobin consisting of four globins 
(in grey, blue, yellow and red ribbons). Subunits of haemoglobin interact cooperatively; once a heme 
binds an oxygen molecule (red spheres) then all other hemes bind oxygen too. Right: Bond-line 
structure of heme. Oxygen binds to the ferrous in the centre of heme. Image was reproduced from 
Wu et. al, 2010 (71). 
 
 
Oxygen collected in the lungs is insoluble in water and it is transported to the tissues by Hb, which 
forms red oxyhaemoglobin upon the binding to O2. Hb adopts two states, the tense (T) and the 
relaxed (R) state. In the absence of O2, the T state is more stable than the R. O2 binds to the exposed 
binding sites of the R state (72). Factors that affect O2 binding are the pH, temperature and Hb 
allostery. Carbon compounds affect the pH; CO2 in the respiratory system decreases the pH in the 
blood (CO2 + H2O ⇌ H2CO3 →HCO3− +H+) and decreases O2 binding affinity (73). Furthermore, the 
allosteric inhibitor 2,3-BPG is absent in the tissues, therefore O2 binding affinity is high, preventing 
its release (66). Upon O2 release to the tissues, oxygenated Hb turns to darker red 
deoxyhaemoglobin (71).  
Production of Hb depends on the plasma proteins hephaestin and ceruloplasmin; iron absorption 
from the intestine is enabled by hephaestin and ceruloplasmin, a copper transport protein. Both 
catalyse iron oxidation from Fe2 to Fe3+, a form that allows transferrin to bind iron. Unbound iron in 
tissues can lead to organ damage (74). Both heme and vitamin B12 (cobalamin) derive from a 
common pyrrole precursor and their synthesis is facilitated using zinc as a co-enzyme. Vitamin B12 
and the B vitamin folate function as co-enzymes in DNA synthesis by the class II ribonuceotide 
reductase enzymes, thus, they are very important for cell generation, including RBC. Porphyrin is 
produced in the cytoplasm and mitochondria of RBC (74).  
Components of Hb are recycled once RBC are phagocytosed. Globin, the protein part of Hb, is 
degraded into amino acids that can be transported to the BM for RBC synthesis. Globin chain 
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remnants are degraded in the circulation and removed by the kidneys. Almost 2x106 RBC, with 
2.7x1011 Hb molecules in each RBC, are recycled every second (75). Heme is transported to the 
cytosol to be metabolised to biliverdin, free iron, and CO by heme-oxygenase using NADPH and 
oxygen as catalysts (76). Iron is stored as either ferritin or hemosiderin in the spleen or liver, or it is 
transported by transferrin to the BM for RBC generation. Biliverdin is converted to bilirubin by 
biliverdin reductase (77).  
Removal of excess Hb and its constituents from the circulation is facilitated by the serum proteins 
haptoglobin (Hp) and hemopexin (Hx), which are both induced in inflammation. Hp has high affinity 
for free Hb, while Hx scavenges free heme. In pathological conditions where extended haemolysis 
is triggered, such as SCD, increased Hb levels cannot all be cleared by Hp and therefore released 
Hb is oxidised. This occurs either by O2 in the circulation to produce methaemoglobin (Fe3+) or by 
reactive oxygen species (ROS) producing ferryl Hb (Fe4+) (78), which is unstainable and is further 
degraded to methemoglobin. Hb oxidisation along with metabolic products from pathogens, as well 
as pro-inflammatory cytokines produced, disrupt the oxidative-reductive balance of RBC and 
oxidation of intracellular Hb to methaemoglobin is induced, increasing the ROS levels and leading 
to lysis of proximate RBC (79, 80).  
 
1.2.4.2 Red cell membrane composition 
The RBC membrane is comprised of phospholipids, cholesterol, and more than 100 proteins with 
red cell antigens, which contribute to its elasticity (81). Membrane proteins facilitate important 
functions such as nutrients transportation, cytoskeleton support and communication with other cells 
like neutrophils and platelets (81). Τhe cytoskeleton is mainly comprised of α- and β-spectrin, protein 
4.1R, actin and actin binding proteins α-adducin, dematin, tropomyocin and tropomodulin (Figure 
1.4). The major structure of the cytoskeleton is a tetramer consisting of triple helical repeats of α- 
and β-spectrin placed antiparallelly to form a heterodimer. The resulting tetramer is bound together 
by the side interaction of two spectrin dimers with the N‐terminal domain of α‐spectrin of one dimer 
with the C‐terminus of β‐spectrin of the second dimer (82). The other end of the dimer forms a 
complex with actin and with protein 4.1R to facilitate connection between the cytoskeleton and the 
membrane (83, 84). The ankyrin complex consists of ankyrin, band 3 tetramer, glycophorins A and 
B (GPA and GPB), Rh proteins, Rh-associated protein (RhAG), CD47, glycoprotein LW and protein 
4.2. The protein 4.1R complex contains 4.1R, band 3 dimer, glycophorins C and D (GPC and GPD), 
as well as glycoproteins Kell, XK and Duffy. These protein complexes penetrate the membrane lipid 
bilayer and link it with the spectrin-based skeleton through interactions of their cytoplasmic domains 
(85, 86). Skeletal proteins interact with anionic phospholipids to further support the connection 




Figure 1.4 Red cell major membrane proteins and their connection to the cytoskeleton. 
Transporters aquaporin1 and GLUT1 are depicted on the left. The ankyrin complex (proteins Rh, 
RhAG, LW, CD47, band 3, 4.2, GPA, GPB and ankyrin) is presented in the middle and complex 4.1R 
(glycoproteins XK, Kell, Duffy along with band 3, GPC and GPD) is on the right. These complexes 
link the membrane with cytoskeleton (α- and β-spectrin dimers, actin, protein 4.1R, dematin, α-
adducin and tropomodulin). Image was modified from Anstee 2010 (87). 
 
 
RBC membranes contain ion channels that control cell hydration and proteins such as glucose 
transporter 1 (GLUT1) and aquaporin-1 that transport glucose and water, respectively (88). Band 3 
serves as a chloride/bicarbonate anion exchanger, Kidd protein transports urea and RhAG is a gas 
transporter (51) (89). Band 3 is an integral protein and it is the most abundant protein on RBC along 
with the major sialoglycoprotein GPA, present at approximately 106 copies per cell (90). Both carry 
blood group antigens (see section 1.2.4.4), are highly polymorphic and apart from RBC, they are 
also found on the kidney cells (91). GPA acts as a chaperone for band 3 transport to the membrane 
and prevents RBC aggregation in the circulation. It also contributes to the negative charge on the 




Phospholipids penetrate the RBC membrane asymmetrically; neutral phospholipids comprised of 
choline, such as phosphatidylcholine and sphingomyelin, are located on the external part of the 
membrane, while charged amino-containing phospholipids, such as phosphatidylserine (PS), 
phosphatidylinosirol and phosphatidyl-ethanolamine, can be found in the inside leaflet of the 
membrane (93). PS exposure on the outer side of the membrane attracts phagocytic cells, as it is a 
known apoptotic signal (94). Three enzymes control the distribution of the phospholipids in the 
membrane; an amino phospholipid translocase, called ATP dependent flippase, transfers (flips) 
amino-containing phospholipids from the external part of the membrane to the inside. The ATP-
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dependent floppase controls the transfer of the choline-containing phospholipids from the inner 
leaflet of the membrane to the outside, a slower process compared to flippases. Finally, a bivalent-
cation activated scramblase facilitates the distribution of the phospholipids, as it bidirectionally 
transfers (scrambles) them according to their concentration gradient, to achieve a symmetrical 
membrane (95). PS translocation on the external leaflet of the membrane has been reported to take 
place through vesicles by bidirectional trafficking between cytoplasm and plasma membrane (96). 
Disturbances in membrane asymmetry and exposure of PS can not only trigger phagocytosis but 
they are also critical points in RCDP formation (95). Such a disturbance takes place when the 
intracellular calcium concentration increases. This results in flippase inhibition and scramblase 
activation which leads to further disturbance of the membrane asymmetry and PS exposure (95, 97). 
The role of floppase in membrane asymmetry disturbance is not clear yet (98). Low levels of Ca2+ 
(1μM) are enough to inhibit the flippase, whereas the scramblase needs much higher concentrations 
for its activation (approximately 100μM) (99-101). Physiologically, this is avoided by the plasma 
membrane Ca2+ pump, which is the only active Ca2+ transporter. However, high PS exposure in blood 
disorders, such as SCD, is thought to be associated with an increased electrogenic cation 
permeability induced by deoxygenation, in coordination with decreased Ca2+ pump activity leading 
to increased Ca2+ levels (102-104). High levels of calcium also activate proteolytic enzymes, e.g. 
calpain, which disrupt the binding between the cytoskeleton and plasma membrane, leading to the 
formation of vesicles (105). Intracellular Ca2+ levels and extracellular PS exposure have been 
reported in higher levels during RBC aging (106, 107). 
 
1.2.4.4 Red blood cell antigens 
RBC antigens are carried on proteins or sugars exposed on the erythrocyte membrane. They can 
elicit an immune response and are detected by specific alloantibodies. The ABO glycosyltransferase 
was the first blood group discovered by Landsteiner in 1901 (108), demonstrating that matching 
blood groups between patient and donor is vital for a successful blood transfusion. This was done 
through observation of RBC clumping (agglutination) when mixing RBC and plasma from different 
people (108). The precursors for ABO are H antigens. Rare individuals lacking H are consequently 
A and B negative and were first reported in Bombay (Bombay phenotype) (109).  
The Rh antigens, which were discovered 40 years later than ABO, consist of proteins. Rh was 
originally named after the Rhesus monkey, as it was mistakenly thought to be similar to the antigens 
produced by these monkeys (110). The RhD antigen, a large protein encoded by the RHD gene, 
together with the ABO blood group antigens, are of major clinical significance, as they must be 
matched before a blood transfusion takes place to prevent haemolysis. This is attributed to the 
immune system defence, which produces antibodies against foreign proteins (111). Additionally, 
ABO group antigens are naturally found in food and some microorganisms, hence it was thought 
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that antibody production was stimulated by the environment (112, 113). Interestingly however, the 
presence of anti-A and -B antibodies in the blood of people lacking the corresponding blood group 
antigens has been reported, e.g. individuals with A or B blood group produce anti-B and anti-A 
respectively, even in infants and new-borns. Such antibodies were not derived from the mother, 
showing that these antibodies are naturally produced (114, 115). On the other hand, anti-RhD 
production by a RhD-negative person is only stimulated after exposure to the RhD antigen. Anti-RhD 
are mostly small immunoglobulins (Ig) consisting of IgG monomer and can cross the placenta easier 
compared to the larger pentameric IgM, anti-A and anti-B. If the mother is D-negative, fatal 
haemolysis can be caused via the haemolytic disease of the foetus and newborn (116). 
There are 38 formally registered blood groups at present, encoded by 45 genes (117). Some of these 
clinically important blood group antigens are RhC/c and RhE/e in the Rh system, K/k in Kell, Fya/Fyb 
in Duffy, Jka/Jkb in Kidd, as well as M/N and S/s in the MNS system (116). The naming of the antigens 
was often haphazard. Kell, Duffy and Kidd systems were named by the original patients in which the 
antibody was initially found (118). M and N for MNS were taken from the word “immune” and S from 
Sydney, as a place where anti-S was first described (89). The majority of the blood antigens are 
carried by RBC proteins; MNS antigens are carried by GPA and GPB, whereas band 3 carries the 
antigens of the ABO (119) and the Diego systems (91). The Diego blood group was also named after 
the first patient in which it was described (118). RBC antigens exhibit high polymorphism caused by 
single-nucleotide substitutions, single nucleotide insertions or deletions and gene rearrangements 
(116). For patients who require frequent blood transfusions, like those with SCD, blood screening of 
not only the ABO and Rh, but the minor blood groups must be taken into consideration. This is 
needed because RBC antigen prevalence differs greatly between patients with African ancestry and 
mostly Caucasian donors who represent the majority of donating population. Some antigens are 
commonly present in white but rarely in black populations, such as RhC, RhE, Kell, Duffy, Kidd and 
MNS. Minor blood groups can be highly immunogenic after a blood transfusion, leading to haemolytic 
reactions and alloimmunisation (120), which are further discussed in section 1.5.3. 
 
1.2.5 Ex vivo generation of red cells 
RBC generation in culture is of scientific interest for many laboratories around the world, as it may 
increase the blood bank supplies for blood transfusion, especially for patients with rare blood groups. 
A pool of cultured reticulocytes expressing or lacking particular blood groups, could also contribute 
to prevent mismatched blood and decrease alloimmunisation (section 1.5.3) (121). A source material 
for erythroid cell cultures can be human embryonic stem cells or stem cells from adult peripheral 
blood, cord blood and bone marrow (122-124). An alternative source is using immortalised cell lines, 
which can proliferate continuously preserving their phenotype, through transformation of 
haemopoietic progenitor with transcription factors by using viral vectors. However, attempts to 
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generate mature RBC at large scale have been challenging and not feasible for the time being (125). 
To date the highest amplification achieved is >105-fold from 106 CD34+ from cord blood and 
peripheral blood. The reticulocytes were generated using a well-established protocol according to a 
good manufacturing practice compliant procedure, comprised of three stages using different 
supplemented media (126). Cultured cells were found to be similar to the donor cells in terms of 
deformability, oxygen-binding capacity and immunogenicity using serology (123, 127). Interestingly, 
significantly higher levels of cultured cells remained in the circulation of a mouse transfusion model, 
compared to RBC from a donor. This demonstrated the feasibility of using cultured reticulocytes, 
which represent a homogenous population of young red cells, in vivo. Additionally, cells from both 
sources did not exhibit toxicity when introduced in a mouse model (126). Blood transfusions are 
further discussed in section 1.5.2. 
 
1.2.6 Animal models of erythropoiesis 
Despite the fact that in vitro RBC cultures have enhanced our knowledge about cell cycle and 
function, the information provided is limited. This is mainly due to lack of other cells in the culture 
system producing natural signals like cytokines that can affect RBC fate in a living organism. Another 
limiting factor is the limited two-dimensional environment in culture plates, in contrast to 3-D 
structures found in an organism (128, 129). Immune deficient mice are commonly used as study 
models of haematopoiesis, due to the absence of immune cells such as T, B, and NK, as their 
presence would cause graft rejection (130). Although the engraftment of human peripheral blood 
mononuclear cells (131) or HSC (132) in humanised animal models was achieved by the discovery 
of the severe combined immunodeficiency mutation (scid) (133), there are limitations. These concern 
the restricted engraftment of multiple hematopoietic lineages, which fail to generate a functional 
immune system in xenograft models (134, 135). While human myeloid lineage and erythropoiesis 
can arise from human HSC in the BM of immunodeficient mice, they cannot differentiate into mature 
RBC and the presence of megakaryocytes is limited (129, 130). Hence, studies in diseases with 
impaired erythropoiesis like SCD are difficult to be performed.  
Elimination of murine macrophages using liposomal clodronate was shown to allow short-term (up 
to 7 days) RBC detection in the circulation (136). However, murine macrophages recover quickly 
and destroy the transfused human cells. RBC from a donor along with cultured reticulocytes 
generated from CD34+ cells, isolated from cord and peripheral blood, were introduced in a NOD/LtSz-
scid IL-2Rγc null (NSG) mouse model (126). These mice are immune deficient, lacking T, B and NK 
cells and can be used for the engraftment of normal and malignant human blood cells (137, 138). 
The use of liposomal clodronate allowed the expansion of the grafted cells. Cultured reticulocytes 
could differentiate into mature RBC in the animal model, indicating that macrophages were not 
involved in the formation of the biconcave shape but they may participate in removing unwanted 
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material (see sections 1.3.2 and 1.3.3). This showed that the selected animal model closely imitated 
a blood transfusion (126).  
Animal models can be genetically modified using gene-targeted knockout techniques, knock-in 
mutations and random mutagenesis methods to provide a good framework for in vivo studies (128, 
129). Synthetic peptides exhibiting the K immunogenic antigen of the Kell brood group were shown 
capable to induce tolerance in HLA-transgenic mice, by suppressing responses of T helper (Th) 
subsets (139). In addition, KEL1 and KEL2 transgenic mice, that express the human immunogenic 
antigens from the Kell system K and k, respectively, were generated by vectors (140). These 
systems were used to examine the effects of IgG subclasses in alloantibody production during 
alloimmunisation (section 1.5.3) (141). Lately, SCD and normal mouse models having both human 
α-globin and healthy or sickle β-globin genes, knocked into the mouse locus, were used to 
investigate the effect of SC in coagulation. The results suggested that retention of SC in clots occurs 
not only due to their shape but also through thrombin production (142). 
 
1.2.7 Material exported by red cells 
Mature RBC still contain a few cellular components, such as structural proteins like spectrin, which 
supports cell formation and allow RBC to move into small capillaries. Interestingly, mammals are the 
only organisms with enucleated RBC. Mitochondria, ribosomes and endoplasmic reticula are lost 
during the enucleation stage (143). It was suggested that enucleation and organelle extrusion 
through RCDP increased the ratio of cell surface area to volume, leading to better gas exchange as 
well as leaving more space for Hb (144, 145). However, ejection of endoplasmic reticulum deprives 
RBC of protein synthesis and export of mitochondria prevents oxygen consumption by the cell, 
maximising the amount transported to the tissues (58). In addition, since RBC produce a high 
number of free radicals, mitochondria exported by mammalian RBC may decrease harmful ROS, 
which reduce Hb oxygenation (146, 147) and consequently damage the membrane deformability 
(148, 149). This theory is in contrast to avian RBC, which preserve mitochondria and nuclei but have 
lower levels of oxidative stress and similar levels of Hb (144). The mechanisms by which organelles 
are removed in RCDP are discussed in sections 1.3.2 and 1.3.3. 
 
1.3  Cellular microparticles 
1.3.1 Circulating microparticles in plasma 
RBC-derived particles are referred to in this dissertation as RCDP and belong to a larger group of 
extracellular vesicles or microparticles (MP) which are secreted from most cells, if not all (150). They 
are comprised of membrane lipid bilayers and they differ in composition and physicochemical 
proteins. In 1967, MP were thought to be cellular dust or to originate from platelet membrane 
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splintering (151). They have been implicated in intracellular communication in health and pathology 
by transferring cargo between cells (152). MP were showed to trigger and/or modulate immune 
responses in cells which take them up. They have even been reported to alter cell migration in cancer 
cells. For these properties, MP are studied to be used as therapeutic targets, diagnostic aids and 
prognosis predictors, like biomarkers, e.g. in lung disease (153, 154). MP can be formed as 
membrane blebs in the extracellular space, known as microvesicles or ectosomes (Figure 1.5). They 
can also be formed as exosomes, by membrane endocytosis and development of multi-vesicular 
bodies, which subsequently fuse with the membrane and are then exported extracellularly (155). 
Microvesicle sizes vary between 100–1,000nm in diameter, whereas exosomes are smaller, ranging 
from 40–150nm in diameter. A third category of MP is apoptotic bodies (Figure 1.5), resulting from 
fragments of old cells, ranging from 50–5,000nm in diameter. Microvesicles and apoptotic bodies 
expose PS on their membrane surface (155, 156), while most exosomes expose cytoplasmic 
proteins like actin, tetraspanins, heat shock proteins, such as Hsp70 and Hsp90 and biogenesis-
associated proteins like Alix and Tsg101 (157-160). 
  
Figure 1.5 Secretion of microparticles. MP are formed as apoptotic bodies (top right), exosomes 
(bottom left) and microvesicles (bottom right). Apoptotic bodies are membrane blebs and fragments 
from senescent cells, whereas microvesicles are formed by membrane shedding. Both expose 
extracellular membrane components (in blue and yellow). Exosomes form multi-vesicular bodies by 
membrane endocytosis, which then fuse with the membrane and are exported outside the cell. They 
expose cytoplasmic membrane components (depicted by red and green on the image). Image was 




1.3.2 Red cell-derived particles and clinical significance  
In healthy people, the majority of MP come from platelets and RBC (151). Two different studies in 
1983 showed the export of RCDP, as well as exosomes, from immature reticulocytes (162, 163). 
RCDP are formed by shedding of the lipid bilayer of the RBC membrane which is rich in 
phospholipids and proteins (164), therefore they have a right-side out membrane orientation. RCDP 
are naturally shed during RBC aging due to membrane disturbance and collapse of cytoskeleton 
network. It was suggested that disturbance of the band 3-ankyrin anchoring complex increased the 
compression and generated a bud of the RBC membrane bilayer, forming RCDP (165). 
RCDP may also be involved in inflammation and immunomodulation. It is suspected that RCDP 
down-regulate macrophage activity whilst being phagocytosed when inhibiting the production of 
tumour necrosis factor α (TNF-α) and IL-8. This was reported in macrophages that had cleared up 
RCDP after exposure to known macrophage stimulators like zymosan A and lipopolysaccharide 
(166). Furthermore, phospholipids on the RCDP membrane are substrates of the phospholipase A2 
enzyme, which may lead to lysophosphatidic acid production, known to participate in inflammation, 
cell proliferation and migration (167). RCDP are also involved in nitric oxide (NO) availability. NO is 
a major contributor to vasodilation (168-170) but it can be efficiently scavenged by RCDP (168). This 
should be taken into consideration before using stored blood for transfusion, as RCDP numbers 
increase rapidly during storage and can thus decrease NO availability (171).  
In haemolytic anaemias such as β-thalassaemia and SCD, RBC are more fragile due to defective 
mechanisms in membrane integrity, enzymes or Hb. In such conditions, RCDP levels were found to 
be significantly increased (172-175). PS abundance on RCDP triggers phagocytosis by 
macrophages and promotes coagulation since it catalyses the conversion of prothrombin into 
thrombin, which is involved in coagulation (176). Another initiator of coagulation is tissue factor 
(CD142) which has been reported to be found on RCDP membranes (177). It has also been shown 
that RCDP participate in the initiation of vaso-occlusive crises in SCD (178). Recently, we have 
shown that removal of large RCDP exposing PS and prothrombotic factors from SCD plasma has 
led to decreased plasma clotting times. This suggests that removing this population from patients’ 






1.3.3 Autophagic vesicles  
Apart from RCDP formation by membrane shedding, reticulocyte membrane fragments were also 
thought to be exported through membrane endocytosis by the endosome-exosome pathway and 
formation of multivesicular particles. These fuse with the plasma membrane and are exported 
extracellularly as exosomes (Figure 1.6) (179, 180). Removal of excess organelles is thought to 
occur by autophagy, in which organelles are encapsulated in the double membrane forming 
autophagosomes, transferred to lysosomes and then exported outside the cell (180). There is 
evidence that endocytosis and autophagy may merge, leading to the formation of autophagic 
vesicles (AV) (181). This term is used in this dissertation to describe inside-out membrane AV 
secreted by RBC, where their orientation is different to RCDP, which are the right-side out (Figure 
1.6).  
Using an in vitro culture system, our colleagues suggested that reticulocyte maturation and AV 
formation takes place in two phases; one in the BM where excess membrane is removed by the 
endosomal-exosome pathway and the other occurring later in the circulation, where large membrane 
particles are endocytosed and fused with autophagosomes forming AV. Then, AV are exported 
outside of the cell, probably during passage through the spleen. Interestingly, both were found to 
take place in the absence of lysosomes (123, 182). Our colleagues also showed that in SCD patients, 
and in individuals splenectomised due to other haemoglobinopathies, PS was expressed on the 
surface of RBC in similar levels to that of the AV from cultured reticulocytes (127). The properties of 




Figure 1.6 Suggested mechanisms of particle formation in erythrocytes. On the left, the red 
cell membrane is internalised by endocytosis to form a microparticle that fuses with an 
autophagosome to form a large vesicle, which is expelled and released extracellularly. The resulting 
AV expose the cytoplasmic components of the maternal cell on their membrane. RCDP are formed 
by membrane budding and instead expose the extracellular components.  
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1.3.4 Storage vesicles 
RBC units for transfusion contain storage vesicles (SV), the levels of which increase exponentially 
during storage (183, 184). RBC are isolated from whole blood by plasma separation after 
centrifugation and RBC units are then leukofiltered prior to storage, to prevent alloimmunisation by 
human leukocyte antigen (HLA) antigens (185). In continental Europe, the United States, Canada 
and other countries, RBC units are kept for up to 42 days (186), whereas in the United Kingdom 
(UK) they are kept for up to 35 days, at 2–6°C (187).  
 
 
1.3.4.1 Formation of storage vesicles 
SV are a heterogenous population of vesicles forming round or rod structures (188). Generation of 
SV is stimulated by several events taking place during RBC storage. RBC undergo biochemical, 
mechanical and immunological changes with time spent in storage, for instance changes in ATP and 
NO levels (189-191). ATP levels decrease while oxidative conditions promoted by depletion of 
glutathione and its associated enzymes, such as glutathione peroxidase and glutathione reductase, 
harm membrane lipids and proteins. This leads to transformations in membrane structure and 
morphology, known as storage lesions (192). Changes caused by storage lesions can be restored 
in vivo after transfusion, in contrast to other changes, e.g. membrane remodelling (190, 191). 
Reduction in ATP is thought to cause vesiculation. In parallel, this leads to further vesiculation by 
increasing intracellular calcium (193, 194). In addition, oxyhaemoglobin is released extracellularly, 
either free or within RCDP, and both forms may scavenge NO and decrease vasodilation (see 
section 1.2.4.1). In vivo, rats inoculated with plasma from stored blood units were found to show 
increased haemolysis and significant vasoconstriction, potentially caused by NO elimination (168).  
 
1.3.4.2 Storage vesicle characteristics 
The number of SV and haemolysis levels amongst different blood units is primarily linked to various 
features of the donor RBC, such as membrane fragility, levels of Hb and intracellular calcium (195, 
196). Different levels of uric acid could be another factor in vesiculation, as it acts as an antioxidant 
and could reduce oxidative stress reactions (197). SV characteristics have been reported to depend 
on the leukoreduction method and the additives in RBC concentrates (198). Two different methods 
of leukoreduction using whole blood and buffy coat filtration were compared to assess potential 
effects on SV size (199). The SV population was initially 100nm size and reached up to 200nm during 
storage in both methods. However, SV from units prepared by whole blood filtration were always 
smaller in size than those prepared from buffy coats, throughout the whole storage period (199). 
Interestingly, the number of SV generated by whole blood filtration was higher than that from buffy 
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coats (200). This is of great importance, as SV size and absolute number may affect their bioactivity, 
as well as their coagulation activity (201). Furthermore, stored RBC from buffy coat leukofiltration 
had higher ATP levels and were less affected by storage osmotic changes, than from non-
leukofiltered units (202). The above differences in SV size and cellular components when generated 
by different RBC isolation methods could affect SV composition and bioactivity, thus further research 
on this is required (186). 
Additives in storage RBC bags, used to preserve cells for up to 6 weeks by providing nutrients, can 
also affect SV characteristics (203). SAGM is a popular additive solution, named according to its 
constituents, saline-adenine-glucose and mannitol, which scavenges free radicals and stabilises the 
cell membranes (204). While SAGM is widely used in Europe, it is not approved by the United States 
Food and Drug Administration (USFDA) and instead the citrate–phosphate-dextrose-adenine 
(CPDA) based additives are used in the USA (205). Comparisons of RBC stored in SAGM or CPDA 
showed that SV numbers were reduced in SAGM, potentially because of a lower oxidation status 
(198, 206). Newly developed additives like alkaline preservatives such as ATP 2,3-BPG seem to 
maintain higher levels of important metabolites, as well as lower haemolysis levels when compared 




1.3.4.3 Storage effect on red cell proteins 
RBC storage temperature can also affect vesiculation. The RBC membrane permeability decreases 
at 4°C, triggering an increase of intracellular calcium, therefore promoting vesiculation (209). 
Permeability is further decreased by inhibition of the ATP-dependent Na+/K+ cationic pumps at this 
temperature, resulting in increased intracellular Na+, which stimulates further transport of calcium 
into the cell (193, 194). Oxidative stress reactions occurring in RBC during storage are enhanced by 
a reduction in endogenous antioxidants, such as glutathione and peroxiredoxin-2, which protect the 
cell from hydrogen peroxide (191, 210, 211). The most affected proteins by oxidative stress are band 
3, spectrin, β-actin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), band 4.1, band 4.2, 
band 4.9 and ankyrin (210, 212). ROS can cause vesiculation by interference with cytoskeletal 
proteins such as β-actin, spectrin and band 4.1, or with proteins involved in membrane formation 
and stability, such as ankyrin, band 3, band 4.2 and band 4.9 (210, 211). These proteins can also 
react with GAPDH and Hb and subsequently affect RBC metabolism. GAPDH is found in two forms; 
an active cytosolic and an inactive membrane bound to band 3, where both are essential for 
glycolysis. During ROS reactions, reversible oxidation of GAPDH switches glycolysis to a pentose 
phosphate pathway and NADPH production, which facilitates redox reactions compensating the 
oxidation and preserving Hb, as well as cell integrity (213). Two GAPDH oxidative mechanisms have 
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been reported for RBC stored in SAGM. One is a reversible oxidation of the enzyme, resulting in 
NADPH production to preserve stored RBC (214). The second is an irreversible oxidation of 
membrane bound GAPDH that reduces its activity. It occurs through continuous enzyme oxidation 
during storage, which results in export of excess oxidised enzyme through SV, suggesting that 
vesiculation is facilitated to remove unused material from the cell (215). Oxidation has been reported 
to affect functional parts of the β chain of Hb, such us the proximal cysteine 94 that is implicated in 
NO scavenging and histidine 144, which is involved in the maintenance of the stability of the 
deoxygenated form (216). 
With the use of proteomics, SV have been reported to contain the apoptosis stimulating fragment 
proteins called Fas, their related Fas-associated death domain proteins and caspases 3.8 (206), as 
well as ubiquitinated proteins (198). They are also rich in Hb and raft proteins acetylcholinesterase, 
flotillin-2 and stomatin (183, 216). The levels of the last two were two-fold higher when compared to 
RCDP produced in vivo (217). Flotillin-2 is a cytoskeleton protein that anchors band 3 complexes 
during storage and both proteins were found highly associated (218). Stomatin is a membrane, 
cytoplasmic protein and acetylcholinesterase is an extracellular enzyme anchored to the membrane 
(219, 220). PS has been reported not only on SV but also in RCDP and stored RBC (183, 217), 
which could result from the decreased flippase activity triggered by ATP elimination and the pH 
changes during storage (183, 205, 221). 
 
1.3.4.4 Storage vesicle analysis methods 
The International Society for Extracellular Vesicles has published protocols for microparticle isolation 
in plasma. In terms of SV, however, several isolation methods have been described (reviewed by 
Wannez et. al, 2019). Double centrifugation is a feature of most of them, starting from 400g and 
reaching 12,500g at 4°C (186). SV size is usually calculated by dynamic light scattering (DLS), 
nanoparticle tracking analysis (NTA), atomic force microscopy and tunable resistive pulse sensing 
(199, 219, 222). DLS and NTA use the Brownian motion of microparticles in suspension and the 
laser light scattered allows measurement of the average size and the zeta potential, using the 
Stokes-Einstein relationship (222). DLS is effective for monodispersed samples but less accurate for 
polydisperse samples. NTA on the other hand uses a camera and allows particle visualisation (223). 
Tunable resistive pulse sensing uses voltage change readings caused by particle passage through 
a pore. It allows concentration of particles of a specific size range (224). Atomic force microscopy 
can generate precise, versatile data on three-dimensional characteristics, such as size, as well as 
protein abundance simultaneously. However, despite the detailed results, the method is not often 
chosen due to the object immobilisation required during analysis (225).  
SV morphology can be examined by transmission electron microscopy (TEM) or cryo TEM (226), 
while usually flow cytometry is used to determine the SV phenotype, including PS exposure (183, 
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199, 200, 227). For this, beads are commonly used for instrument calibration, which help in gating 
populations with different size and scatter characteristics (228, 229). However, most flow cytometers 
are not sensitive enough to detect SV smaller than 300nm (230) and consequently NTA is the most 
popular method used for characterisation of small SV (231). Imaging flow cytometry is a new method 
which combines flow cytometry with microscopy, allowing visualisation of individual objectives. This 
technique was proven to be sensitive for populations above 200nm (232, 233) and can be optimised 
for even smaller populations close to 100nm (234). 
 
1.3.4.5 Clinical significance of storage vesicles 
It is suspected that SV could have clinical applications because of their constituents (186). An 
increase in the coagulation properties of stored RBC, which is linked to the exposure of tissue factor 
(TF) has been previously described (235-237). The effects of SV in stored RBC after blood 
transfusion were examined by spiking blood from healthy donors with SV from expired RBC units, 
which lead to a significantly decreased clotting time from 194 to 161 seconds (237). Plasma and 
monocytes showed increased TF levels, while TF messenger RNA expression was found to increase 
with time and SV concentration. Levels of proinflammatory cytokines, IL-1β and -6, and activated 
platelets were significantly increased. It was also suggested that platelet interactions with neutrophils 
and monocytes were promoted, indicating that SV may trigger inflammation after blood transfusion 
(237). In other studies, proinflammatory cytokines IL-2, -7 and -15 and TNF-α were produced by 
macrophages post stimulation by SV. It was also shown that SV, up to 200nm, activated CD4+ and 
CD8+ T-cells through antigen presentation and led to their proliferation (237). Furthermore, since 
phospholipids are converted to arachidonic acid and lysophospholipids by phospholipase A2, it is 
possible that lysophosphatidylcholine exposed on senescent RBC and SV results from consumption 
of high phospholipid levels by phospholipase A2. As these lysophospholipids have a contiguous 
structure to platelet activating factor, they could be involved in neutrophil activation or priming. 
Furthermore, CD11b, which is a marker of neutrophil priming, has been found to be increased upon 
stimulation with SV (238-240). It was also shown that neutrophils could produce superoxide and 
undergo phagocytosis, after interactions with SV (240). Results from all of the above studies suggest 
that SV may be involved in immune responses, however further investigation on this should be 




1.4 Red cell disorders 
1.4.1 Haemoglobinopathies 
In pathological conditions, differences in RBC numbers or levels of free Hb and oxyhaemoglobin, 
result in different types of anaemias (from Greek anaimia, from an- un, ‘without’ and haima ‘blood’). 
Anaemia particularly affects pregnant women and young children; the World Health Organisation 
(WHO) estimates that 40% of pregnant women and 42% of children less than 5 years old suffer from 
anaemia, usually due to dietary deficiencies (241). Haemoglobinopathies and infectious diseases 
are other causes of anaemia. HbA is the major type of Hb in adults, comprising 95% of the total Hb. 
HbA2, with two delta chains instead of beta (2α/2δ), comprises less than 3.5%, while HbF accounts 
for <1% of the total Hb in adults. Abnormalities in Hb genes’ expression lead to inherited anaemias, 
i.e. haemoglobinopathies, which is a greater burden for health care systems worldwide, including 
the UK. There are two main categories of haemoglobinopathies; (i) thalassaemias, where mutations 
in the genes for α or β globin chains cause reduced or inadequate synthesis of normal α- or β-globin 
chains leading to decreased levels of HbA and (ii) structural abnormalities in HbA, such as sickle Hb 
(HbS), resulting from the mutations in the genes for α or β globin chains (242). As stated previously, 
RCDP levels are significantly increased in β-thalassaemia and SCD patients (172-175). 
 
1.4.2 B-thalassaemia 
One of the main categories of thalassaemia is β-thalassaemia major, caused by absence of β-globin 
chains due to mutations of the beta-globin gene on chromosome 11. More than 200 mutations are 
reported to cause β-thalassaemias (243). Most patients originate from the Mediterranean 
(thalassaemia from Greek word Thalassa for sea), Middle East, South Asia or the Far East. In the 
UK, there are more than 1000 patients with β-thalassaemia, most of them relying on frequent blood 
transfusions, usually every 3-4 weeks. Most patients require life-long transfusion regime, since they 
may suffer from life-threatening anaemia from an early age of one year old (242). The anaemia 
occurs because HbF would normally be replaced by HbA (α2,β2) in adults, but as HbA is absent in 
these patients, the HbF (α2,γ2) levels remain increased. This causes unpaired α chains to precipitate 
on the RBC membrane as hemichromes, which can lead to further RBC membrane oxidation and 
cell damage (243). Treating children with β-thalassaemia using HSC transplantation is the only 
curative procedure. It is possible but finding suitably matched donors is usually problematic. 





1.4.3 Sickle cell disease 
SCD is a hereditary disorder caused by a single base mutation at codon 6 in the β-globin gene, 
replacing glutamic acid to valine (245). It is estimated that over 300,000 babies are born every year 
suffering from SCD, most in sub-Saharan Africa (246). In 2018, it was estimated that there are 
approximately 14,000 SCD patients in the UK; that is one patient in 4,600 people (247). Most 
heterozygous patients, who have one HbS gene, are asymptomatic (known as sickle cell trait). In 
contrast, homozygous patients suffer from sickle cell anaemia (245).  
 
1.4.3.1 Formation of sickle cells  
The sickle cell shape forms after RBC deoxygenation in the circulation. In normal conditions, Hb 
undergoes changes during oxygen binding. Atoms of heme in the deoxygenated Hb (T state Hb), 
are bound to hydrogen and electrostatic bonds. Binding of oxygen forms oxygenated Hb in the R-
state and leads to disruption of these bonds and formation of the new ones. Thus, the binding of only 
one molecule of oxygen to the tetramer dramatically changes the tetramer conformation (248, 249). 
Replacement of the polar glutamic acid with hydrophobic valine disrupts the bond formation and 
alters Hb structure. Instead, the formation of new hydrophobic bonds between valine residues on 
the β-globin chain of one HbS and alanine, phenylalanine and leucine of another HbS molecule on 
a different β-globin chain, is forming double strands. This can occur only in the T-state Hb when 
hydrophobic areas are exposed to form the new bonds. At low oxygen concentrations, increased 
strand numbers result in formation of long fibres and HbS polymerisation, disrupting the RBC 
membrane deformability and leading the biconcave cells that transform into the sickle cell shape 
(Figure 1.7) (248-252).  
  
Figure 1.7 Sickle haemoglobin polymerisation. Hydrophobic valine (Val) forms bonds with 
phenylalanine (Phe) and leucine (Leu) residues. At low oxygen levels, deoxy-HbS polymerises and 
gives long fibres that alter RBC shape from biconcave to sickle. Image was reproduced from Odièvre 
et. al, 2011 (253). 
36 
 
In contrast to healthy RBC, sickle cells (SC) flow slower in the circulation and can adhere to the 
endothelium. The inflexible SC membrane prevents cell passage through the microvasculature and 
eventually, they block the capillaries (245, 252, 254). Furthermore, repeated reversible HbS 
polymerisation result in haemolysis, followed by increased free Hb and RCDP levels in the circulation 
(255). RCDP levels were found to be up to 3- to 4-fold higher than in healthy individuals and along 
with SC, they contribute to vaso-occlusion. This can lead to further complications, such as organ 
damage, severe anaemia, stroke and infections (252, 255), discussed in section 1.4.3.3.  
In the early stages of RBC deformability disruption, polymerisation of Hb affects other cellular 
functions and ion channels such as the K-Cl transport system and the Ca-dependent K-channel 
(Gardos channel), which decrease the intake of potassium and water molecules (256).This results 
in increased intracellular Hb levels which further contribute to HbS polymerisation and make cells 
irreversibly sickled (253). Additionally, cytoskeletal proteins, particularly band 3 are released as 
hemichromes, which are defective Hb aggregates in the internal leaflet of the membrane (257, 258). 
In parallel, heme decreases and Fe3+ is released, leading to oxidising conditions. PS levels on the 
cell membrane increase, disrupting the phospholipid asymmetry on the membrane. Anti-band 3 IgG 
target band 3 clusters and phagocytosis by macrophages is triggered, leading to haemolysis (257). 
All of the above processes trigger RCDP formation (259). 
 
1.4.3.2 Mechanisms of coagulation 
SC adhesion to the endothelium was shown to result from immature reticulocytes, called stress 
reticulocytes, which are released into the blood stream too early. This is due to their increased 
production by the bone marrow in response to anaemia, attempting to maintain the oxygen levels 
(259). Adhesion of the stress reticulocytes to the endothelium decreases the blood flow rate and 
supports the accumulation of SC, leading to blockage of the blood vessels (259). Adhesion is 
facilitated by a number of molecules on the RBC surface and on the endothelium. They include α4β1 
integrin or very late antigen-4 binding to the vascular cell adhesion molecule-1 (VCAM-1), CD36 on 
RBC binding to CD36 on endothelial cells via plasma thrombospondin, Lutheran blood group Lu/ 
basal cell adhesion molecule isoform antigen binding to laminin and CD44 on the RBC membrane 
binding VCAM-1 through fibronectin (260, 261).  
Stress reticulocyte levels are increased within hours of blood loss, which has also been shown in 
other types of anaemia, i.e. pyruvate kinase deficiency. However, acute painful episodes (crises) 
caused by vaso-occlusion (vaso-occlusive crisis, VOC) have not been reported in other haemolytic 
diseases and are associated with HbS (253). Along with stress reticulocytes and endothelial cells, 
activated platelets, leukocytes and plasma components also contribute to VOC. PS exposure on 
RBC and TF expressed by endothelial cells trigger thrombin production that leads to coagulation 
(253). Even low thrombin concentrations combined with ischaemia-reperfusion injury (damaged 
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tissue due to interrupted oxygen supply) can contribute to hypercoagulation and inflammation by 
stimulating proinflammatory cytokines (262, 263). Furthermore, oxidative stress leads to haemolysis 
and release of iron inducing the production of endothelial molecules, which are involved in the 
adhesion of stress reticulocytes and leukocytes activation. Two of these molecules are nuclear 
factor-kappa β and activating protein-1, which are implicated in VCAM-1, inter-cellular adhesion 
molecule-1 and E-selectin production in the endothelium (264). Additionally, NO bioavailability is 
limited, as release of Hb leads to NO scavenge and decreases vasodilation and free erythroid 
arginase, produced by haemolysis, degrades L-arginine, the precursor for NO synthesis (265). NO 
decomposition produces free radicals one thousand times more quickly than in RBC (265). All the 
above, along with clearance of deformed SC by macrophages in the spleen and subsequent release 
of heme and SC products, exacerbate existing haemolysis (266). 
RCDP and MP are produced from cells participating in the inflammation response, such as 
endothelial cells, platelets and leukocytes (267). However, the majority are RBC-derived (267-269). 
Elevated RCDP numbers in SCD have been reported, due to the lack of a functional spleen. Initially, 
these RCDP were found by Allan et. al in 1982 to be HbS loaded and lacking spectrin (255). RCDP 
were found to contribute to coagulation as well as vaso-occlusion and were found at increased levels 
during VOC (267). Because of their altered components, due to RBC transformation to SC, they are 
considered to have clinical implications (253). Recently, it was shown that removal of large PS 
exposing RCDP from patient plasma may alleviate any symptoms caused by hypercoagulation in 
these patients (Smith et. al, manuscript submitted). 
 
1.4.3.3 Complications caused by coagulation in sickle cell disease 
Pain and life-threating conditions 
Microvascular occlusion and tissue ischaemia caused by SC are characteristic features of the 
disease. Acute pain, which is related to SCD severity, is caused by blood flow blockage in capillaries 
and small vessels and it is the most common reason for hospital admission (266). Acute pain is also 
associated with acute chest syndrome, caused by several respiratory features like chest pain and 
tachypnoea, which can be life-threatening for many patients (270). Painful VOC are related to cellular 
interactions in the vascular endothelium and the inflammation (253, 271). VOC can lead to 
cerebrovascular accidents like stroke, affecting 11% of 20 years old patients and 24% of 45 year 
olds (272). The abnormal SC shape, combined with VOC and inflammation, can also cause organ 
damage, particularly the spleen, liver, bone, lungs, brain and kidney. Another serious complication 
can be acute splenic sequestration crisis, which can be lethal, especially for children under two years 
of age. It is caused by increased SC numbers in the spleen, resulting in splenomegaly and can also 





Patients with SCD are susceptible to infections, probably due to splenic dysfunction caused by 
repeated sickling in the spleen, damaging its filtration capability, as well as impaired opsonisation of 
encapsulated pathogens, which is essential for phagocytosis (275-277). Such infections can be 
bacterial, mycobacterial, viral or parasitical (278). In malnourished children, further deficiencies in 
innate and humoral immunity are caused by lack of nutrients, low immunoglobulin levels and zinc 
deficiency (279).  
The main function of the spleen is to filter and destroy circulating pathogenic organisms captured by 
macrophages. Opsonisation mediated phagocytosis is mainly facilitated by macrophages and 
neutrophils. It is dependent on complement cascade activation through three major pathways: 
classical, lectin and alternative. Tagging the pathogen surface with different complement opsonins 
mediates its uptake by phagocytic cells (280). If mechanisms using antibodies and/ or complement 
are defective during opsonisation, macrophages cannot effectively kill pathogens (275, 276). Splenic 
hypofunction is characterised by defective filtration and RBC shunting. It usually starts in early life 
and can be identified by circulating Howell-Jolly bodies (281). These are found as spots on RBC 
comprised of packed DNA, which was not exported during reticulocyte enucleation in the BM and 
are usually cleared by a healthy spleen (282). Ischaemia and chronic vaso-occlusion injure the 
spleen and result in its dysfunction in early life, usually leading to splenectomy around 3-5 years of 
age (283).  
Defective B- and T-cell functions in children with SCD lead to susceptibility to bacterial and viral 
infections, due to low memory B-cells and limited antibody production by T-cells (277). For example, 
impaired immunity can cause B-cells to produce only very low IgM antibody levels in response to 
influenza vaccine (284). CD4+ and CD8+ T cells are also decreased in SCD. CD4+ T-cells can kill 
infected cells, while CD8+ assist in antibody production. Both can trigger macrophage and neutrophil 
recruitment to the infected site (111). In SCD patients, these populations cannot mature properly 
(285), leading to a reduced number of T helper cell subpopulations, Th1 and Th2. The humoral 
immune response is facilitated by Th2 and Th1 cells that are responsible for cell mediated immune 
responses. It is thought that lack of CD4+ cell mediated immunity may be the reason for the severe 
influenza infections in children suffering from SCD (286).  
 
1.4.3.4 Sickle cell disease management 
Early prognosis of SCD not only assists in alleviating the symptoms but also prevents early death 
due to sepsis or acute splenic sequestration crisis (281, 287). Various treatments including natural 
approaches such as heat, oral hydration and massage can relieve pain (288). On the other hand, 
non-opioid analgesics and anti-inflammatory drugs like ibuprofen can help patients to control pain 
(289). When hospitalised, due to acute and aggressive pain, management by intravenous opioids is 
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used (290). Blood transfusions, including simple transfusion of packed RBC and exchange 
transfusions, are often used to alleviate symptoms and anaemia from early in childhood, whereas 
regular transfusions given on a monthly basis can be used to prevent stroke episodes. Blood 
transfusion increases oxygen-carrying capacity by providing the patient with healthy RBC. However, 
complications such as alloimmunisation - an immune response to antigens from genetically different 
donors, iron overload and cost should be taken into account (291).  
Hydroxyurea is a myelosuppressive agent that was shown to reduce painful episodes, potentially by 
increasing HbF levels (292). Although the exact mechanism is unknown, hydroxyurea was shown to 
inhibit deoxyribonucleic acid (DNA) synthesis and potentially cytotoxicity by inhibiting the enzyme 
ribonucleotide reductase, which is involved in ribonucleoside conversion to deoxyribonucleosides. 
In this way, hydroxyurea inhibits DNA synthesis and any cytotoxic events by increasing 
erythropoiesis via HbF promotion. Furthermore, hydroxyurea seems to be beneficial by decreasing 
the production of cells involved in inflammation and vaso-occlusion, such as neutrophils and 
reticulocytes (292, 293). 
HSC transplantation using mobilised peripheral blood or BM cells, is the only cure for SCD. For this, 
normal HSC from an HLA-matched healthy donor can be transplanted into patients. However, graft 
(donated cells) versus host disease can occur, where donor leukocytes present in the transplant 
attack recipient cells. This can last for several months and can be life threatening. Graft rejection can 
also occur. Gene therapy is promising but it is only in early stage clinical trials (294). In the UK, all 
above treatments are available to patients (295). The USFDA has also approved L-glutamine, 
Crizanlizumab and recently voxelotor (296). L-glutamine improves RBC flexibility and circulation, 
allowing improved oxygen transport to the tissues (297). Crizanlizumab targets P-selectin which is 
involved in SC adhesion to the endothelium and thrombin activation (298), assisting smooth flow of 
SC and preventing their adhesion to blood vessels (299). Voxelotor binds Hb increasing its affinity 
for oxygen, promoting oxyHb. Therefore, deoxygenated sickle Hb polymerisation is inhibited and SC 
adherence is avoided (300)  
Most treatment options mentioned above are used to alleviate SCD symptoms, as drugs can 
decrease VOC painful crisis episodes (292, 293, 297, 299, 300). Blood transfusions are widely used 
but complications such as alloimmunisation are common (discussed in section 1.5.3) (291). 
Likewise, haematopoietic stem cells transplantation (HSCT) are not without risk and HSCT are 
restricted by a lack of HLA-matched donors. While gene therapy may benefit the patients in future, 




1.5 Immunology of blood transfusions  
1.5.1 Overview of the immune system  
As was previously discussed in section 1.1, the BM gives rise to lymphoid progenitors, which can 
differentiate to leukocytes that comprise the organisms defence against foreign antigens. Some of 
the most important immune cells are neutrophils, which respond early and perform phagocytosis, T- 
and B- lymphocytes that are involved with adaptive immunity and monocytes that are early 
responders, carry out antigen presentation and mature to macrophages. Basophils and eosinophils 
are rarely found in the circulation. They can bind IgE, destroy parasites and are present during 
allergic reactions (111). When an antigen enters the organism, the innate immune system responds 
with neutrophils and macrophages that act first by secreting proteolytic enzymes and phagocytosing 
pathogens. Surviving invaders are confronted by lymphocytes; T-cells produce specific antibodies 
or kill specific cells, while B-cells remember specific features of the antigens and so generate 
antibodies faster in the event of future exposure (111, 301). 
Antibodies are Ig consisting of light and heavy chains and are divided into several isotype groups. 
The main isotypes are: IgD that is a B-cell receptor; IgG, a monomer carrying out opsonisation and 
complement activation; IgM, a pentamer found on B-cells that activates complement; IgE, found in 
allergic reactions and IgA, which is responsible for mucosal immunity (111). If an antigen enters the 
organism for first time, several days are needed for an IgM antibody to be generated and then IgG 
production follows. IgM has a weak affinity for the antigen whereas IgG binds strongly and kills it 
effectively. If the antigen has been exposed to immune cells in the past, circulating memory B-cells 
will quickly scale up IgG production. This is known as a secondary immune response (302). 
Antibody production is stimulated by antigen presenting cells (APC) and T-cells, via the T-cell 
receptor (TCR) that recognises the antigen on the APC. Lymphocytes can identify specific groups of 
molecules on cells known as major histocompatibility complex (MHC) molecules. HLA are the human 
equivalent of MHC (303, 304). MHC molecules are mainly comprised of peptides of the digested 
antigen exposed in a way that lymphocytes can recognise them. HLA molecules are divided into 
different groups, with class I and II being the best characterised. All human nucleated cells, except 
RBC produce HLA-I, while HLA-II proteins are only expressed on immune APC, specialised in 
antigen identification and digestion. These APC are B- cells, activated granulocytes and T-cells, 
monocytes and dendritic cells (DC) (303, 305). The human immune system diversity arises due to 
approximately 9 HLA molecules inherited randomly from one’s parents (306). The HLA-I and -II 
define the tissue type and HLA matching is vital for a successful HSC or organ transplant. HLA 
variability in humans is vast; amongst 20 million donors there will not be an exact match but for 2–
5% of patients. This is the reason that compatible donors are usually close relatives who share 




1.5.2 Blood transfusions and the immune system 
The immune response can be humoral, using antibodies, and cellular involving immune cells. 
Antibodies already found in plasma or produced against foreign blood cell antigens, known as 
alloantibodies, can destroy incompatible donor RBC after a blood transfusion. These cells express 
ABO group antigens and/or RhD that are absent from patient RBC. RBC lysis occurs either by 
binding to and coating the foreign RBC, or activating the complement cascade, or even causing RBC 
to adhere and clump together, known as agglutination (Figure 1.8). Agglutinated RBC may survive 
or are removed by macrophages in the spleen or liver, which also phagocytose donor RBC coated 
with antibodies (302). 
 
Figure 1.8 Red cell agglutination. Antibodies bind to foreign RBC antigens resulting in 
agglutination (clumping). Image modified from Parslow et. al, 2004 (307). 
 
During an incompatible blood transfusion, mainly macrophages, monocytes and to a smaller extent 
DC and granulocytes will engulf antigens and then load the antigen peptides on MHCII. A Th1 cell 
recognises the MHCII / antigenic peptides, binds to them and gets activated by APC through cytokine 
secretion. The Th1 cell produces cytokines to induce production of cytotoxic T-cells (308). 
Eventually, the activated Th cells are released and bind to B-cells, which in turn will proliferate to 
produce antibodies specific for the antigen or memory B cells which will circulate for many years and 
will recognise the antigen (302). 
For a blood transfusion, matched ABO blood group and RhD status of donor and recipient are crucial. 
However, there may be other blood group antigens on donor cells, which can be attacked by the 
recipient’s antigens. Thus, a "type and cross match" test is carried out, in which recipient’s plasma 
is mixed with donor RBC. If agglutination is observed by microscopy, the RBC are incompatible and 
transfusion cannot take place. An incompatible transfusion causes haemolytic reactions, in which 
the donor RBC are destroyed by the recipient alloantibodies (302). For patients who require frequent 
blood transfusions, matching should take into account minor blood group antigens such as RhC/c, 
RhE/e, K/k in Kell, Fya/Fyb in Duffy, Jka/Jkb in Kidd, M/N and S/s in the MNS system, which can cause 





Multiple blood transfusions can cause alloimmunisation, an immune response to antigens from 
genetically different donors. Alloimmunisation can also occur naturally during pregnancy (309). It can 
be dangerous as it can lead to acute and delayed haemolytic transfusion reactions. In SCD, 
haemolytic transfusion reactions can result in hyperhaemolysis, a life-threating condition in which 
RBC from both donor and patient are destroyed (120, 310, 311). Whereas the alloimmunisation rate 
for most individuals is generally low (2-5%) following transfusion, around 30-40% of transfused SCD 
patients are affected (312). This is mainly caused by genetic and racial differences between patients 
of African ancestry and mostly Caucasian white donors that represent the majority of donors, due to 
blood group antigen disparity between these ethnic groups (313). The most common highly 
immunogenic antigens that have been reported are C, D and E in the Rh group, K in the Kell system, 
Jkb in Kidd system, S in the MNS system and Fya and Fyb in Duffy system (120, 312). Even 
phenotypically matched blood cannot prevent alloimmunisation due to notable diversity of the RH 
genes among patients of African origin (314).  
RhC, Fya, Fyb, Jkb and S antigens are significantly less common in the majority of black SCD patients 
than in most white donors (315). Consequently, alloantibodies against these antigens are found more 
frequently in SCD patients (120, 312). The exact mechanism of alloimmunisation is unknown (316). 
A small study of multiply transfused patients with SCD showed that CD4+ regulatory T cells (Tregs) 
which control the proliferation of cells like DC, T- and B-cells during an immune response, were 
suppressed in alloantibody responders when compared to non-responders. In addition, responders 
showed lower IL-10 and higher levels of IFN-γ which is a Th1 cytokine, along with altered Th2, 
humoral immune response subpopulation (317). These results are in line with a SCD model in which 
underlying inflammation could disturb the equilibrium between Tregs and Th cells (318). It was 
suggested that since Tregs can either suppress B cell function directly (319, 320), or decrease IgG 
production through Th suppression (321), their low levels detected in non-responders can explain 
antibody generation in responders (316, 317).  
Alloimmunisation has been found to be dependent on the patient’s immune system, since a weak or 
immature immune system will not develop antibodies efficiently. The age of first blood transfusion 
was also shown to play an important role, as infants who received their first transfusion before age 
of three had significantly lower rates of alloimmunisation compared to children transfused after this 
age. This is thought to be due to their undeveloped immune system (322-326). It was also reported 
that a subpopulation of splenic conventional DC (cDC) was involved in alloimmunisation in a mouse 
model. Deletion of cDC2 diminished alloimmunisation, in contrast to deletion of cDC1 which had no 
effect on alloantibody production (327). As cDC2 are absent from neonatal mice until week 3, this 
could indicate that these cells are actively involved in alloantibody induction. However, further 
research on human cDC1 and cDC2 is needed, in order to identify if these populations can affect 
alloimmunisation in humans in a similar manner to that in mice (328, 329).  
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Alloimmunisation prevention by RBC antigen matching is challenging due to the limited availability 
of rare blood groups units (314). However, since SV have been previously shown to expose RBC 





Extracellular vesicles have been identified in RBC from healthy donors and patients with SCD. The 
reasons for the increased levels of RDCP, in particular circulating in SCD patients, is not known and 
their effects have not been fully elucidated. Therefore, the main goal for this body of work was to 
investigate potential differences in RCDP and AV from SCD patients and healthy individuals and 
determine their potential to induce tolerance to RBC antigens.  
The aims were as follows: 
1. Identification and isolation of RCDP and AV from SCD patients and healthy donors. 
2. Extensive characterisation of RCDP and AV from SCD patients and healthy donors.  
3. Comparison of RCDP characteristics to ex vivo generated reticulocytes and SV from outdated 
blood.  





 Materials and methods 
2.1 Samples 
2.1.1 Patient Samples 
For all experiments, apart from the mass spectrometry proteome analysis, blood samples from 
anonymised SCD patients, presenting at University Hospitals Bristol Trust for clinical haematological 
analysis, were used. These patients were classed as ‘steady state’, defined by the hospital as 
“attending the clinic for a routine red cell exchange transfusion and not having had a transfusion in 
the previous 4 weeks”. Patients were also characterised as “functionally asplenic” although there 
may be a few who still had some splenic function. The patients were not on regular transfusion, most 
will be transfused rarely but were likely to have received a transfusion sometime in the past. 
For the proteomic analysis: blood samples were obtained from SCD patients attending University 
College London Hospitals (UCLH) in a steady state. Blood samples were collected immediately, prior 
to any transfusion procedure and anonymised. Patients from both hospitals gave informed written 
consent and the study was approved by NRES Committee London (Harrow).  
 
2.1.2 Normal Blood Samples 
For all experiments, blood units (ABO type A RhD positive or O RhD negative or positive) were 
obtained from routine blood donations at NHS Blood and Transplant (NSBT), Filton in Bristol and 
processed identically to the patients’ blood. However, the normal samples were processed 48 hours 
after collection, which was the effective time of release.  
 
2.2 Sample processing 
2.2.1 Plasma and red cells 
SCD blood samples from UCLH were centrifuged at 2,000g for 15 minutes, at room temperature with 
no brake, within 1 hour of collection. Plasma was separated from RBC and as soon as it arrived in 
Bristol, it was centrifuged twice at 2500g for 20 minutes at room temperature. The pellet, composed 
mainly of platelets, was discarded after each spin. The resulting platelet free plasma (PFP) was 
aliquoted and stored at -80°C until analysis, when it was thawed at room temperature and used 
immediately. Repeat freeze‐thaw cycles were avoided. SCD samples from UHBT were processed 
in the same way once clinical haematological analysis had been completed, which was after 72 
hours.  
RBC used for the in vivo studies: blood units (ABO type O or A RhD positive) from healthy donors 
were collected between 2-14 days from the day of bleeding. To isolate RBC, 10ml of whole blood 
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was centrifuged at 400g for 10 minutes and the supernatant was discarded. RBC pellets were 
dissolved in Alsever’s (Lorne Laboratories, Berkshire, UK) medium and were either stored at 4˚C for 
up to 3 weeks, or snap-frozen as droplets in liquid nitrogen. Prior to use, cryopreserved RBC were 
thawed at 37˚C in Alsever’s and kept at 4˚C up to a week. The remaining whole blood was stored at 
4˚C up to 22 days from day of donation, for RBC ghost membrane preparations, or for 35 days for 
SV isolation. 
 
2.2.2 Red cell ghost membrane preparation 
Reagents and centrifuges were chilled to 4˚C to prevent protein degradation and locking of 
haemoglobin inside the membrane during production of the red cell ghosts. Packed RBC from 
healthy donors (22 days after donation) were washed twice in PBS at 1,660g for 10 minutes, at 4˚C 
then 1ml of RBC was added per Nalgene™ Oak Ridge tube (Thermo Fisher Scientific) on ice, topped 
up with RBC lysis buffer (5mM Na2HPO4 and 0.2M NaH2PO4 (both Sigma Aldrich, pH 7.4) and left 
for 5 minutes. Tubes were centrifuged at 15,000g for 10 minutes, at 4˚C and pellets were washed in 
RBC lysis buffer supplemented with 100mM protease inhibitor phenylmethylsulfonyl fluoride (PMSF, 
Sigma-Aldrich), until the haemoglobin (red colour) in the pellets was washed off. Ghost membranes 
were aliquoted (100μl) and stored at -80˚C. 
 
2.2.3 Storage vesicle isolation 
Blood from healthy donors was centrifuged twice at 2,500g for 20 minutes at room temperature, then 
pelleted RBC were removed. Plasma was filtered through a 1.2μm filter, to remove RBC ghosts and 
large particles, and then it was centrifuged at 20,000g for 30 minutes at 4˚C. Pellets were rinsed in 
HBSS supplemented with a complete protease inhibitor cocktail (Roche , Welwyn Garden City, UK) 




2.3 Monoclonal Antibodies 
Most monoclonal antibodies used in this study came from the Protein Development and Production 
Unit (PDPU) at NHSBT, unless otherwise indicated. All antibodies and suppliers can be found in 
Table 2.1. Unconjugated antibodies were conjugated to fluorescent dyes using the Alexa Fluor™ 
488, or Alexa Fluor™ 647 Antibody labelling Kit, or EZ-Link Micro Sulfo-NHS-Biotinylation Kit, 
(Thermo Fisher Scientific, Paisley, UK) according to the manufacturer’s protocol. In brief, antibodies 
were washed 3 times in phosphate buffered saline (PBS, Sigma-Aldrich, Poole, UK) to remove any 
residual solvent of ammonium ions or primary amines that would compete with the amine groups of 
the reactive dye. Then, they were diluted in PBS and mixed with 1 M solution of sodium bicarbonate 
buffer, provided in the kit, at a 9:1 ratio. One ml of this solution was added to a vial containing Alexa 
Fluor® dye, optimized for labelling 100µg of protein, and incubated for 1 hour at room temperature. 
In order to purify the labelled antibody from the unbound dye molecules, a purification column was 
saturated with purification resin, both provided in the kit and centrifuged at 1,100g for 3 minutes. The 
labelled antibody mix was loaded onto the column and centrifuged at 1,100g for 5 minutes. The 
concentration of the labelled antibody was determined by Nanodrop Gene Flow P3 (Geneflow Ltd, 





Table 2.1 Antibodies used. 
Antigen Supplier Clone Immunoglobulin Class 
CD235/ GPA 
(extracellular domain) 
PDPU1 BRIC256 Mouse IgG1 
CD235/ GPA 
(extracellular domain) 
PDPU R10 Mouse IgG1 
CD235/ GPA 
(cytoplasmic domain) 
PDPU BRIC163 Mouse IgG2a 
CD233 / Band 3 
(extracellular domain) 
PDPU BRIC200 Mouse IgG1 
CD233 / Band 3 
(cytoplasmic domain) 
PDPU BRIC132 Mouse IgG1 
CD233 / Band 3 
(cytoplasmic domain) 
PDPU BRIC155 Mouse IgG2b 
CD233 / Band 3 (N-terminal 
cytoplasmic domain) 
PDPU BRIC170 Mouse IgG1 
CD233/ Band 3 
(extracellular domain) 
PDPU BRAC18 Rat IgG2a 
CD233/ Band 3 (N-terminal 
cytoplasmic domain) 
PDPU BRAC66 Rat IgG2a 
CD236R/ GPC 
(cytoplasmic domain) 
PDPU BGRL100 Mouse IgG1 
GLUT1 PDPU BRAC67 Rat IgG2c 
Anti-HLA Class I antibody Abcam2 W6/32 Mouse IgG2a 
CD41/ CD61 PDPU PAB1 Mouse IgG1 
CD238/ Kell PDPU BRIC68 Mouse IgG2a 
SLC14A1 (contains an 
epitope identified as Kidd) 
R&D Systems3 888418 Mouse IgG2b 
Streptavidin-horseradish 
peroxidase conjugate (HRP) 
Sigma-Aldrich - Polyclonal 
Stomatin In house4 anti-STOM Rabbit IgG 
Anti-rabbit HRP Agilent Dako5 - Goat polyclonal 
Lub blood group CD239 PDPU BRIC108 Mouse IgG2b 
1Protein Development and Production Unit (PDPU) of the International Blood Group Reference  
Laboratory, NHS Blood and Transplant, Filton, UK,  
2Cambridge, UK 
3Abingdon, UK 




2.4 Production of red cell-derived particles from cultured reticulocytes 
2.4.1 CD34+ progenitor cell isolation  
RCDP are produced from the maturation of the reticulocytes into RBC. To culture RCDP in vitro, 
CD34+ progenitor cells were isolated from whole blood and differentiated down the red cell lineage 
(see Fig. 1.2 from Introduction). Cells from apheresis cone filters or buffy coat packs were left to 
drain into a tube and then were diluted 1:1 in Hanks buffered salt solution (HBSS, Sigma-Aldrich) 
containing 0.6% (v/v) acid citrate dextrose (ACD, Sigma-Aldrich). The mononuclear cell (MNC) 
fraction was enriched using Ficoll-Hypaque (Sigma-Aldrich). Cells were re-suspended in 5ml red cell 
lysis buffer (RCLB, pH 7.5, containing 150mM ammonium chloride (Sigma-Aldrich), 1mM 
K2EDTA.2H2O (Sigma-Aldrich), 10mM KHCO3 (Sigma-Aldrich)) and incubated at room temperature 
for 10 minutes. HBSS/ACD was added up to 50ml and the cells washed twice at 200g for 10 minutes. 
Cells were re-suspended in 20ml of cold PBS buffer (1% (v/v) with 0.5% (w/v) human serum albumin 
(HSA, FUJIFILM Irvine Scientific, Newtownmountkennedy, Ireland) and 0.6% (v/v) citrate-
phosphate-dextrose (CPD, Sigma-Aldrich), counted using a haemocytometer and centrifuged at 
400g for 5 minutes. PBS buffer (500µl per maximum 1x109 cells) was added together with 75µl Fc 
blocking agent and 75µl MACS-CD34+ magnetic beads (both Miltenyi Biotec Ltd). Cells were mixed 
and incubated at 4°C for 30 minutes with gentle rotation on mixer, at an angle of approximately 30°. 
Afterwards, cells were washed in 5ml of cold PBS buffer/1x109 cells and centrifuged at 400g, for 5 
minutes. The supernatant, containing unbound beads, was discarded and the cell pellet was re-
suspended in 8ml of cold PBS buffer. 
To enrich for CD34+ cells, an LS MACS® column was placed in a magnet and washed in cold PBS 
buffer. Cells were applied to the LS column and washed in 8ml cold PBS buffer three times to remove 
the non-magnetically stained cells. The column was removed from the magnet and the retained 
CD34+ cells were flushed out using PBS buffer. In order to remove any smaller cells and particles, 
which potentially had not been washed off and remained adherent to the CD34+ cells, enriched cells 
were applied to an MS MACS® column, prepared as in LS column above. CD34+ cells were eluted 
and washed as described above for LS column and centrifuged at 400g, for 5 minutes. 
 
2.4.2 Ex vivo generation of reticulocytes from CD34+ cells  
CD34+ cells were resuspended at 12x105 per ml in Iscoves basal medium (Source BioScience, UK) 
containing 3% human serum from male AB Plasma (Sigma-Aldrich), 2mg/ml HSA, 10µg/ml Insulin 
(Sigma-Aldrich), 3U/ml heparin sodium salt (Sigma-Aldrich), 3U/ml EPO (Roche) and 500µg/ml Iron 
saturated human transferrin (R&D Systems). Cells were incubated at 37°C with 5%CO2. For days 0-
5, cells were maintained at a density of 2x105 cells/ml in the basal medium along with 10ng/ml 
recombinant human stem cell factor (SCF, Medsafe, Sweden) and 1ng/ml recombinant human IL-3 
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(R&D Systems) to expand the cells. Every day, cells were counted using a haemocytometer and 
sufficient media was added in order to gradually expand cells to 40x105 cells/ml up to day 20, when 
cells have usually enucleated. Cytospin preparations were used to check the morphology of the cells 
(see below paragraph), in order to ensure that reticulocytes had grown normally and that they have 
enucleated. Enucleated reticulocytes were leukofiltered using a leucoflex LXT filter (Macopharma, 
Twickenham, UK) and centrifuged at 600g for 5 minutes. The supernatant was discarded and the 
cell pellet was resuspended in HBSS and cells counted. Cells were then centrifuged at 600g for 5 
minutes and cultured for RCDP production.  
In order to assess reticulocyte morphology throughout maturation, the cells were suspended in 200μl 
HBSS at a concentration of 105cells/ml, loaded in a cytopsin funnel and centrifuged onto a slide at 
218g for 5 minutes. The slide was left to dry, then 90μl Leishman’s Staining Solution (VWR 
International, Lutterworth, UK) was added to the cell disc for 2 minutes, to stain the cells. Afterwards, 
180μl of 1x Sorenson’s buffer (dilution 1:20 of a 20x stock pH 6.8, 508ml 9.1g/l of KH2PO4 and 492ml 
9.5g/l of Na2HPO4) was added, mixed with the remaining Leishman’s buffer and left for 7 minutes. 
Slides were rinsed with 1x Sorenson’s buffer then immersed in 1x Sorenson’s buffer for 2 minutes, 
before being left to air dry. Images were taken using a Leica DM750 (Leica Microsystems, Milton 




2.4.3 Red cell-derived particle collection from cultured reticulocytes  
For the RCDP production, the media had to be cleared of all extracellular MP before the reticulocytes 
were suspended into it. Thus, 25ml Iscoves media were ultra-centrifuged at 200,000g for 2 hours at 
4ºC and then filtered through a 0.2μm filter and stored at 4ºC. Foetal bovine serum (FBS) has been 
found to contain MP and so was not used further in the cell expansion protocol (330). Reticulocytes 
were cultured at 5x106 cells/ml in ultra-centrifuged media at 37ºC with 5% CO2 for 96 hours. After 
this, the cells were counted and centrifuged twice at 400g for 5 minutes, the supernatant was 
collected and centrifuged, as above to remove any remaining cells. An Amicon filter (Sigma-Aldrich) 
was used to concentrate the vesicle media 10-fold, by centrifugation at 2,100g for 7 minutes. 





2.5 Isolation methods of red cell particles and autophagic vesicles from plasma 
2.5.1 Centrifugation 
Ultra-centrifugation 
One to two millilitres of plasma samples were diluted to 11.2ml with PBS supplemented with PMSF 
at a final concentration of 2mM. PBS/PMSF was previously filtered through a 3µm filter (Whatman 
International Ltd, Dassel, Germany). The diluted plasma was transferred into 11.2ml Optiseal tubes 
(Beckman Coulter, London, UK) and ultra-centrifuged in a fixed angle NVT65 rotor (Beckman 
Coulter) at 100,000g for 2h, at 4˚C. The pellet was resuspended in 100μl of filtered PBS/PMSF and 
stored at −80°C until further analysis. Repeat freeze‐thaw cycles were avoided. 
 
High-speed centrifugation 
One millilitre of previously separated PFP (see section 2.2) was centrifuged at 20,000g for 30 
minutes at 4˚C. Pellets were diluted in 100μl PBS with 0.2mM PMSF and stored at −80°C until further 
analysis. Repeat freeze‐thaw cycles were avoided. 
 
 
2.5.2 Immunomagnetic enrichment  
PFP was filtered through a 1.2μm polyethersulfone acrodisc filter (PALL Life Sciences, Farlinton, 
UK) to remove RBC ghosts and large particles. RCDP were enriched from SCD or healthy donor 
PFP using anti-CD235a (extracellular GPA) MicroBeads (Miltenyi Biotec Ltd) and AV were enriched 
using anti-Cy5/Alexa Fluor-647 MicroBeads (Miltenyi Biotec Ltd) in conjunction with BRIC155, 
BRIC163 or BRIC132 (see Table 2.1 and Fig. 2.1). Antibodies were filtered through a 15nm filter 
(Whatman International Ltd, Allington, UK) to remove aggregates. Microbeads (10μl) and, if 
appropriate, 5μg BRIC155, BRIC163 or BRIC132 were added to 500μl of PFP and incubated with 
rotation at 4˚C for 30 minutes. PFP and beads were passed through MS MACS® column, in a 
magnetic field, under gravity and collected in PBS buffer containing 0.5% (v/v) HSA and 0.6% (v/v) 





Figure 2.1 Schematic representation of red cell vesicle isolation. PFP was incubated with either 
anti-extracellular GPA MicroBeads for RCDP (left) or with antibodies detecting cytoplasmic domains 
of either band 3 (BRIC155, BRIC132) or GPA (BRIC163) conjugated to Alexa Fluor-647, along with 
anti- Alexa Fluor-647 MicroBeads for the AV enrichment (right). 
 
 
2.6 Flow cytometry  
In order to identify RCDP in plasma samples, several antibodies against abundant RBC proteins 
were used (Table 2.1) or 80μl of 0.22μm filtered annexin V binding buffer containing fluorescent 
annexin V (annexin-V-FLUOS Staining Kit, Sigma-Aldrich) detecting PS, or calcein AM (Tocris 
Bioscience, Abingdon, UK), a marker for intact cells. Twenty microlitre aliquots of plasma samples 
diluted in PBS buffer (1:5), containing 1% serum bovine albumin (BSA, Sigma-Aldrich) and 0.05% 
sodium azide (Sigma-Aldrich), were mixed with 20μl of antibody and incubated for 30 minutes in ice. 
For RBC, 1μl of packed RBC was diluted to 100μl in HBSS, then 20μl were stained with 20μl of 
antibody and incubated for 30 minutes at room temperature. RBC were washed in 1ml HBSS by 
centrifugation at 400g for 5 minutes, at room temperature, three times. The pellet was dissolved in 
100μl PBS buffer. The optimum concentration of the antibodies (Table 2.1) was initially identified by 
titration at a range of concentrations (0.156μg/ml - 10μg/ml) and the one giving the best staining 
without shifting the negative population into the positive range, as this indicates non-specific staining. 
PFP and RBC samples were then diluted to a final volume of 400μl in PBS buffer and analysed using 
a MACSQuant 10 flow cytometer (Miltenyi Biotec Ltd, Bisley UK). Data were analysed using FlowJo 
V10 software (BD Biosciences, Wokingham, UK). Plasma samples were plotted in forward-scatter 
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(FSC) vs side-scatter (SSC), in order to detect small RCDP, which have a similar size to instrument 
noise (Fig. 2.2A). FSC area (FSC A) that represents area vs FSC height (FSC H) maximum signal 
plot was used to separate individual events (singlets) from doublets (two stacked events that 
instrument records as one, Fig. 2.2B). An unlabelled sample, gated on singlets, was used to set the 
quadrants on the negative populations (Fig. 2.2C). These quadrants were applied to gated singlets 
of stained sample to determine the positive populations (Fig. 2.2D). The sensitivity was set based 
on diluent (PBS flow buffer) by acquiring some events, excluding the instrument noise and allowing 
small microparticles to be detected. Size estimation was carried out using commercially available 
size beads (Flow Cytometry Sub-micron Particle Size Reference Kit, Thermo Fisher Scientific). 
 
Figure 2.2 Flow cytometry gating strategy. PFP stained for extracellular (ex.) and cytoplasmic 
(cyt.) GPA. Plasma sample plotted (A) in FSC area (FSC A) vs SSC A of all events. (B) in FSC A vs 
FSC height (FSC H) in order to determine the singlet gate. (C) The gated singlets of unlabelled 
samples were used to set the quadrants on the unstained population (cyt.GPA- / ex.GPA-), which 
defined where the quadrants for the stained populations should be (cyt.GPA+ / ex.GPA-, cyt.GPA- / 
ex.GPA+, cyt.GPA+ / ex.GPA+). (D) Ex. and/or cyt. GPA populations on a stained sample.  
 
 
2.6.1 Negative control for flow cytometry 
HL-60 cells (ATCC® CCL-240™), human myeloblastic cells derived from a patient with acute 
promyelocytic leukaemia (331), were used as a negative control for the flow cytometry experiments, 
as they do not extrude reticulocytes-derived vesicles. HL-60 cells were suspended in Iscove’s basal 
medium with 10% FBS at 3 x 106 cells in 10ml, at 37ºC and 5% CO2. Cell numbers and viability were 






2.7 Imaging flow cytometry (ImageStream) 
PFP, RCDP and AV, enriched using immunomagnetic separation (described in section 2.5.2), were 
also analysed on Amnis ImageStream® X Mark II (Merck Millipore, Hertfordshire, UK), at Cardiff 
University. Twenty microlitres of sample were mixed with antibodies (Table 2.1) at optimum 
concentration or 80μl of 0.22μm filtered annexin V binding buffer containing fluorescent annexin V, 
or 50μΜ calcein AM and placed on ice. The samples were analysed upon arrival in Cardiff. Data 
were analysed using Ideas software (Merck Millipore). The calibration programme of the 
ImageSteam uses “speed beads” that scatter the signal to monitor the samples during acquisition. 
These were excluded from analysis by creating a plot of scatter intensity vs scatter max pixel, since 
the speed beads had a higher scatter than other particles detected (Fig. 2.3A). The resulting 
population was split on the basis of size on SSC scatter into low scatter for small RCDP (Fig. 2.3B) 
and high scatter for large particles (Fig. 2.3C). Histograms of brightfield area of the respective RCDP 
were set up using normalised frequency vs area scatter plot, to exclude large area events and small 
area events from the “low scatter” and “high scatter” populations, respectively. This is because the 
smallest particle that can be confidently measured on brightfield at 60x magnification is 0.5μm, so it 
was used to remove large aggregates that may have a low scatter. Scatter plots were created using 
the “low scatter-low area” gate, showing low scatter events (Fig. 2.3D) and the “high scatter-high 
area” gate, representing high scatter events (Fig. 2.3E). Similarly to flow cytometric analyses, gates 
were set on Alexa Fluor 488 versus Alexa Fluor 647 based on unstained samples (Fig. 2.3 Di & Ei), 
to identify populations on stained samples (Fig. 2.3 Dii & Eii). Random individual events from the 
gated populations in each quadrant were observed in the image gallery of the software to confirm 
that the gates were placed accordingly. Counts were used from the stained samples (Fig. 2.3 Dii & 
Eii) to obtain the absolute number of “high scatter” and “low scatter” events/ml that were positive for 




Figure 2.3 ImageStream gating strategy. PFP was stained with fluorescent antibodies. (A) Scatter 
intensity was plotted against Scatter Max Pixel and gates were drawn to exclude speed beads 
(green) and select low scatter (blue) and high scatter (yellow) events. Low scatter events (B) and 
high scatter events (C) were plotted in a histogram of brightfield area. Scatter plots of Alexa Fluor 
488 and Alexa Fluor 647 intensity were created for low scatter and low area events- small (D) and 
high scatter & high area events- large (E). Unlabelled samples (Di & Ei) were used to set the gates 






2.8 Fluorescence activated cell sorting (FACS) 
In order to isolate RCDP, 100μl PFP were stained with anti-extracellular GPA and sorted using a BD 
Influx high speed fluorescence activated cell sorter (BD Biosciences). Gates for GPA+ populations 
(Fig. 2.4) were set based on the unstained population of the whole sample, as it was previously 
shown for flow cytometry (see section 2.6, Fig. 2.2). The GPA+ RCDP were gated and collected in 
50μl PBS. Excess sorted RCDP were stored at -80ºC in 500μl aliquots. 
 
 
2.9 Microscopy techniques 
2.9.1 Confocal microscopy 
Two hundred microlitres of poly-L-lysine 0.1% (Sigma-Aldrich) was used to keep sorted GPA+ RCDP 
immotile on the microscopy slides. Three conditions were tested: prior to addition of 20μl RCDP, 
poly-L-lysine was left to settle (i) 30 minutes, (ii) overnight at 4˚C or (iii) poly-L-lysine along with 
RCDP were left overnight at 4˚C to settle. Non adherent poly-L-lysine was washed off the slides with 
200μl PBS, twice. Samples were imaged either on a Leica DMI 6000 inverted microscope with phase 
contrast connected to a Leica TCS SP5 confocal imaging system, or on a Leica SP8 Inverted 
Confocal Microscope System with a LAS X 3D Visualisation operating system. Images were obtained 
using Leica LAS AF software and subsequently processed using Adobe Photoshop (Adobe).  
 
2.9.2 Spinning-disk confocal microscopy 
Twenty microlitres of poly-L-lysine 0.1% (Sigma-Aldrich) was used in each well of a 96well plate 
(Greiner Bio-One Ltd, Stonehouse, UK), to keep sorted RCDP or GPA stained RBC (as described 
in section 2.6) as immotile as possible. The plate was centrifuged at 2,500g for 10 minutes to assist 
the poly-L-lysine adherence, it was washed twice in PBS buffer and 20μl of sorted RCDP were 
added. The plate was centrifuged again, to ensure RCDP adhered. RCDP were examined using an 
Opera LX HCS spinning-disk confocal system (Perkin Elmer) with a 60x (NA 1.2) water-immersion 
lens and Acapella analysis software. The digital images were visualised by ImageJ. The size and 
shape of RCDP were analysed using a custom MATLAB script developed by the Wolfson Bioimaging 
Facility, University of Bristol. The script uses a built-in circular Hough transform in XY axes to detect 
particles. The 3D shape was determined by fitting an active contour to the radial average of the 
image, centred on Z-axis of each particle. The Hough transform tool is selective for objects with a 




Figure 2.4 Detecting circular objects using spinning disk confocal. (A) Digital image of the 
detected particles, the approved round ones are circled in red. (B) Individual images of selected 
detected particles. Particles on the upper panel were found to be non-circular and were excluded 
from diameter measurement. The lower images were confirmed to be circular and were included in 
the measurement. Image was obtained using a 60x water-immersion lens.     
 
 
2.9.3 Transmission electron microscopy and immunolabelling  
Three microlitres of enriched right-side RCDP or inside-out AV were placed on a carbon coated 
copper grid, left to dry, then fixed in 4% (v/v) paraformaldehyde (Sigma-Aldrich) with 0.05% (v/v) 
glutaraldehyde (Agar Scientific, London, UK) at room temperature for 30 minutes. RCDP or AV were 
washed in PBS, quenched in 20mM glycine (Thermo Fisher Scientific) for 10 minutes and incubated 
with 1% acetylated BSA (Aurion, Wageningen, The Netherlands) in PBS for 10 minutes to block non-
specific binding. Grids containing RCDP were placed in R10, which detects extracellular GPA and 
those containing AV were stained with BRAC66 to cytoplasmic band 3, for 1 hour at room 
temperature, then washed in 0.1% BSA/PBS. Aurion conventional gold reagents (particle size 10 
nm) were added to the grids. Anti-mouse gold particles detecting the mouse antibody (R10) were 
used for right side-out RCDP and anti-rat gold particles against the rat antibody (BRAC66) were 
used for inside-out AV. Unbound gold was removed by washing in 0.1% BSA/PBS. Grids were 
counterstained with a solution of 0.3% (w/v) uranyl acetate (Electron Microscopy Sciences, Hatfield, 
UK) in 1.8% methylcellulose (Sigma-Aldrich) for 10 minutes on ice then air-dried using the wire loop 
method. Grids were examined on a Tecnai12 120 kV BioTwin Spirit transmission electron 
microscope (FEI Company, Eindhoven, The Netherlands) and visualised using a FEI CETA camera 
and TIA software.  
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2.9.4 Super-resolution microscopy 
One hundred microlitres of poly-L-lysine 0.1% were added to a slide and left overnight at 4˚C. Then, 
excess poly-L-lysine was washed off using HBSS, twice. Twenty microlitres of SV (section 2.2.3) 
were incubated with 1μl of neat antibody against the extracellular domain of GPA (BRIC256- Alexa 
Fluor 647) and band 3 (BRIC200- Alexa Fluor 488) for 30 minutes at room temperature. Unbound 
antibody was removed by washing in HBSS with 0.5% (w/v) HAS, twice and SV were added to the 
slide and left for 4 hours to settle. Samples were imaged on a Zeiss LSM 800 Airyscan (Zeiss, 
Cambridge, UK) compact confocal laser scanning microscope. Images were processed using ZEN 
Blue (Zeiss).  
 
2.10 Dynamic Light Scattering 
Particle size measurements of enriched RCDP, AV and SV were carried out by dynamic light 
scattering (DLS) using a Malvern Nano ZSP Zetasizer (Malvern Instruments Ltd, Worcestershire 
UK). Samples were diluted 1:1 in PBS and size was defined at 10°C with minimum equilibration time 
of 5 minutes. Measurements on each sample were carried out 15 times comprising a set. 
 
 
2.11 Protein determination of enriched red cell particles and autophagic vesicles 
2.11.1 Protein lysate preparation  
RCDP and AV were put on ice and ice-cold 10X radioimmunoprecipitation assay (RIPA) buffer 
(Abcam), protease inhibitor (1X) and PMSF (2mM) were added then left for 15 minutes. Lysates 
were mechanically forced using a 1ml syringe, or sonicated for 3 seconds at 60% power, 3 times, in 
order to break any protein interactions. Then, they were centrifuged for 5 minutes at 17,000g at 4°C 
to pellet cell debris and insoluble proteins. Supernatants were transferred into new tubes on ice in 
preparation for protein assay and precipitation.  
 
2.11.2 Bradford assay 
One hundred microlitres RCDP or RBC ghost preparations were added to 400µl PBS, then made up 
to 1ml with Bradford reagent. Seven BSA standards (Sigma-Aldrich) were prepared in Bradford 
reagent (Sigma-Aldrich) in concentrations between 0-0.015mg/ml. Standards and samples were 
kept in the dark and on ice during the preparation and incubated at room temperature for 5 minutes 
before the measurement. Triplicate measurements of each standard/ sample were taken using a 
Benchmark Plus Microplate Spectrophotometer (Biorad Laboratories Ltd, Watford, UK) at 595 nm. 
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The absorbance values of the BSA standards were plotted and the concentration of the samples 
were calculated from the resulting equation. 
 
2.11.3 Bicinchoninic acid assay 
Pierce™ BCA Protein Assay Kit -Reducing Agent Compatible kit was used (Thermo Fisher Scientific) 
and the manufacturer’s protocol was followed. In brief, 25μl of the lysates and protein BSA standards 
(provided in the kit) were mixed with equal volumes of Compatibility Reagent Stock Solution 
(provided in the kit) and incubated at 37°C for 15 minutes in a water bath. One millilitre of the working 
agent (provided in the kit) was added to each sample/standard and they were incubated for 30 
minutes at 37°C. Samples and standards were let to cool down and triplicate measurements using 
a Benchmark Plus Microplate Spectrophotometer at 562 nm were taken, as mentioned in the 
Bradford assay method above. 
 
2.11.4 Protein precipitation 
Six volumes of chilled acetone (-20°C) were added to one volume of lysates. Samples were left 
overnight at -20°C to precipitate protein then centrifuged for 10 minutes 8,000g at 4°C. Supernatants 
were removed and the precipitant protein was air dried for 20 minutes at room temperature. Dry 
pellets were dissolved in 20μl of 200nM triethyl ammonium bicarbonate (TEAB, Thermo Fisher 
Scientific). Protein concentrations were determined with a Nanodrop Lite spectrophotometer 
(Thermo Fisher Scientific), using 200nM TEAB as a blank. Lysates were stored at -80˚C for 
subsequent analysis by immunoblotting or mass spectrometry. 
 
2.11.5 SDS-PAGE and protein staining 
In order to visualise the total amount of protein in enriched RCDP in early experiments, NuPAGE 4-
12% Bis-Tris Protein Gel (Biorad Laboratories Ltd) was used and covered in 1x running buffer, which 
was made by diluting a 10x running buffer [25mM Tris base (Sigma-Aldrich), 192mM glycine (Severn 
Biotech Ltd), 0.1% Sodium dodecyl sulfate (SDS, Thermo Fischer Scientific), pH 8.3] to 1x with 
water. Lysates were prepared by diluting different volumes of enriched RCDP (1-10μl) and 
immunomagnetic beads were used for the RCDP isolation with equal volume of 2x SDS sample 
buffer [125mM Tris-HCl, 20% (v/v) glycerol (Thermo Fischer Scientific), 4% (w/v) SDS], 2mM 
ethylenediaminetetraacetic acid (EDTA, Sigma-Aldrich), bromophenol blue 0.1mg/ml and 0.1mg/ml 
xylene cyanol, along with 2mM PMSF and 50mM diothiothreitol (DTT, Sigma-Aldrich). Samples were 
boiled for 45 seconds to fully denaturate the proteins and break the disulphide bonds. SDS was used 
to unfold the proteins and ensure all proteins are negatively charged and so will be separated 
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according to their molecular weight. DTT is a reducing agent that eliminates disulphide bridges. The 
protein markers used were Prosieve Pres ladder (Thermo Fisher Scientific) or MagicMarkerTM 
WesternSure Pre-stained (Life Technologies, Warrington, UK). After electrophoresis, the gel was 
stained with 35ml of GelCode™ Blue Stain Reagent (Thermo Fisher Scientific) for 20 minutes at 
room temperature. This is a Coomassie-based stain, which binds only to proteins and stains them 
blue. Then, the gel was washed three times with distilled water at room temperature and digital 
images were captured using an Odyssey® Fc (LI-COR Biosciences UK Ltd, Cambridge, UK). The 
band of interest was cut and sent for protein identification by mass spectrometry (section 2.12.1). 
 
2.11.6 SDS-PAGE and immunoblotting 
In order to detect band 3 (90-100,000kDa) and GPA (43,000kDa) from precipitated lysates on the 
same gel, a commercial 10% Mini-PROTEAN® TGX Stain-Free™ Protein Gel (Biorad Laboratories 
Ltd) was used. Samples were prepared by mixing 20μg protein with equal volume of 2x SDS sample 
buffer and the gel was run under the same conditions as described in 2.11.5. When electrophoresis 
finished, samples were transferred in a semi-dry transfer system using blotting apparatus on a PVDF 
membrane (Merck Millipore), pre-soaked in methanol (Fisher Scientific), to activate the PVDF. The 
membrane was then blocked in 5% (w/v) BSA in PBS (blocking buffer) overnight, to block non-
specific protein binding sites. After incubation for 1 hour at room temperature with the biotinylated 
primary antibody (anti-GPA or anti-band 3 or anti-stomatin, see Table 2.1) diluted in blocking buffer, 
the membrane was washed in PBS-Tween 20 [0.05% Tween 20 (Sigma-Aldrich) in PBS]. Then, the 
membrane was incubated with the respective secondary antibody (see Table 2.1) diluted in blocking 
buffer for 1 hour at room temperature, then was washed in PBS Tween. Chemiluminescent detection 
was carried out using ECL Plus reagent (Western Lightning; PerkinElmer, Beaconsfield, UK) and 
visualised in Odyssey® Fc. 
 
2.12 Mass spectrometry 
2.12.1 Mass spectrometry of proteins from gel bands 
The gel band of interest (section 2.11.5) was subjected to in-gel tryptic digestion using a DigestPro 
automated digestion unit (INTAVIS Bioanalytical Instruments AG, Cologne Germany). The resulting 
peptides were fractionated using an Ultimate 3000 nano-LC system in line with an LTQ-Orbitrap 
Velos mass spectrometer (Thermo Fisher Scientific). In brief, peptides in 1% (vol/vol) formic acid 
were injected onto an Acclaim PepMap C18 nano-trap column (Thermo Fisher Scientific). After 
washing with 0.5% (vol/vol) acetonitrile 0.1% (vol/vol) formic acid peptides were resolved on a 
250mm x 75μm Acclaim PepMap C18 reverse phase analytical column (Thermo Fisher Scientific) 
over an 80 minutes organic gradient, (1-50% solvent B over 55 minutes, 50-90% B over 0.5 minutes, 
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held at 90% B for 5 minutes and then reduced to 1% B over 0.5 minutes) with a flow rate of 300nl 
min−1. Solvent A was 0.1% formic acid and Solvent B was aqueous 80% acetonitrile in 0.1% formic 
acid. Peptides were ionized by nano-electrospray ionization at 2.1kV using a stainless-steel emitter 
with an internal diameter of 30μm (Thermo Fisher Scientific) and a capillary temperature of 250°C. 
Tandem mass spectra were acquired using an LTQ- Orbitrap Velos mass spectrometer controlled 
by Xcalibur 2.1 software (Thermo Fisher Scientific) and operated in data-dependent acquisition 
mode. The Orbitrap was set to analyze the survey scans at 60,000 resolution (at m/z 400) in the 
mass range m/z 300 to 2,000 and the top twenty multiply charged ions in each duty cycle selected 
for MS/MS in the LTQ linear ion trap. Charge state filtering, where unassigned precursor ions were 
not selected for fragmentation, and dynamic exclusion (repeat count, 1; repeat duration, 30seconds; 
exclusion list size, 500) were used. Fragmentation conditions in the LTQ were as follows: normalized 
collision energy, 40%; activation q, 0.25; activation time 10 minutes; and minimum ion selection 
intensity, 500 counts. 
The raw data files were processed and quantified using Proteome Discoverer software v1.4 (Thermo 
Fisher Scientific) and searched against the UniProt Human database (downloaded September 2017: 
140000 sequences) using the SEQUEST algorithm. Peptide precursor mass tolerance was set at 
10ppm, and MS/MS tolerance was set at 0.8Da. Search criteria included carbamidomethylation of 
cysteine (+57.0214) as a fixed modification and oxidation of methionine (+15.9949) as a variable 
modification. Searches were performed with full tryptic digestion and a maximum of 2 missed 
cleavage sites were allowed. The reverse database search option was enabled and all peptide data 
was filtered to satisfy a false discovery rate (FDR) of 1%.   
 
2.12.2 Nano- Liquid Chromatography Mass Spectrometry 
Precipitated lysates (100µg, section 2.11.4) were resuspended into 100 mM TEAB and digested with 
2.5µg trypsin (Thermo Fisher Scientific) at 37°C overnight. Samples were desalted using a SepPak 
cartridge, according to the manufacturer’s instructions (Waters, Milford, Massachusetts, USA). 
Eluate from the SepPak cartridge was evaporated to dryness and resuspended in 1% formic acid 
prior to analysis by nano-LC MSMS using an Orbitrap Fusion Tribrid mass spectrometer (Thermo 
Fisher Scientific). For total proteome analysis, peptides were fractionated using an Ultimate 3000 
nano-LC system in line with an Orbitrap Fusion Tribrid mass spectrometer (Thermo Fisher Scientific). 
In brief, peptides in 1% (vol/vol) formic acid were injected onto an Acclaim PepMap C18 nano-trap 
column (Thermo Fisher Scientific). After washing with 0.5% (vol/vol) acetonitrile 0.1% (vol/vol) formic 
acid peptides were resolved on a 250mm × 75μm Acclaim PepMap C18 reverse phase analytical 
column (Thermo Fisher Scientific) over an organic gradient for 150 minutes, using 7 gradient 
segments (1-6% solvent B over 1 minute, 6-15% B over 58 minutes, 15-32%B over 58 minutes, 32-
40%B over 5 minutes, 40-90%B over 1 minute, held at 90%B for 6 minutes and then reduced to 
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1%B over 1 minute) with a flow rate of 300nl minutes−1. Solvent A was 0.1% formic acid and Solvent 
B was aqueous 80% acetonitrile in 0.1% formic acid. Peptides were ionized by nano-electrospray 
ionization at 2.2 kV using a stainless-steel emitter with an internal diameter of 30μm (Thermo Fisher 
Scientific) and a capillary temperature of 250°C.  
All spectra were acquired using an Orbitrap Fusion Tribrid mass spectrometer controlled by Xcalibur 
2.1 software (Thermo Fisher Scientific) and operated in data-dependent acquisition mode. FTMS1 
spectra were collected at a resolution of 120,000 over a scan range (m/z) of 350-1,550, with an 
automatic gain control (AGC) target of 400,000 and a max injection time of 100ms. Precursors were 
filtered according to charge state (to include charge states 2-7), with monoisotopic peak 
determination set to peptide and using an intensity range from 5E3 to 1E20. Previously, interrogated 
precursors were excluded using a dynamic window (40s +/-10ppm). The MS2 precursors were 
isolated with a quadrupole mass filter set to a width of 1.6m/z. ITMS2 spectra were collected with an 
AGC target of 5000, max injection time of 50ms and HCD collision energy of 35%. 
 
2.12.3 Data Analysis 
The raw data files were processed and quantified using Proteome Discoverer software v2.1 (Thermo 
Fisher Scientific) and searched against the UniProt Human database using the SEQUEST HT 
algorithm. Peptide precursor mass tolerance was set at 10ppm, and MS/MS tolerance was set at 
0.6Da. Search criteria included oxidation of methionine (+15.995Da), acetylation of the protein N-
terminus (+42.011Da) and Methionine loss plus acetylation of the protein N-terminus (-89.03Da). 
Searches were performed with full tryptic digestion and a maximum of 2 missed cleavage sites were 
allowed. The reverse database search option was enabled and all data was filtered to satisfy a false 
discovery rate (FDR) of 5%.     
 
2.13 In vivo studies 
2.13.1 Animals and study protocol 
Six week old Balb/c mice were purchased from Charles River and maintained in conventional open 
cages at ambient temperature, at the University of Bristol, Animal Services Unit. On day 0 separate 
groups of mice were primed subcutaneously either with 104-106 RBC ghost membranes or 106 SV 
and HBSS (control mice) 1:1 in Complete Freund’s adjuvant (CFA, BD Difco- Fisher Scientific) 
subcutaneously (Fig. 2.5A). Five to ten microlitres of peripheral blood were aspirated from the lateral 
tail vein every 7 days to assess immune response by serology (see section 2.13.4). Fourteen days 
(d14) after the first inoculation, if no immune response was detected, mice were given a boost of 
ghost membranes or SV, at the same dose as the initial inoculum and left for two weeks (Fig. 2.5B 
above), whereas if mice showed an immune response, they were left for 1 week (Fig. 2.5B below). 
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Then, test animals and controls were challenged with human RBC (day 28 for mice given a boost 
and day 21 for those that did not), at the same dose as the initial inoculum (Fig. 2.5C). These RBC 
were from the same donor used to prime the animals. Later in the experiments, mice were challenged 
again 2 weeks later (Fig. 2.5D), terminated 2 weeks after the final RBC challenge and 
exsanguinated, by cardiac puncture under anaesthesia with isoflurane (Fig 2.5.E). Cardiac blood 
and spleens were collected for further analyses. 
 
 
Figure 2.5 Schematic representation of immunotolerance experiments. (A) Mice were 
inoculated with HBSS (control) or RBC ghosts or SV and left to develop an immune response until 
day 14. (B) If no immune response was detected (above), mice were given a boost of the same 
source used to prime the mice and left for 2 weeks. If an immune response was observed, mice were 
left for 1 week (below). (C) Mice that had developed an immune response along with control mice 
were challenged with human RBC, from the same donor as the initial inoculum on day 21 (below) or 
on day 28 if they were given a boost (above). (D) Two weeks later, mice were challenged again with 
the same RBC. (E) Mice were culled 2 weeks later.  
 
 
2.13.2 Processing mouse cardiac blood 
Cardiac blood from mice was centrifuged at 2,000g for 15 minutes and pelleted RBC and plasma 
from the top layer of the supernatant were separated. Plasma was either assayed immediately for 
cytokine content and serology or stored at -20˚C. RBC were added to Alsever’s in the same volume 




2.13.3 Mononuclear cell isolation from spleens   
Spleens were excised and kept in Iscove's Modified Dulbecco's Medium (IMDM, Invitrogen, Thermo 
Fisher Scientific) with 50% FBS (Thermo Fisher Scientific) at 4˚C for a maximum of 24 hours. 
Spleens were ground by using a syringe plunger on a 70μm filter (Miltenyi Biotec Ltd) and cells were 
washed in 10ml IMDM, then centrifuged at 350g for 5 minutes. Pellets were dissolved in 1ml of HBSS 
buffer and MNC were separated via density gradient centrifugation using Ficoll-Hypaque at 450g for 
20 minutes. The MNC layer was collected in 1ml HBSS and centrifuged at 1,000g for 5 minutes. 
Pellets were suspended in 90% FBS and 10% dimethyl sulfoxide (DMSO, Origen Biomedical, 
Solihull, UK) and stored in liquid nitrogen prior to use. 
 
 
2.13.4 Assessment of immune reactions 
To assess immune reactions generated by the mice, a gel agglutination assay was used (Bio-Rad 
Laboratories). The gel card is designed for identification of paroxysmal nocturnal haemoglobinuria, 
however, the gel contains rabbit antiserum against mouse immunoglobulins which will bind mouse 
antibodies. Gel in the microtubes acts as a filter and retains any agglutinated cells carrying mouse 
antibodies in the upper part of the microtube (positive result, Fig. 2.6 right), while cells that do not 
express mouse proteins will settle to the bottom of the tube (Fig. 2.6 left). Three human reference 
RBC (cell screens in Alsever’s, NHSBT) ABO O RhD positive, designed for identification of minor 
antigens, such as Lub, Fy and Jk, were used as reference controls and added to the first three tubes. 
Human RBC were the actual test (4th tube), investigating whether ghost membranes or SV from the 
same donor generated an immune response and murine packed RBC (m-RBC) were used as a 
negative control (5th tube). One hundred microlitres of murine and donor RBC were washed 5 times 
in PBS at 1,000g for 45 seconds and 3 human reference RBC were washed once, as they were 
cleaner due to storage in Alsever’s. All cells were then washed once in modified low ionic strength 
saline (LISS, Source BioScience, Nottingham, UK) followed by 1 wash in ID- Diluent 2 (Biorad 
Laboratories Ltd) and a red cell solution (0.8%) was prepared for human and murine red cells. Then, 
50μl of 0.8% RBC were added to each microtube of the gel card, along with 25μl of mouse antibody 
against human Lub (positive control, see BRIC108 on Table 1), or mouse plasma previously 
centrifuged at 1,660g for 45 seconds. When assessing aspirates at days 14-21, half the volumes 
were used: 25μl of 0.8% RBC with 12.5μl antibody or plasma. Samples were incubated for 15 
minutes at 37˚C to assist antibody binding and the gel card was centrifuged for 10 minutes in an ID-
centrifuge (Biorad Laboratories Ltd). To compare antibody levels between different groups of 





Figure 2.6 Mouse antibody screen test using a gel card. RBC (0.8%) from human standards, 
human donor and mouse RBC were added along with mouse plasma (first 5 tubes) or anti- mouse 
Lub (tube 6). (Left: No agglutination - negative test representation; all human RBC sink to the bottom 
apart from the positive control (tube 6). Right: RBC agglutination of all human RBC -positive test 




2.13.5 Cytokine assay 
The Proteome Profiler Mouse Cytokine Array Kit, Panel A (R&D Systems) was used to identify 
selected cytokine and chemokine responses to SV and ghosts preparations. Cardiac mouse blood 
was centrifuged at 2,000g for 15 minutes within 2 hours of collection. One hundred microlitres of 
plasma was added to 500μm Array buffer 4, topped up to 1.5 ml with Array buffer 6, which is a 
blocking buffer, and then 15μl of reconstituted Mouse Cytokine Array Panel A Detection Antibody 
Cocktail (all provided in the kit) was added and incubated for an hour at room temperature. Plasma 
and Antibody Cocktail mix were added to a provided membrane, which was pre-soaked in Array 
buffer 6, and incubated on a rotor overnight at 4˚C. Then the membrane was washed, probed with 
HRP streptavidin, provided in the kit and then exposed on X-ray film. 
 
2.14 Statistical analyses 
Data represent results from at least 3 independent experiments, unless otherwise stated. Statistical 
analyses were performed using nonparametric ANOVA using Kruskal-Wallis test for groups>3, 
whereas 2 groups were compared using non parametric t-test in Prism 8 (Graphpad, San Diego, 
USA), unless otherwise stated. P values < 0.05 were considered significant. Results are reported as 
mean ± standard deviation (SD) unless otherwise stated. Significant results are designated by 
asterisks on graphs. 
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  Identification of red cell-derived particles and autophagic vesicles  
3.1 Introduction  
In patients with SCD, deformed cells can block blood vessels and cause vaso-occlusion, severe 
pain, known as crisis, infections, anaemia and stroke. The spleen, which clears senescent cells and 
extracellular vesicles, is frequently damaged in SCD patients, resulting in significantly higher 
numbers of RCDP in the plasma. These RCDP expose PS and were originally reported using flow 
cytometric analyses (255, 269, 332). PS is well known to cause hypercoagulation in SCD (333). 
RCDP in SCD are thought to be produced through membrane budding as a result of repeated 
erythrocyte sickling. In physiological conditions, RCDP are produced by membrane budding when 
reticulocytes form mature RBC. Thus, they are right-side out and expose the extracellular domains 
of the proteins present on the RBC membrane. Our colleagues identified a type of autophagic 
exosome in SCD and in media from cultured reticulocytes (CR media) using confocal microscopy. 
These AV exposed PS and cytoplasmic protein domains, therefore, they have an inside-out 
orientation (123, 127, 334) (see Chapter 1, Fig. 1.6).  
The different characteristics and role of RCDP and AV in normal and pathological conditions have 
not been fully investigated. PS exposure on RCDP and AV in SCD suggests potential contributions 
to hypercoagulation. In addition, the fact that higher levels of RCDP have been reported in SCD 
patients, could be an indicator of the severity of the disease. SCD plasma was used in order to detect 
and isolate these populations using several methods. Additionally, CR media from cultured 
reticulocytes, using a well-established protocol (123, 334), was assessed for RCDP and AV using 
flow cytometry and different microscopy methods. This would potentially enhance our knowledge of 
reticulocyte maturation in culture. RCDP from SCD PFP and CR media were characterised by flow 
cytometry and then isolated by FACS. Confocal microscopy, DLS and imaging flow cytometry were 
used to assess morphology of sorted and unsorted populations, while protein content was assessed 
by Bradford assay. SV of predetermined size were used as controls (Fig. 3.1). 
 
Figure 3.1 Schematic of the analytical methods for vesicle characterisation in CR media and 




3.2 Assessment of reticulocyte morphology  
In order to characterise RCDP from ex vivo expanded reticulocytes, CD34+ cells were isolated and 
grown under appropriate conditions to produce enucleated reticulocytes (123, 334). The morphology 
of the cultured cells was checked frequently throughout the maturation of the polychromatic (day 11-
16) to orthochromatic blasts (day 15-19). When most reticulocytes were enucleated (day 20), 
leukocyte filtration was used to isolate enucleated reticulocytes from free nuclei and immature 
reticulocytes (Fig. 3.2). Mature reticulocytes were cultured for a further 96h and RCDP produced 
were isolated and analysed for RBC protein content.    
Figure 3.2 Morphology of reticulocytes during their maturation. (A) Light microscope images 
acquired. Reticulocytes appear in grey. At day 12 (left image), immature reticulocytes containing 
dark round purple nuclei (polychromatic blasts) are shown by white arrows, orthochromatic blasts 
with smaller size nuclei (in dark blue) are shown by yellow arrows and cells expelling nuclei are 
shown by red arrows. At day 17 (middle image), most nuclei have reduced in size (orthochromatic 
blasts showed by yellow arrows). Enucleated reticulocytes can be seen (blue arrows), as well as 
reticulocytes ready to expel their nuclei (red arrows). At day 20 (right image) after leukocyte filtration, 
a homogeneous population of enucleated reticulocytes remains. Scale bars indicate 20μm. (B) Cell 
counts of 20 fields per coverslip at different stages in three different cultures. Data represent mean 
± SD. Numbers for day 20 are before leukocyte filtration. 
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3.3 Identification of red cell-derived particles and autophagic vesicles 
3.3.1 Optimising flow cytometry analysis 
Flow cytometry is routinely used for RCDP detection and has revealed that numbers of RCDP are 
higher in SCD patients than healthy individuals (255, 269, 332). Usually, an antibody targeting the 
extracellular (ex.) domain of GPA is used to detect RCDP. Colleagues have demonstrated the 
extrusion of AV from CR media by confocal microscopy using BRIC163 antibody, which detects a 
cytoplasmic (cyt.) epitope of GPA. This suggested that such AV have an inside-out orientation of the 
membrane (123, 127, 334). In order to detect RCDP and AV, different antibodies recognising 
extracellular and cytoplasmic domains of abundant proteins expressed on RBC (GPC, band 3 and 
GLUT1) were incubated with PFP from SCD patients or CR media and analysed by flow cytometry.  
 
3.3.1.1 Antibody titration 
Typically, antibody titrations using flow cytometry are carried out to determine the antibody 
concentration that will show the maximum stained population without shifting the negative population 
into the positive range (see Flow-cytometry in Chapter 2.6), as this indicates non-specific staining. 
All antibodies used for flow cytometry were titrated in equal volumes of CR media or SCD PFP, as 
described in the methods (Chapter 2.6). The titrated antibody concentration in the stained samples 
ranged from 0.156 to 5μg/ml and for most antibodies the optimum concentration was between 0.156-
0.625μg/ml. When higher concentrations (10μg/ml) were tested, non-specific staining was observed 
since most of the populations appeared positive and shifted to the right (see following section), 
indicating that antibody concentration was too high. During all antibody titrations and flow cytometry 
experiments, the diluent (PBS buffer) was stained with the same antibody concentration as the 
sample and any fluorescence observed in the buffer was subtracted from the stained samples. 
RCDP from CR media were a homogeneous population and the optimum antibody concentrations 
were easier to determine. For most antibodies tested, the optimum concentration was 0.625μg/ml, 
apart from ex. GPA (clone BRIC256), which was 0.312μg/ml. On the other hand, the first experiments 
in SCD PFP samples, showed many events that were difficult to distinguish in the stained and the 
unstained subpopulations. Additionally, variability was observed in the scatter characteristics (FSC 
for size and SSC for granularity) among different patients. In order to get a better defined RDCP 
population and check the antibody specificity, different conditions were tried: (i) diluting SCD PFP, 







i) Dilution of plasma 
SCD plasma was diluted 1:1, 1:2 and 1:5 in PBS buffer (Chapter 2.6) in order to dilute the cellular 
debris and permit better discrimination. The antibody used for this work recognised the ex. GPA, one 
of the most abundant proteins in human erythrocytes. The discrimination of positively stained and 
the negative populations in PFP diluted 1:5 was better than undiluted PFP and all other dilutions 
tested (Fig. 3.3). The antibody concertation used ranged from 0.156 to 5μg/ml and serial half dilutions 
of ex. GPA were carried out. The optimum concentration was 1.25μg/ml. Subsequently, SCD PFP 
was diluted only in 1:5 when used in flow cytometry experiments and all the antibodies were titrated 
in this plasma dilution. The optimum concentration for each antibody is summarised in Table 3.1, at 
the end of this subsection. 
 
 
Figure 3.3 Antibody titration in plasma. Ex. anti-GPA-AlexaFluor 488 titrations of undiluted (upper 
panel) and diluted SCD PFP 1:5 (lower panel) using concentrations 0.156-5μg/ml. Left and right 
gates in each plot represent the negative and the positive populations, respectively. The gates were 
set based on unlabelled samples (left column). PFP samples were from the same patient.  
 
 
ii) Negative control 
HL-60 cells were chosen as a negative control because they do not expose RBC proteins, so no 
positive population was expected. HL-60 cells were analysed under the same experimental 
conditions as the SCD PFP samples and CR media. The results showed that these cells did not 







(iii) Alternative negative control 
Despite having HL-60 cells as a negative control, introducing an isotype control would be beneficial 
since some of the populations were still not distinct. Isotypes are produced in a similar manner to 
the antibody of interest but they target a different epitope, showing that the tested antibody is specific. 
As the antibodies were conjugated to AlexaFluor (AF) 488 or 647 (described in Chapter 2.6), a similar 
antibody to be used as an isotype control was not available. As an alternative to confirm antibody 
specificity and that the concentrations used were appropriate, plasma from murine blood was used, 
mixed in different ratios with SCD PFP and serial half titrations were repeated. Further diluting the 
human SCD PFP with a known negative cell population should allow the best antibody dilution to be 
determined, in order to get better discrimination.  
Ex. anti-GPA was found to be human specific, since only human RCDP were stained (Fig. 3.4). Also, 
when human and mouse plasma were used at ratios of 9:1 and 7.5:2.5, the GPA+ populations were 
more distinct and better discriminated. Again, non-specific staining was observed upon incubation 
with higher concentrations of the antibody. The optimum concentration was 0.625μg/ml. These 
results indicated that better discrimination of the stained populations was obtained in further diluted 
SCD PFP samples using a negative population, providing confidence that the antibody staining 
works better with diluted SCD PFP. 
 
Figure 3.4 Use of mouse plasma as an alternative control in antibody titration, in SCD plasma. 
Histograms of antibody titrated in pure SCD PFP diluted 1:5 in PBS (upper panel), mouse plasma 
(middle panel) or PFP mixed with mouse plasma 9/1 and 7.5/2.5. Gates were set based on the 




At the end of the experiments, 2 ideal concentrations were obtained from each antibody titration 
using 2 SCD PFP dilution methods: one diluting SCD PFP 1:5 in PBS buffer and a second using 
murine plasma. The final optimum concentration was defined as the average of both concentration 
values (Table 3.1). It was determined for all the antibodies available at that time and it was used for 
all subsequent flow cytometry experiments. The optimum concentration provided maximum labelling 
whilst avoiding non-specific staining. For all antibodies, except ex./cyt. GPA and GLUT1 (highlighted 
in Table 3.1), the optimum concentration was the same obtained from both methods, whereas for 
ex./cyt. GPA and GLUT1 the average of the two concentrations was used. Since both methods 
showed the same antibody concentrations for most of the antibodies, it was decided that for new 
antibodies, only antibody titrations in PFP diluted 1:5 would be carried out and the laborious titrations 
in murine plasma were omitted.  
 





Best concentration (μg/ml) in 
PFP diluted: Final optimum 
concentration (μg/ml) 
(average) 1:5 murine plasma 
Ex. GPA-AF 488* BRIC256 1.25 0.625 0.937 
Ex. GPA- AF 647* BRIC256 0.312 0.312 0.312 
Cyt. GPA- AF 488 BRIC163 1.25 0.625 0.937 
Ex. Band 3- AF 488 BRIC200 2.5 2.5 2.5 
Cyt. Band 3- AF 488 BRIC155 1.25 1.25 1.25 
Cyt. GPC- AF 488 BGRL100 0.156 0.156 0.156  
GLUT1- AF 488 BRAC67 2.5 1.25 1.875 
*AF: AlexaFluor  
 
 
3.3.1.2 Investigation of platelets and HLA cells in plasma 
SCD PFP from different patients were found to have populations with different scatter characteristics 
(see PFP from 1 patient in Fig. 3.5A and 2 patients in Fig. 3.5B). In order to identify the origin of 
different populations in the SCD PFP, a directly conjugated PAB-PE antibody, which is a specific 
marker for platelets, was used. A human anti-HLA class I (FITC) marker was also used to detect 
GPA+ RCDP from HLA+ cells in plasma. The rationale behind was that HLA is expressed by 
nucleated cells (303), thus, RCDP which result from enucleated cells do not expose HLA and could 
be distinguished from the rest of the PFP components. Both antibodies were used separately, along 
with anti-GPA antibody. Platelets and HLA cells were detected in 3/3 and 19/19 samples tested 
respectively (Fig 3.5A and B). GPA+, PAB+ and HLA+ populations were assigned specific colours 
then FSC and SSC characteristics of all events were examined (GPA red, PAB and HLA orange), to 
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determine the scatter characteristics. Platelet presence in SCD PFP (Fig. 3.5A) showed that they 
were not totally removed by centrifugation. As was seen with RCDP, dilution of SCD PFP allowed 
better detection of platelets compared to undiluted SCD PFP. Furthermore, platelets were found to 
have comparable scatter characteristics with GPA+ events, as both populations showed similar FSC 
and SSC values (Fig. 3.5A). HLA cells were distributed along the whole population and their scatter 
characteristics differed (Fig. 3.5B). All samples were shown to have a distinct GPA+ population. CR 
media from 3 cultures was also examined for HLA+ events but they could not be detected. This was 
to be expected, since this media was collected from enucleated reticulocytes only. Following 
investigation of platelets and HLA+ cells in SCD PFP, as well as optimising the flow cytometry 
protocol, GPA+ events from SCD PFP and CR media were also examined for the presence of other 
proteins expressed on RBC. 
 
 
Figure 3.5 Platelet and HLA detection in plasma by flow cytometry. (A) FSC and SSC plots from 
SCD plasma stained with ex. GPA+ (in red) and PAB (in orange) in undiluted PFP (left) and diluted 
PFP (right). (B) Dot plots showing the distribution of GPA+ (red) and HLA+ (orange) in PFP diluted 




3.3.2 Abundance of red cell proteins 
Protein abundance was examined using an antibody panel (GPA, GPC, band 3 and GLUT1, see 
Table 3.1). Flow cytometry results showed that SCD PFP samples expose all the tested proteins 
(Fig. 3.6A). The levels of protein exposure on 111 SCD PFP samples were highest for ex. GPA 
(mean ± SD, 41.92% ± 24.35%) and ex. Band 3 (26.60% ± 25.55%), whereas lower levels of cyt. 
GPA (3.37% ± 9.88%), cyt. Band 3 (2.58% ± 7.81%), cyt. GPC (0.42% ± 1.06%) and GLUT1 (1.95% 
± 5.42%) were detected (Table 3.2). Ex. GPA was significantly higher than all other proteins 
(P0.02). Similarly, ex. Band 3 expression was also significantly increased compared to the 
cytoplasmic proteins and GLUT1 (P<0.0001), whereas cyt. GPA was only significantly elevated 
compared to cyt. GPC (P=0.04, Table 3.2). Since the presence of extracellular domains of the 
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proteins corresponds to RCDP and cytoplasmic domains to AV, it was shown that RCDP levels are 
higher than AV in SCD PFP. With regards to GLUT1, the exact epitope is yet unknown. The 
manufacturer (PDPU) assumed the antibody detects an intracellular one. This is in line with the low 
detected levels of GLUT1, which indicated it potentially detects a cytoplasmic epitope of GLUT1. 
 
 
Figure 3.6 Proteins detected in plasma and CR media by flow cytometry. SCD PFP and CR 
media was stained with a panel of antibodies targeting abundant RBC proteins. Exposure of RBC 
proteins (A) in PFP from 111 patient samples and (B) 3 reticulocyte cultures. Dotted lines divide 
extracellular protein domains associated with RCDP and cytoplasmic domains associated with AV. 
(C) PS exposure in 14 SCD PFP samples. Lines represent mean and standard deviation. Statistical 




In CR media (Fig. 3.6B) the levels of ex. GPA exposure were higher than other proteins examined 
(34.73% ± 12.96%) but only significantly increased compared to GLUT1 (P= 0.04). The extracellular 
domain of band 3 was not assessed in CR media. Low levels were detected for cyt. GPA (2.01% ± 
1.0%), cyt. Band 3 (0.65% ± 0.61%), GPC and GLUT1 (0.03% ± 0.01% and 0.06 ± 0.07% 
respectively). This indicates that cultured reticulocytes mainly produced RCDP.  
SCD PFP was also examined for PS exposure which is an indicator of deformed RBC membrane 
and RCDP formation (95, 176). Annexin V binds PS and it is widely used for PS detection (335, 336). 
PFP from 14 SCD patients were stained with ex. GPA and annexin V (Fig. 3.6C). Levels of annexin 
V+ events were higher (47.38% ± 30.13%) than ex. GPA+ (13.07% ± 18.51%, P=0.001) and ex. 











P value  
ex. Band 3 cyt. GPA cyt. Band 3 cyt. GPC GLUT1 
ex. GPA 41.92 24.35 0.02 <0.0001 <0.0001 <0.0001 <0.0001 
ex. Band 3 26.60 25.55 - <0.0001 <0.0001 <0.0001 <0.0001 
cyt. GPA 3.37 9.88 - - >0.999 0.04 >0.999 
cyt. Band 3 2.58 7.81 - - - 0.38 >0.999 
cyt. GPC 0.42 1.06 - - - - 0.08 
GLUT1 1.95 5.42 - - - - - 
Results of proteins detected in SCD patient samples (n=111) were compared using a nonparametric 




3.3.3 Size estimation  
The size of the detected RCDP (stained with anti-ex. GPA-AF 488) and AV (stained with anti-cyt. 
GPA-AF 488) in SCD PFP and CR media was assessed by flow cytometry. Two different populations 
of known size were selected as controls: (i) SV and (ii) commercially available size beads. 
 
3.3.3.1 Use of known size storage vesicles 
During initial flow cytometry experiments, some SV prepared by a colleague were used. Their size 
was calculated to be 175nm by using the NanoSight LM10 system, as has been previously reported 
for such vesicles (183). However, these SV were undetectable by flow cytometry, showing that the 
RCDP and AV detected by flow cytometry were larger than 200nm. 
 
3.3.3.2 Size beads 
Commercially available size beads were used ranging in diameter from 0.02µm to 2µm and tested 
on the flow cytometer. The instrument detected beads of 2µm, 1µm and 0.5µm diameter but it was 
not sensitive enough to detect the smaller sizes (0.2, 0.1 and 0.02µm). When FSC and SSC of SCD 
patients (Fig. 3.7 left upper panel) and CR media (left lower panel) were plotted, ex. GPA+ events (in 
red) were located close to the 0.5µm size beads (light blue) for both sources. Histograms of 
abundance of detected populations were also created in order to better discriminate the scatter of 
each population (Fig 3.7 right). Cyt. GPA+ AV (green, right upper panel) from SCD PFP were found 
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to have a similar size to ex. GPA+ RCDP (0.5µm), whereas AV from CR media (green, right lower 
panel) were found to be smaller and were located below the 0.5μm beads. However, since the 
instrument could not detect the 0.2µm size beads we can assume that AV in CR media are larger 
than 0.2μm.  
 
Figure 3.7 GPA+ red cell vesicle size estimation using size beads. Representative samples from 
5 SCD PFP (above) and CR media (n=1, below) were stained with anti-ex. GPA-AF 488 (for RCDP) 
or anti-cyt. GPA-AF 488 (for AV), along with commercial FITC-labelled size beads and examined by 
flow cytometry. In a plot of SSC versus FSC (left dots plots), the position of the size beads was 
shown using gates, to illustrate the relationship between events detected on SCD PFP (upper plot, 
representative of 5 SCD patient samples) and CR media (lower plot) and size. Beads are shown in 
dark blue, blue and light blue for 2, 1, 0.5μm size, respectively. Ex. GPA+ RCDP is in red, cyt. GPA+ 
AV in green and the unstained population in black. Histograms of SSC versus event count were also 
created (right plots) to quantitate the detected events in PFP (upper plot) and CR media (lower plot). 
The unstained population is shown in grey. 
 
 
Size estimation for ex. and cyt. Band 3+, cyt. GPC+ and GLUT1+ was also attempted in 2 SCD PFP 
samples. All these populations had the same scatter characteristics as GPA+ events and AV when 
examined by flow cytometry and so it was expected that they would have similar sizes. However, all 
protein domains in both samples were found in particularly low levels and could not be easily 
discriminated when plotted on FSC vs SSC. Therefore, size assessment for these populations was 
not possible and additional proteins on RCDP and AV were tested. 
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3.4 Examination of highly immunogenic proteins on sickle cells 
CR media express most of the RBC proteins (unpublished data from collaborators). In an attempt to 
further characterise the protein content of RCDP and AV, immunogenic proteins that contribute to 
alloimmunisation in SCD, such as Kell, Kidd and Duffy, were examined on RCDP from SCD PFP, 
CR media and SV from outdated blood units (day 35). The antibody specificity was tested on SC 
and on a panel of RBC designed for identification of minor antigens, such as Rh, Fy and Jk, which 
was used as a positive control (see Table 2.1 for antibodies used). Individual samples from 19 SCD 
patients and 2 healthy donors were tested and all were found to be strongly positive (mean ± SD, 
79.06 ± 7.34% and 69.03 ± 1.13%, respectively) for the Kell protein. However, the results from the 
antibodies targeting Kidd and Duffy proteins were negative, even for the positive control. This 
showed that the antibodies were not sensitive enough for this analysis, hence SCD PFP, CR media 
and SV were not further examined. Instead, RCDP and AV were sorted using FACS, to further 
assess morphology and investigate whether true microvesicles or cell debris were isolated.  
 
3.5  Isolation of red cell-derived particles and autophagic vesicles using FACS  
3.5.1 Optimisation of red cell-derived particle isolation using FACS  
In order to isolate adequate numbers of RCDP from SCD PFP, only samples with a high number of 
RCDP detected by flow cytometry were used. The sample preparation was modified to maximise the 
sorting yield (Chapter 2.8). For this, some factors should be taken into account and adjusted, like 
determination of SCD PFP and CR media dilution, antibody dilution and RCDP enrichment using 
sedimentation. 
 
3.5.1.1 Sample dilution 
Due to the small size of the microvesicles, stained RCDP do not sediment using conventional 
centrifugation and could not be washed, hence stained SCD PFP was further diluted up to twenty 
times to remove unbound antibody. However, this led to further dilution of GPA+ events and sorting 
took several hours, without achieving a sufficient yield for further experiments (< 1x104 events). After 
testing several SCD PFP and CR media dilutions, it was decided to dilute both sources 1:10.  
 
3.5.1.2 Antibody dilution 
Since ex. GPA was highly present among the tested RBC proteins when analysed by flow cytometry, 
the respective antibody (BRIC256) was chosen for sorting by FACS. For the early sorting 
experiments, a higher concentration was used than that for flow cytometry (1.25μg/ml), in order to 
achieve good discrimination of GPA+ events. CR media was stained in the same way. 
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3.5.1.3 Pelleting samples  
Prior to sorting, some SCD PFP samples were pelleted using ultra-centrifugation (100,000g) and 
high-speed (20,000g) centrifugation (as described in Chapter 2.5.1) in order to enrich RCDP. Sorted 
populations were compared with those obtained from non-pelleted SCD PFP. Non pelleted samples 
from both SCD PFP and CR media were shown to have a distinct GPA+ population with relatively 
high SSC (Fig. 3.8A). This population had higher scatter than the main population when plotted 
against FSC (Fig. 3.8B). Although FSC represents size, SSC, which indicates granularity, is more 
sensitive for microparticle detection, thus, sorting was based on GPA+ and SSC characteristics. In 
terms of the pelleted SCD PFP, the high scatter population was decreased compared to the non-
pelleted samples. However, pelleted samples also had a lower scatter GPA+ population that 
overlapped with the main population when plotted against FSC. This population is more 
representative of small RCDP than the higher scatter one, which seem to correspond to large RCDP. 
In this Chapter, terms “sorted small” and “sorted large” RCDP were used to describe GPA+ events 
sorted from the low and high SSC gate, respectively.  
  
Figure 3.8 Sorting strategy for GPA+ vesicles from plasma. (A) Non-pelleted PFP (upper dot 
plot) and pelleted PFP (lower plot), by ultra-centrifugation (100,000g). Samples were stained for ex. 
GPA and plotted against SSC. (B) Forward and side scatter characteristics of samples. Large GPA+ 
(higher SCC events) are shown in red, small GPA+ (lower SSC) from pelleted PFP are green and 
the GPA negative population is black. 
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3.5.1.4 Refining plasma pelleting and antibody titrations 
The effects of SCD PFP sedimentation using high-speed centrifugation at 20,000g (as described in 
Chapter 2.5.1), as a less “harsh” method that would not damage the RCDP, was examined in 3 SCD 
samples. Pelleted RCDP from equal SCD PFP volumes, isolated by ultra- and high-speed 
centrifugation from the same patient, were compared. Furthermore, pelleted RCDP were stained 
with 3 different concentrations of ex. GPA (0.312μg/ml, 0.625μg/ml and 1.25μg/ml). Higher antibody 
concentrations resulted in better discrimination of small GPA+ events, whereas large GPA+ events 
were found well-discriminated for all concentrations used (Fig. 3.9). Furthermore, sorting of small 
GPA+ events was only possible from the samples stained with the highest antibody concentration 
(1.25μg/ml), since the lower concentrations did not succeed to stain a discrete population that could 
be sorted. Thus, it was confirmed that staining SCD PFP using a GPA concentration of 1.25μg/ml 
was right, as a good discrimination for sorting is required.  
 
Figure 3.9 Comparison of methods of vesicle sedimentation for isolation by FACS. 
Representative plots of PFP from SCD patients (n=3). Samples were split and pelleted by ultra-
centrifugation at 100,000g (upper panel) or high-speed centrifugation at 20,000g (lower panel). 
Pellets were stained using 3 different concentrations of ex. GPA (0.312μg/ml, 0.625μg/ml and 
1.25μg/ml). Instrument noise and negative events are shown in the red gate. GPA+ events in the 
green gate were further separated based on higher SCC (large events, orange gate) and lower SSC 




Both centrifugation methods did not reveal variability in small and large ex. GPA+ populations: means 
of 0.70% ± 0.36% and 0.24 ± 0.30% large GPA+ events were detected after ultra- and high-speed 
centrifugation, respectively, while the proportions of small GPA+ events were 5.32 ± 5.39% and 5.22 
± 7.60%, respectively (Table 3.3). However, variability in small GPA+ events numbers among 
different patients was observed. Both methods gave similar numbers of small and large GPA+ 
events, which were not found statistically significant and were equally used for sample 
sedimentation. As populations below 1.5% were too low to be sorted, none of the large GPA+ events 
from pelleted PFP could be collected and small GPA+ events were sorted instead.  
 
Table 3.3 Assessment of sorting potential using the proportions of GPA+ events in pelleted 
plasma, by two centrifugation methods. 
SCD Patient ID Ultra-centrifugation High-speed centrifugation 
Small GPA+ (%) Large GPA+ (%) Small GPA+ (%) Large GPA+ (%) 
1 11.47 0.78 13.98 0.59 
2 3.08 1.01 1.30 0.10 
3 1.40 0.30 0.38 0.04 
Mean 5.32 0.70 5.22 0.24 
SD 5.39 0.36 7.60 0.30 
Statistical analysis between small and large GPA+ events from both methods was carried out using 
a paired nonparametric t-test (P>0.999 and P=0.25, respectively). 
 
 
3.5.1.5 Determination of size limit detection by FACS compared to flow cytometry 
SV of known size (175nm) were tested on the cell sorter, as was previously described in section 
3.3.3.1 for flow cytometry. Again, the instrument was not sensitive enough to detect these SV. This 
means that small RCDP detected by FACS had a diameter bigger than 0.2µm, as was shown before 
for flow cytometry. Small and large sorted GPA+ from pelleted and non pelleted PFP, respectively, 
were subsequently analysed using a MACSQuant flow cytometer and only large RCDP could be 





3.5.2 Yields of sorted red cell-derived particles 
When sorting non pelleted SCD PFP from 9 patients was examined, a large variability among 
different samples was observed; 100μl non-pelleted SCD plasma gave 4x103-3.6x105 (mean ± SD, 
1.33x105 ± 1.20x105 large RCDP (Table 3.4). Variability was also observed in 4 pelleted SCD 
samples using ultra-centrifugation. Yields for large GPA+ ranged from 3x104-3x105 (1.30x105 ± 
1.18x105). Small GPA+ events were not detected in non pelleted SCD PFP. In the 4 pelleted samples, 
yields of small RCDP were higher up to 5.6x106, (19.50x105 ± 25.30x105 GPA+ events). This showed 
that ultra-centrifugation assisted in RCDP enrichment, as more GPA+ events were obtained from a 
concentrated pellet rather than non pelleted PFP. Large GPA+ events from all samples and small 
events from pelleted samples only, were collected for morphology and protein content 
characterisation. Media from one reticulocyte culture gave 3x105 GPA+ large events. 
 
Table 3.4 Event number of small and large GPA+ particles in pelleted and non pelleted plasma. 
Non pelleted SCD PFP Pelleted SCD PFP 
SCD Patient Large GPA+ (x105) SCD Patient Small GPA+ (x105) Large GPA+ (x105) 
4 0.04 13 0.21 2.00 
5 0.42 14 56.45 0.27 
6 1.42 15 6.98 0.34 
7 1.05 16 14.36 2.60 
8 0.44 Mean 19.50 1.30 
9 1.50 SD 25.30 1.18 








Attempts to isolate AV using FACS 
The cytoplasmic domains of GPA and band 3 were used for sorting AV from different SCD PFP 
samples, along with calcein AM, a marker of intact microvesicles. However, the AV events detected 
were too low to be sorted. 
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3.6  Protein determination on sorted red cell-derived particles by Bradford assay 
Although the Bradford assay is routinely used to detect total protein in SV preparations, protein 
detection in sorted GPA+ events proved extremely challenging. As sorted samples were used in 
other analyses, only a limited number could be used for the protein assay. Replicate readings from 
different aliquots of the same sample were always variable and inconsistent. After many 
unsuccessful attempts using both sorted large and small RCDP from SCD PFP and CR media, it 
was concluded that the quantity obtained was insufficient for accurate protein detection. The majority 
of the sorted GPA+ events were used for size and morphology assessment. 
 
 
3.7 Size estimation of sorted red cell-derived particles using DLS 
Sorted small and large GPA+ populations from SCD PFP and CR media were examined using DLS, 
in order to get an estimation of their size. Since small RCDP from CR media could not be sorted, 
only large RCDP populations were analysed from this source. SV populations from donated blood 
of known size (185nm on the NanoSight LM10 system) were prepared by a colleague and used as 
controls. Large and small sorted RCDP were diluted using filtered PBS (as described in Chapter 
2.10) and measurements were carried out on a DLS machine. For several large and small sorted 
RCDP, measurements could not be taken as the samples were too polydisperse. PBS buffer 
particles were shown to be 8-9nm and SV (n=3) were around 200 nm (Fig. 3.10A), confirming the 
NanoSight measurement.  
Large sorted RCDP from 3 individual SCD patients had peaks at 4-5μm, which was same for large 
sorted RCDP from one reticulocyte culture. Small sorted RCDP from one SCD patient were found to 
range between 1-5μm giving a flatter peak at 3-4μm (Fig. 3.10B, magnification of 3.10A). The results 
were different to those from flow cytometry using size beads, which suggested that GPA+ events 
were approximately 0.5μm. However, these data indicate that DLS is accurate for small particles, 
such as SV, and that the majority of the small sorted RCDP are 1-2μm smaller than the large sorted 
RCDP from SCD PFP or CR media. These populations were not detected in SV or PBS buffer (Fig. 





Figure 3.10 Size estimation of sorted GPA+ events using DLS. Large and small sorted RCDP 
from SCD PFP and CR media, diluted in PBS buffer, along with SV of known size (185nm) were 
analysed by DLS. (A) Histogram of the detected populations. (B) Magnification of the histogram (A). 
SV populations (n=3) are shown in pink, green and dark blue. Large sorted RCDP from SCD PFP 
(n=3, in brown, blue and red) have a similar size to large sorted RCDP from CR media (n=1, in 
cerise), whereas small sorted RCDP (n=1, in light blue) had a lower size distribution. (C) 
Magnification of a histogram showing the PBS buffer and the SV populations (n=3) demonstrating 
that no populations larger than 200nm are detected.  
 
3.8 Size estimation of large sorted particles using microscopy 
To assess the morphology of sorted large and small RCDP, they were examined by conventional 
confocal, as well as spinning disk confocal microscopy. Confocal microscopy gave variable results. 
Tracking small numbers of sorted GPA+ events on slides proved to be extremely difficult. Sorted 
RCDP were shown to form aggregates and clusters in most cases (Fig. 3.11). GPA+ events from CR 
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media could not be detected. Unpublished data from laboratory colleagues using confocal 
microscopy estimated such RCDP to be smaller than 2μm. Here, these sorted large RCDP from 
SCD PFP were 1-6μm, which is closer to that of RBC (7-8μm) (50). Images from GPA+ events larger 
than 2.5μm were not captured, since they were thought to be remaining RBC/SC. However, 
considering the multiple centrifugation steps in order to get SCD PFP, these findings suggested the 
presence of membrane blebs and/ or macrovesicles (MaV), with size similar to RBC ghosts, rather 
than small RCDP, or that the instrument was not sensitive enough to image GPA+ events. For these 




Figure 3.11 Confocal analysis of sorted GPA+ events from plasma. Sorted large GPA+ RCDP 
were examined by confocal microscopy and found to form aggregates (left). Their size was between 
1-2.4μm on bright field, estimated by Adobe Photoshop (right). Images are representative from 5 
SCD patients and were visualised using 40x magnification. 
 
 
Images from spinning-disk confocal microscopy showed that sorted populations from SCD and CR 
media were mainly comprised of round particles (Fig. 3.12A). In order to calculate the size and radial 
symmetry of these RCDP, the Hough circle transform, a tool selective for round objects which 
ignores ellipses, was used. Images from 5 individual patients were analysed and were found to have 
a median size of 7μm (range 6.8-7.8μm, Fig. 3.12B), which is the size of erythrocytes (50). Knowing 
that all red cells were removed from the SCD PFP by centrifugation, it is possible that these particles 




Figure 3.12 Spinning-disk confocal analyses. Populations were stained using anti-ex. GPA- AF 
488 before visualisation. Digital image of: (A) large GPA+ sorted events from SCD PFP and (B) 
scatter plot of size of each individual round object detected in samples from 5 SCD patients. Line 
represents median, raw data are shown in table. (C) Digital images of cultured GPA+ sorted RCDP, 
(D) SC, (E) media from stored blood units and (F) 200nm diameter SV. Red circles (A-E) represent 
round SV of a size that was close to the instrument diffraction limit. Images were visualised using a 
60x (NA 1.2) water-immersion lens. 
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Images taken of sorted, cultured GPA+ RCDP showed a mixed population of spherical particles along 
with blebs or broken membrane (Fig. 3.12C), in which it was difficult to determine the size. 
Morphology of SC, media from stored blood units from which RBC had been removed, as well as 
200 nm SV, were also examined for comparison. A mixed population of deformed SC and RBC was 
detected, as well as smaller round particles (Fig. 3.12D). Storage media revealed the presence of 
large apoptotic bodies, MaV or even ghost membranes (Fig. 3.12E). The SV population was found 
to be below the diffraction limit of the instrument, thus, too small to be detected (Fig. 3.12F). Since 
the morphology of RCDP from CR media, SC, storage media and SV did not reveal round particles, 
their size could not be detected by the Hough circle transform method. Furthermore, the fluorescent 
signal in SC which corresponds to GPA abundance, was higher than the signal of GPA+ events from 
CR media and SV. This suggests that detected RCDP were membrane structures with less integral 
membrane rather than intact cells. Small sorted GPA+ RCDP could not be detected with either 
microscope. 
  
3.9 Analysis using imaging flow cytometry (ImageStream) 
3.9.1 ImageStream analysis of GPA+ sorted particles from plasma 
In addition to microscopy methods, SCD PFP as well as sorted large from non pelleted PFP and 
small GPA+ from pelleted SCD PFP were analysed using ImageStream, an imaging flow cytometer 
with high sensitivity and resolution, as well as the ability to visualise each individual event. Scatter 
intensity vs max pixel scatter were plotted (Fig. 3.13A) and from this, as was described before 
(Chapter 2.7), 2 main populations were distinguished: one comprised of small, low scatter events 
and the other contained larger events with high scatter. Large events from non-pelleted SCD PFP 
were found in low and high scatter areas (Fig. 3.13A left), while the vast majority of pelleted samples, 
from either ultra-centrifugation or high-speed centrifugation, were located in the low scatter area (Fig 
3.13A right). When images from low and high scatter events were viewed by bright field, differences 
in size and morphology were revealed: GPA+ RCDP and AV, exposing the extracellular or 
cytoplasmic domain, respectively, were detected in the low scatter area were found to be below 1μm 
(Fig. 3.13B), which is a similar size to microvesicles (155). Generally, AV were less abundant in SCD 
PFP and were shown to have a smaller size than RCDP. Large particles, which mainly corresponded 
to MaV and/or RBC ghosts, were detected in the high scatter area (Fig. 3.13C). In addition, the 
majority of small sorted GPA+, which could not be detected by conventional flow cytometry 
previously, were visualised to be as small as microvesicles by imaging flow cytometry (Fig. 3.13B). 
Presence of ex. GPA+ /cyt. GPA+ events was also observed in both areas, indicating unsealed 
membrane fragments or large unsealed RBC ghosts (Fig. 3.13Bii and 3.13Cii). Healthy, intact 
erythrocytes (Fig. 3.13Di) and MaV or ghost membranes (Fig. 3.13Dii and iii) were observed using 





Figure 3.13 Morphology of objects detected by imaging flow cytometry. (A) Scatter intensity vs 
max pixel scatter of sorted GPA+ events in non-pelleted samples (left panel) and pelleted SCD PFP 
(right panel). High SSC area containing MaV (in orange) and low SSC area containing small 
RCDP/AV (blue) were gated as shown. Speed beads had the highest scatter and were excluded 
(green). (B) SCD plasma stained with anti-ex. GPA-AF 488 and anti-cyt. GPA-AF 647. Images of 
(B) low scatter and (C) high scatter MaV from SCD PFP (i) ex. GPA, (ii) dual and (iii) cyt. GPA 
positive. (D) Bright field views of (i) RBC from a healthy individual, (ii) MaV from SCD PFP and (iii) 
side views of MaV from SCD PFP. Figures B, C and D were provided by Dr Tosti Mankelow. 
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3.9.2 Comparison of imaging flow cytometry with conventional flow cytometry  
The above findings revealed that imaging flow cytometry could detect small populations, like small 
sorted GPA+ and size beads of 0.2μm, which could not be previously detected by flow cytometry. To 
compare instrument sensitivities, PFP from 4 SCD patients was stained with the same antibody 
panel against RBC used for flow cytometry (ex. and cyt. GPA, cyt. GPC, cyt. Band 3 and GLUT1, 
see Table 3.1). Stained samples were divided into two; one was analysed by flow cytometry (FC) 
and the other by ImageStream (IS, Fig 3.14A). In this experiment, samples were not separated into 
low and high scatter but the whole population was gated, in order to include all events in the 
calculations, and allow comparison with the flow cytometer data. The results showed that levels of 2 
out of the 6 protein domains analysed, ex. Band 3 and ex. GPA, were found to be higher by IS than 
flow cytometry. IS detected mean ± SD, 49.63% ± 29.64% for ex. GPA levels, whereas FC detected 
only 9.99% ± 11.50%. Ex. Band 3 was also detected at higher levels by IS compared to flow 
cytometry: 40.95 ± 21.14% to 6.25% ± 7.26%. All cytoplasmic domains of GPA, band 3, GPC and 
GLUT1 were detected in particularly low levels (<0.5%, Fig 3.14B). Statistical analysis using 
nonparametric ANOVA was applied to all results and only ex. GPA and ex. Band 3 were significantly 
higher than GLUT1 (P=0.054 and 0.008, respectively), when detected by IS. The above revealed 
that the imaging flow cytometry is more sensitive for detecting RCDP exposing ex. Band 3 and ex. 
GPA. The barely detectable levels of cytoplasmic GPA, band 3, GPC and GLUT1 suggest that SCD 
patients produce far less AV than RCDP. 
In addition, SCD PFP along with size beads and SV 175nm were also analysed, as was previously 
done by FC (section 3.3.3.2 and Fig 3.7). The imaging flow cytometer was able to detect the SV 
population (peak in red), as well as the 0.2μm size beads (green) (Fig 3.14C), whereas the 
conventional flow cytometer could not detect these populations (see Fig. 3.7). Both populations were 
well discriminated. A colleague, passed some SCD PFP through a 1.2μm filter then analysed by IS. 
Interestingly, all MaV were removed and the low scatter population remained (purple). This 
population had the same scatter characteristics as the low scatter population of an unfiltered SCD 
PFP sample (blue). These two populations were distributed between the SV and the 0.2μm size 
beads peaks, revealing that the majority of the low scatter events were under 200nm. MaV had a 
bigger scatter and the peak (white) was just below the peaks of 0.5μm (orange) and 1μm (yellow) 
beads. However, these findings were different to the large particles observed in bright field (Fig. 
3.13C, D). Previously, the flow cytometer was unable to detect not only the SV and the 0.2μm size 
beads, but also the small sorted RCDP (Fig. 3.7). Flow cytometry showed that detected GPA+ RCDP 
and AV for SCD PFP had a size close to 0.5μm (red, green, light blue and blue, respectively on 
Figure 3.6), whereas the IS showed that such populations correspond to MaV (Fig. 3.13C, D and 





Figure 3.14 Comparison of imaging flow cytometry and conventional flow cytometry.  
(A) SCD PFP was stained for 6 RBC proteins and analysed by flow cytometry (FC) and ImageStream 
(IS). Bars represent mean ± SD from 4 SCD patient samples. Statistical analyses were performed 
by nonparametric ANOVA using Kruskal-Wallis test (*P<0.05, **P≤0.01, ***P≤0.001). (B) Table 
showing mean ± SD of protein levels detected by FC and IS. (C) SCD PFP was analysed by imaging 
flow cytometry along with size beads. Histogram showing the scatter intensity of different size 
populations detected by imaging flow cytometry: SV 175nm (red), RCDP from SCD PFP (low scatter, 
blue), 1.2μm filtered SCD plasma RCDP (low scatter, purple), 0.2μm beads (green), MaV from SCD 
PFP (high scatter, white), 0.5μm beads (orange) and 1μm beads (yellow). High scatter events (white 
MaV population) can be removed by filtration through a 1.2μm filter. Figure C was provided by Dr 
Tosti Mankelow. 
 
3.9.3  Summary of populations identified using different methods 
The results of the populations detected by different techniques are summarised in Figure 3.15. 
RCDP and AV from SCD plasma and CR media were found to expose extracellular and cytoplasmic 
domains of proteins, respectively, by flow cytometry. Their size was estimated to be 0.5-1μm for 
RCDP and below 0.5μm for AV by size beads (range 0.2-2μm using SSC feature), whereas 0.2μm 
beads could not be detected by the flow cytometer. Ex. GPA+ from both sources were prevalent and 
FACS was used to isolated them. In an attempt to increase the yield of sorted ex. GPA+ events, 
some SCD samples were pelleted and a population with lower scatter than what was detected in 
non pelleted plasma was revealed. Hence, three different populations were sorted: large GPA+ 
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events with high scatter from non pelleted SCD PFP and CR media, as well as lower and high scatter 
populations containing small and large ex. GPA+, respectively, from pelleted SCD PFP. The protein 
content, morphology and size of these sorted populations were further assessed. Flow cytometry 
could detect sorted large GPA+ events but not the small ones. Total protein could not be determined 
for any sorted population by the Bradford assay. Size was found to be 4-5μm for large GPA+ events 
from SCD PFP and CR media and 3μm for small GPA+ events by using DLS. The size of small GPA+ 
events and SV 0.2μm, used as a control, could not be estimated by spinning-disk confocal analysis 
either. However, large GPA+ events from SCD PFP were 7μm, which is the size of RBC. This is in 
line with the findings from conventional confocal, whereas the other 2 populations could not be 
detected.  
Assuming that large sorted events from SCD PFP correspond to MaV, imaging flow cytometry was 
used to identify protein content and morphology of small and large GPA+ events from SCD PFP, as 
well as unsorted plasma. Sorted small GPA+ events, SV and size beads of 0.2μm were visualised 
for first time using this technology. Size estimation showed that small GPA+ events were 
approximately 0.2μm, whereas MaV were larger than this, <0.5μm. When using bright field, detected 
populations revealed a size range starting from below 1μm, which corresponds to true microvesicles 
or AV and reaching to larger MaV of 7μm. Imaging flow cytometry proved more sensitive than 
conventional flow cytometry for small particle detection.  
 
Figure 3.15 Schematic of populations detected by different methods. Isolated sorted GPA+ and 
unsorted RCDP from CR media and SCD PFP, as well as controls used and the methods 
investigated for analysis are shown. Hyphens indicate that the population was not examined by the 




Defective SC and low reticulocyte maturation due to splenic dysfunction lead to release of free Hb 
and RCDP into the circulation (255). RCDP are thought to form during RBC maturation by membrane 
blebbing, resulting in right side-out microvesicles that expose PS (267, 269, 337). A number of 
studies have measured the presence of RCDP in SCD patients and healthy individuals and they 
have been reported to be more abundant in SCD patients, probably because of their inefficient 
clearance by patients’ dysfunctional spleens (179, 180, 255, 269). Our colleagues have previously 
identified AV on the surface of maturing reticulocytes with an inside-out orientation, exposing PS and 
the cytoplasmic domains of RBC membrane proteins (127). 
Identification and characterisation of RCDP in the plasma of SCD patients has generally been done 
by conventional flow cytometry, using antibodies targeting extracellular protein domains (267-269, 
337). Here, we aimed to characterise RCDP and AV from cultured reticulocytes using a well-
established protocol (123, 334), as well as SCD plasma. CD34+ cells were isolated from aphaeresis 
cones and differentiated into enucleated reticulocytes, then, they were isolated and cultured to 
produce microvesicles. CR media was assessed by flow-cytometry and showed higher levels of ex. 
GPA+ than the other cytoplasmic protein domains. This indicates that cultured reticulocytes mainly 
produce RCDP. The presence of membrane parts from reticulocytes along with intact RCDP is also 
possible. Despite of low AV levels detected in CR media, their presence was confirmed by the 
cytoplasmic RBC proteins using flow cytometry. This is in line with our collaborators’ findings, 
detecting cytoplasmic protein domains of AV on the surface of cultured reticulocytes by microscopy 
(127). In our study, reticulocytes were removed from analysed CR media. It is probable that the low 
AV levels could indicate that these AV were attached on the reticulocyte surface and more time was 
needed so that AV can be released in the media. In this case, most AV were removed along with the 
cells during the centrifugation step and eventually, CR media contained less quantity of them. 
Protein abundance on SCD PFP was found to be very heterogenous, as populations were difficult 
to discriminate by flow cytometry. For this, different PFP dilutions were tested in order to dilute the 
cellular debris. Plasma diluted 1:5 showed better discrimination than undiluted plasma and other 
dilutions tested. Furthermore, to overcome the difficulty of indistinct populations, as there was no 
appropriate isotype control available, human plasma was diluted with murine plasma and antibody 
titrations were carried out. Titrations were also carried out in SCD PFP diluted 1:5. These 
experiments confirmed that the antibodies used were human specific and did not stain murine cells. 
The heterogenous PFP population was also found to contain platelet remnants, remaining from the 
centrifugation step during PFP separation from RBC in blood. HLA class I cells, were also detected, 
since the plasma contains numerous types of nucleated cells that express HLA (303), such as T-
cells, macrophages, dendritic cells and granulocytes.  
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Detection of the proteins that are important in alloimmunisation, such as Kell, Kidd and Duffy (120) 
by flow cytometry, was attempted. Routinely, such phenotyping is carried out by detecting 
haemagglutination by serology, using RBC from the donor and plasma from the patient (338, 339). 
RCDP would be expected to agglutinate since they are part of the RBC membrane, however, there 
is no evidence in the literature. Additionally, potential agglutination of RCDP would require large 
amounts in order clumping to be visualised. Thus, it was attempted to establish a protocol using flow 
cytometry, in order to be able to examine both RBC and plasma. Initially, SC were assessed and 
patients expressed the Kell protein highly. This indicates that these patients require matched Kell 
blood units to prevent development of alloantibodies that will haemolyse donor RBC post transfusion 
(322, 340). However, results for Kidd and Duffy indicated that the antibodies used were not suitable 
for flow cytometry analysis. Thus, further analysis of these proteins in SCD PFP was not carried out.  
FACS was used to isolate RCDP from SCD PFP and CR media for further characterisation. 
Additionally, SCD plasma was pelleted by ultra-centrifugation (100,000g) to enrich RCDP, as a 
common method for exosome isolation (341, 342). Pelleted SCD PFP showed a low SSC population, 
whereas non pelleted plasma and CR media showed a higher SSC population. Ultra-centrifugation 
was also compared to high-speed centrifugation (20,000g) regarding number of low SSC RCDP and 
both provided similar results of low SSC events. Low scatter RCDP were hypothesised to correspond 
to microvesicles but they could not be visualised by conventional or spinning-disk confocal 
microscopy, neither conventional flow cytometry, so this could not be confirmed. High SSC RCDP 
corresponded to what was described as small microvesicles by others, using flow cytometry (179, 
180, 255, 269). This population had a similar size to RBC when analysed by conventional and 
spinning-disk confocal microscopy. However, high SSC RCDP had a less integral membrane than 
that of RBC/SC, indicating that less bright populations correspond to defective membrane structures 
rather than intact cells and probably correspond to ghosts and MaV. Ghosts come from RBC 
haemolysis and contain RBC membrane but lack haemoglobin. In vitro, ghost membranes can be 
prepared by RBC hypotonic lysis and have been studied to understand the properties of RBC 
membranes (343). We recently showed that particles exposing both the extracellular and 
cytoplasmic domains of GPA or band 3 in SCD samples probably correspond to ghosts, indicating 
that the cytoplasmic domains were exposed during membrane sealing, after the release of Hb (Smith 
et. al, manuscript submitted). 
Protein content of low and high sorted populations, from non-pelleted and pelleted SCD samples, 
was assessed using the Bradford assay. Although this protocol works fine for assessing protein in 
ghost membrane preparations and SV, we never managed to get reproducible results. This may be 
due to the limited number of sorted events used, as sorted populations were examined by different 
methods. Another reason might be the high level of glycosylation of these populations. As the 
Bradford dye binds amino acid residues (mainly arginine, lysine, tryptophan, phenylalanine and 
tyrosine) under acidic conditions (344), post-translational modifications like glycosylation, was found 
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to under-estimate the protein content measured by Bradford, when compared to unmodified proteins 
(345). This indicated that Bradford may not be a suitable protein assay for these glycosylated sorted 
populations. 
Plasma from SCD patients was found to express all the RBC proteins tested by flow-cytometry: 
ex./cyt. GPA, ex./cyt. Band 3, cyt. GPC and GLUT1. Levels of extracellular GPA and band 3 were 
significantly higher than all the cytoplasmic domains tested. This showed that RCDP levels are 
higher than AV in SCD PFP. However, the flow cytometer failed to detect SV and size beads of 
0.2μm, suggesting that it is not sensitive for small populations. Although that RCDP exhibiting 
extracellular RBC proteins have been detected by others using flow cytometry (268, 269, 337, 346, 
347), our results indicated that small RCDP could not be detected. SCD PFP was also examined for 
PS exposure, as other groups have reported that RCDP were PS decorated (268, 269, 337, 346, 
347). PS is usually found on the inner part of the RBC membrane and it is a known “eat me” signal 
for phagocytic cells (94). Its translocation on surface indicates disturbance in RBC symmetry, 
followed by RCDP formation and budding (95, 176). Furthermore, it is well known to cause 
hypercoagulation in SCD (333). PS levels were significantly elevated than ex. GPA, as well as 
GPA/PS decorated RCDP, which is in line to what was previously detected by flow cytometry in 
RCDP in SCD, associated with raping aging of SC (268, 269, 337, 346, 347). Since it was shown 
that AV also expose PS during their formation through membrane endocytosis (127), part of the PS+ 
RCDP detected by flow cytometry, could correspond to AV.   
SCD PFP examination by imaging flow cytometry revealed a wide range of population sizes, from 
MaV and fragments of red cell membrane to small microvesicles, RCDP and AV. Similarly, when 
sorted pelleted and non pelleted SCD PFP were viewed by bright field imaging, it was found that 
high scatter particles mainly correspond to MaV and/or RBC ghosts and low scatter to small RCDP, 
probably exported by cellular blebbing during repeated cellular sickling and recovery (255). This 
demonstrates that circulating RCDP consist of different sizes rather than a single homogenous 
population, previously reported by flow cytometry (179, 180, 255, 269). Comparison of the results 
from imaging flow cytometry with those from conventional flow cytometry leads us to conclude that 
RCDP detected by many conventional flow cytometers are in fact not microvesicles but larger MaV. 
This could be attributed to differences in the light scattering intensity between biological particles 
and polystyrene sized beads (232).  
Recently, we showed that RCDP are much more abundant in SCD PFP than AV (Smith et. al, 
manuscript submitted). Furthermore, similarly to previous studies using conventional flow cytometry 
(346, 347), there are significant differences in the numbers of RCDP present in the plasma of healthy 
individuals and SCD patients. Also, SCD patients in crisis exhibited significantly elevated numbers 
of right side-out RCDP and membrane fragments in plasma exposing both domains of GPA, likely 
formed by the sickling process (Smith et. al, manuscript submitted). The majority of MaV were 
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strongly PS positive. When this population was removed from SCD PFP, the plasma clotting time 
was increased more than 3-fold, whereas removal of all RCDP and MaV led to a 7-fold increase. 
These data indicate that removal of MaV and RCDP exposing PS could contribute to a novel therapy 
for hypercoagulation in SCD (Smith et. al, manuscript submitted).  
DLS was used to get a size estimation of sorted samples. SV of known size 0.2μm, measured using 
nanoparticle tracking analysis by a colleague, gave similar readings to those obtained from DLS 
were in line with measurements. Low and high SSC RCDP were shown to be 3μm and 4-5μm, 
respectively. From the results of spinning-disk confocal analysis and imaging flow cytometry, size of 
high SSC RCDP seems to be under-estimated by DLS. However, all findings agree that sorted high 
SSC RCDP, which are the events detected by a conventional flow cytometer, mainly correspond to 
MaV. We conclude that DLS could be used for a rough estimation of RCDP size but not for accurate 
measurements. It could give accurate reading for small particles like SV though, as it has been 
reported to be accurate for monodisperse populations (224). For accurate results, other methods 
should be explored. Use of NTA was avoided in this study, as the estimated average particle size of 
the analysed population is required for instrument calibration, which was not the case for our 
samples. 
In summary, we showed for the first time the heterogeneity of RCDP in SCD plasma, using imaging 
flow cytometry. Small microvesicles and AV were visualised and it was found that they substantially 
differ from RCDP detected by others using flow cytometry, as they were found to correspond to MaV 
and RBC ghosts. Imaging flow cytometry was more sensitive than flow cytometry for small particle 
detection. Knowing that removal of RCDP and MaV exposing PS reduces plasma clotting time, 
further characterisation of RCDP and AV in SCD PFP and healthy individuals is needed, as it may 





  Characterisation of red cell-derived, autophagic and storage vesicles 
4.1 Introduction 
Vaso-occlusion is a common feature in SCD, caused by blockage of blood vessels due to abnormal 
SC. The spleen, which is responsible for clearance of senescent and damaged cells, gets frequently 
damaged by SC too (52, 56). It is hypothesised that a dysfunctional spleen causes elevated numbers 
of RCDP and AV, as has been reported using flow cytometry (179, 180, 255, 269), since they can’t 
be removed efficiently. In healthy individuals, RCDP are thought to be formed during reticulocyte 
maturation. In SCD however, repeated RBC sickling events probably lead to increased RCDP, 
contributing to higher RCDP levels.  
Whereas RCDP are considered to have a right-side out orientation exposing PS (267, 269, 337), 
AV, as reported by our colleagues, are hypothesised to have an inside-out formation but exhibited 
PS as well (Fig. 4.1) (127). In the previous Chapter, we attempted to examine the role of RCDP and 
AV in SCD and concluded that what others have identified as RCDP in SCD by flow cytometry (179, 
180, 255, 269) were probably MaV and RBC ghosts. Imaging flow cytometry revealed the differences 
in scatter between biological samples and size beads that others have used to determine RCDP size 
and indicated less accurate estimation in the light scattering intensity detected by flow cytometry 
(232). We have recently found that RCDP levels were increased in SCD patients in crisis compared 
to those in steady state. Additionally, removal of MaV was shown to decrease the blood clotting 
times, which suggested that their removal could reduce vaso-occlusive episodes in SCD (Smith et. 
al, manuscript submitted). However, the role of RCDP and AV has not yet been explored. Isolation 
and further characterisation of enriched RCDP and AV in healthy individuals and SCD, as well as 
exploring the differences in the proteome, could reveal potential biomarkers to predict painful vaso-
occlusive episodes in patients. 
 
Figure 4.1 Hypothetical mechanism of autophagic vesicle and red cell-derived particle 
formation. AV are formed via the RBC membrane internalisation by endocytosis and fusion with an 
autophagosome. A large particle is formed, then AV are released extracellularly and exposing the 
cytoplasmic components of the RBC. RCDP are formed by membrane budding and expose the 
extracellular components.  
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Microvesicle isolation usually takes place using sequential or ultra-centrifugation (348). In this 
Chapter, the quality of isolated RCDP and AV from SCD and healthy plasma was compared using 
FACS in pelleted and non pelleted samples, as well as immunomagnetic separation as an alternative 
to pelleting. Potential MaV presence in enriched RCDP was examined by microscopy. TEM was 
used to assess the morphology of enriched RCDP and AV, while DLS provided size estimation of 
the isolated populations. Imaging flow cytometry was used to assess RBC protein exposure on 
enriched RCDP and AV along with calcein AM, a marker for intact MP (349). Annexin V that detects 
PS exposure, indicating apoptosis, (335, 336) was also used. Finally, differences in the proteome 
among enriched RCDP and AV from SCD and healthy plasma were investigated. In most 
experiments, SV from outdated blood units (day 35) were examined as a comparison to RCDP. 
 
RESULTS 
4.2 Red cell-derived particle, autophagic and storage vesicle isolation and characterisation 
4.2.1 Optimisation of particle enrichment in plasma using immunomagnetic beads 
4.2.1.1 Comparison of isolation methods and morphology examination  
In experiments to date, isolation of RCDP and AV was carried out by FACS of samples pelleted by 
either ultra- (100,000g) or high-speed (20,000g) centrifugation (Chapter 2.5.1). The morphology of 
these ex. GPA+ sorted populations was examined by TEM, in order to identify whether these sorted 
RCDP were true microvesicles or membrane fragments. However, during early TEM experiments, 
visualising sorted pelleted GPA+RCDP was not possible. Instead, only membrane fragments were 
observed (Fig. 4.2A). Hence, instead of RCDP it was decided to use controls, such as SV (used in 
Chapters 3.3.3.1 and 3.5.1.5), which were expected to have similar morphology to RCDP, since both 
particle types originate from RBC. SV were shown to be round, enclosed by a lipid bilayer (Fig. 4.2B). 
Also, RCDP enriched by magnetic beads coupled to anti-ex. GPA (see Chapter 2.5.2), were tested. 
It was hypothesised that as these beads would surround RCDP, they may improve detection by 
TEM. Indeed, these beads were observed even to cover pelleted RCDP in some cases (Fig. 4.2C). 
At higher magnifications, magnetic beads appeared as roundish, grey structures on RCDP. Round 
and tubular RCDP structures were also observed in pelleted and non pelleted samples (Fig. 4.2D).  
Low RCDP levels, initially detected in sorted pelleted SCD PFP by TEM, led us to question the 
efficiency of the isolation method. Ultra-centrifugation sediments small size particles (348) but 
practically the sedimentation of all small particles is impossible. Additionally, the sorter could not sort 
particles below 0.2μm (see Chapter 3.5.1.5), hence small PFP particles could not be isolated. 
Furthermore, despite the fact that centrifugation at high velocities is a common method for MP 
isolation (341, 342), the potential damage to RCDP and AV due to the high speed was a concern. 
The morphology of enriched RCDP by both methods was further examined by TEM, in order to 




Figure 4.2 Morphology examination of enriched red cell-derived particles by two different 
methods on TEM. (A) Small sorted pelleted RCDP were mainly comprised of membrane fragments 
rather than round particles. Image is representative of 15 samples. (B) Round SV from 1 blood unit. 
(C) RCDP isolated from pelleted and (D) non pelleted SCD PFP. Magnetic beads (~50nm) appeared 
as roundish, dark structures surrounding circular and tubular RCDP. Scale bars indicate (i) 0.5μm 







4.2.1.2 Examination of macrovesicles present in enriched particles from filtered plasma 
Prior to magnetic isolation, PFP was filtered (3μm) to remove MaV and ghosts. RCDP, enriched from 
SCD PFP using beads, were stained with anti-ex. GPA and then examined by confocal microscopy 
(Chapter 2.9.1), using a newer microscope (Leica SP8 Inverted Confocal Microscope System) than 
what was previously used in Chapter 3.8. The results showed that detected particles close to 5μm 
in size were probably MaV and ghosts and were not retained by the filter (Fig. 4.3Ai). This was also 
confirmed in several RCDP preparations by TEM (Fig. 4.3Bi). Interestingly, in all cases, detected 
MaV were shown to “contain” RCDP (Fig. 4.3Aii, Bii). Furthermore, it was revealed that 
immunomagnetic separation could isolate RCDP below 0.2mm (Fig.4.3Bii), whereas FACS failed. 
 
Figure 4.3 Examination of enriched red cell particles from 3μm filtered plasma. (A) Confocal 
analysis of enriched RCDP stained with anti-ex. GPA-FITC. Round MaV larger than 5μm were 
observed (i). Green dots represent RCDP bonded to MaV. Enlarged image of the same sample (ii). 
Images were from 1 experiment and visualised using 400X magnification. Scale bars indicate 5μm 
(i) and 0.5μm (ii). (B) TEM images of MaV present in isolated RCDP, representative from 10 
samples. (i). Magnified section of an MaV, where small RCDP are present, probably bonded by 
beads (ii). Scale bars correspond to 2μm (i) and 0.1μm (ii).  
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The presence of RCDP inside or on MaV could be due to bonding, either during initiation of 
coagulation by PS or by the magnetic beads used for isolation (Fig. 4.4Ai and ii). To remove MaV 
from RCDP preparations, PFP was filtered (1.2μm), then filtered samples were imaged by TEM (Fig. 
4.4Bi and ii respectively). Similar to what was previously observed by imaging flow cytometry, MaV 
were retained by such a filter (Fig. 4.4 and Chapter 3.9.2). It should be mentioned though that when 
PFP was passed through a 3μm filter by gravity instead of using a plunger, no MaV were found. 
Figure 4.4 Examination of different filters in macrovesicle removal from enriched particles. 
(A) TEM image of two MaV bonded with immunomagnetic beads (i). Magnification of the bonding 
site. The beads (~50nm) appear in the middle as a dark blob. Scale bars indicate 100nm (i) and 
50nm (ii). TEM images are representative from 20 SCD samples tested. (B) RCDP enriched from 




4.2.1.3 Antibody contribution to the total protein. 
So far, the examined populations were isolated using either FACS or magnetic beads. Both methods, 
however, included the use of an anti-GPA antibody, which targeted the RCDP. In order to be able to 
carry out any protein determination, like protein assays or proteomic profile analysis, the contribution 
to the total protein content of the antibody used for sorting (BRIC256), as well as the 
immunomagnetic beads, was examined by SDS-PAGE and Coomassie blue staining, to visualise 
the total protein in each lane. 
Samples analysed were: 
1) sorted small GPA+ from pelleted (100,000g) SCD plasma (patient 17) 
2) sorted small GPA+ from pelleted (100,000g) SCD plasma (patient 18) 
3) isolated RCDP using anti-ex.GPA beads from pelleted (100,000g) SCD plasma (patient 18) 
4) isolated RCDP using anti-ex.GPA beads from pelleted (100,000g) SCD plasma (patient 19) 
5) isolated RCDP using anti-ex.GPA beads from pelleted (20,000g) SCD plasma (patient 19) 
6) 1/5 the quantity of (4) 
7) 1/5 the quantity of (5) 
Using the above samples, total protein was compared in RCDP isolated from FACS and magnetic 
beads in samples pelleted by ultra-centrifugation (Fig. 4.5, lanes 1-3). Ultra- and high-speed 
centrifugation were compared in enriched samples using anti-ex. GPA beads (lanes 4-7). Since there 
was no information in the literature regarding running sorted RCDP on a gel, 3 sample volumes were 
tested: 1x quantity for sorted populations (1-2) which were relatively pure, as they comprised of 
sorted GPA+ events only. For GPA+ events enriched using beads, samples were eluted in MACS 
buffer in the end of the isolation step (see Chapter 2.5.2) and therefore were diluted. For comparison, 
patient plasma used for sorting in lane (2) was also used for RCDP enriched using beads in lane 3. 
In lanes 6-7 double the quantity of plasma was used compared to 1-3. Lanes 4-5 contained the same 
samples as 6-7 but a 5x RCDP quantity was used (10x compared to lanes 1-3), in case these 
samples had a very low protein content. Despite the different RCDP quantities used, final sample 
volumes loaded in the lanes were all the same, topped up with sample buffer (see Chapter 2.11.5).  
The results showed that RCDP enriched by ex. GPA beads (lanes 3-7) contained more protein than 
RCDP sorted by FACS, especially between 50-80kDa (Fig. 4.5). This was obvious among samples 
1-3, which all had the same RCDP quantity and sample 3 revealed stacked protein bands not 
observed in 1 and 2. The highest protein content was observed in samples 4 and 5 that had the 
highest RCDP quantity of all samples tested. Other protein bands below and above 50-80kDa were 
observed, especially for samples 4-7 (Fig. 4.5 indicated with dots). As the molecular weight of GPA 
detected on a gel ranges from 50-100kDa (~98kDa for dimer, ~60kDa for GPA/GPB and 30kDa for 
the monomer) (350, 351), the results from lanes 3-6 indicated that the immunomagnetic beads used 
in lane 3 contributed more to the total protein than the antibody used for sorting (lanes 1-2) but this 
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would need to be confirmed. As beads could be used in non pelleted PFP, RCDP damage due to 
high velocity in pelleted plasma would be avoided. Also, TEM imaging showed that immunomagnetic 
separation could isolate smaller RCDP than FACS (part ii). Hence, it was decided that RCDP 
enrichment would only be carried out using magnetic beads. 
   
Figure 4.5 Comparison of total protein in samples enriched by FACS and magnetic beads. 
RCDP from 3 SCD patients’ plasma (P17-19), enriched using ultra- (100,000g) and high-speed 
(20,000g) by FACS (low SSC events, lanes 1-2), or immunomagnetic beads (3) were run on a gel 
code blue stained SDS-PAGE. RCDP from non pelleted plasma, enriched using beads were also 
examined (lanes 4-7) to determine protein content. Different RCDP quantities are indicated. 
Molecular weight markers (M) indicated in kDa. Detected protein bands on the samples are indicated 
by dotted lines. White arrows indicate sample spillage in empty lanes from the nearby samples. 
Image is representative from one experiment. 
 
 
4.2.1.4 Extent of antibody contribution to protein content. 
To examine the contribution of the magnetic beads to the total protein content, beads along with 
anti-ex. GPA (BRIC256) antibody were run on a Coomassie blue stained gel. The antibody was used 
to indicate the apparent molecular weight of GPA, as the theoretical molecular weight of the dimer 
is 39kD. In parallel, RCDP from a SCD patient (P20) were isolated using 3 different bead 
concentrations (3, 1.5 and 0.75%(v/v)) . Half of the samples were non pelleted (Np.A, Np.B, Np.C) 
and the other half were pelleted (p.A, p.B, p.C, Fig 4.6A). The rationale behind this was that unbound 
beads would pellet and enriched RCDP would remain in the supernatant. Pellets and supernatants 
(supern.) were run separately, to identify whether pelleted magnetic beads contributed to the total 
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protein content. Detected bands from the antibody indicated by black arrows, showed that the 
apparent molecular weights were 69kDa for the GPA dimer, 52kDa GPA/GPB and 27kDa the 
monomer (Fig 4.6B). Similar bands to the first two were observed in all PFP samples, apart from the 
pellets and the samples that contained beads only. Other protein bands were also observed 
(indicated by horizontal yellow arrows). Bands detected in the pellets revealed far less protein than 
supernatants. Visual examination of protein isolated using bead concentrations 3-1.5%(v/v) did not 
show differences in the enriched protein, whereas 0.75%(v/v) isolated lower amounts. Protein bands 
were not quantified though. 
 
Figure 4.6 Assessment of beads contribution to the total protein. (A) Schematic of the sample 
processing. Immunomagnetic beads and non pelleted SCD PFP from one patient (P20) were 
isolated using 3 different bead concentrations: 3,1.5 and 0.75%(v/v) (Np.A, Np.B, Np.C). Half of 
these samples were pelleted (p.A, p.B, p.C) and pellets and supernatant (supern.) were analysed 
separately. Squares indicate tested samples and number corresponds to the lane indicated on the 
gels below. (B) Coomassie blue stained gels of protein identified in pelleted and non pelleted 
samples: immunomagnetic beads (wells 1-3), anti-ex. GPA (wells 4,8), Np.A-C (5,9,12) and p.A-C 
(6-7, 10-11, 13-14 for PFP). Bright area on top left was caused by light reflection during imaging. 
Molecular weight markers (M) indicated in kDa. Black vertical arrows indicate bands of the antibody 
and white vertical arrows sample spillage in empty lanes from the nearby samples. Horizontal yellow 
arrows indicate protein bands observed. 
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In order to identify which protein corresponded to band of approx. 69-70kDa weight, which was 
present in all samples in the experiments above, the band from lane 1 of gel in Figure 4.5 was cut 
and sent for mass spectrometry (see Chapter 2.12.1). Results showed that this protein corresponded 
to BSA, which was present in both enriched samples. Sorted samples were collected in PBS, 
however, BSA was present in the buffer during the staining step before FACS (see Chapter 2.8). In 
samples enriched using immunomagnetic beads, BSA was present in the PBS eluting buffer (see 
Chapter 2.5.2). For all future experiments using magnetic beads, albumin was not added to the 
elution buffer after communication with the manufacturer. However, most importantly, the 
appearance of bands different to GPA (yellow arrows in Fig. 4.6) showed the presence of other 
proteins at adequate levels to be detected by a Coomassie blue staining. 
 
 
4.2.1.5 Bead concentration optimisation for red cell-derived particle and autophagic vesicle isolation  
The findings from assessing different bead concentrations led us to consider which would be the 
best to isolate most RCDP from SCD PFP without saturating the sample. At the same time, 
optimisation for AV isolation was carried out. Commercial beads detecting extracellular GPA were 
available at the time of the experiments but not against cytoplasmic GPA. For this reason, it was 
decided to use one of the antibodies detecting cyt. GPA (BRIC163) or band 3 (BRIC155 or BRIC132) 
conjugated to AF647, as described in Chapter 2.3. Then, commercial beads against AF647 were 
used and AV were eluted similarly to RCDP (Chapter 2.5.2). In most cases, SCD plasma was split 
into 2 parts, each to be enriched for RCDP or AV. 
Initially, our colleagues suggested 10-4%(v/v) anti-ex. GPA beads for RCDP enrichment. This was 
based on observations by imaging flow cytometry, where using these concentrations GPA RCDP 
could not be detected in the flow through buffer used to wash RCDP and beads, therefore they were 
retained by the magnet (see Chapter 2.5.2). No information was available for the anti-AF 647 beads. 
To determine the recovery of enriched RCDP and AV, samples enriched from 4 SCD samples using 
4%(v/v) beads targeting ex. GPA+ and cyt. GPA+ respectively, were analysed by imaging flow 
cytometry. Then, absolute counts were identified in plasma and enriched populations. Results were 
variable, with recoveries ranging 8-33% for RCDP and 4-43% for AV (see Table 4.1) and conclusions 




Table 4.1 Purity calculation before and after vesicle enrichment from plasma using 4% beads. 
SCD 
PFP 












21 5.03 1.67 33.27 39.55 1.61 4.06 
22 76.89 11.03 14.35 6.10 2.24 36.68 
23 86.23 6.85 7.94 18.50 1.34 7.23 
24 12.64 1.16 9.20 2.77 1.18 42.76 
Mean 45.20 5.18 16.19 16.73 1.59 22.68 
SD 42.27 4.67 11.72 16.65 4.65 19.87 
 
To further investigate the bead concentration, different patient samples enriched by different bead 
concentrations starting from 4% were assessed by TEM, in order to identify potential saturation with 
beads in samples. From this, it was revealed that even 1%(v/v) anti-ex. GPA beads was saturating 
the sample (Fig. 4.7, left). After assessing the morphology of different bead concentrations, the 
optimum one was found to be 0.35%(v/v) for RCDP and 0.12%(v/v) for AV (Fig. 4.7). Tubular and 
round RCDP were also observed.  
 
Figure 4.7 Examination of bead saturation by TEM. Enriched RCDP (above) using 
immunomagnetic beads 1%(v/v) (left) and 0.35%(v/v) (right) were examined by TEM, enriched AV 
(below) using 1%(v/v) (left) and 0.12%(v/v) (right) beads. Scale bars indicate 200nm (top left), 50nm 
(bottom left) and 100nm (right column). Images are representative from at least 3 samples tested.  
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4.3 Morphology of enriched populations in health and sickle cell disease 
4.3.1 Red cell-derived particles and autophagic vesicles  
In order to ensure isolation of true MP rather than membrane fragments, RCDP and AV were 
examined by TEM. The presence of extracellular (for RCDP) and cytoplasmic (for AV) domains of 
GPA and band 3 was confirmed by immunogold staining (Chapter 2.9.3). RCDP detected were larger 
and more abundant compared to AV. Despite the unavoidable presence of membrane fragments 
due to sickling, both types were mainly found as round particles with an external lipid bilayer (Fig. 
4.8A for RCDP and B for AV). AV were not found to form rod structures, in contrast to tubular RCDP 
shown before (Fig. 4.2 and 4.7). This is probably due to their formation through endocytosis. 
Magnetic beads appeared as circular, grey structures (blue arrows) and gold particles (~10nm) as 
black dots (yellow arrows). Enriched RCDP were stained with anti- ex. GPA or band 3 (BRIC256 or 
BRIC200, respectively). Isolated AV were already stained with cyt. GPA- or band 3-AF 647, as part 
of the isolation protocol (Chapter 2.5.2). As previously observed by imaging flow cytometry (Chapter 
3.9.2), there was a great diversity in size amongst RCDP found in the plasma of SCD patients (Fig. 
4.8Ci). Moreover, the TEM results showed that RCDP and AV (stained only against extracellular or 
cytoplasmic proteins domains, not both) are structures with an intact plasma membrane (Fig. 4.7, 
and Fig. 4.8). CR media from 1 culture (discussed in Chapter 3.2) was examined by TEM, however, 
no MP were detected. RCDP and AV from healthy donors were also isolated using magnetic beads 
48h from blood collection. After immunogold labelling, round and tubular RCDP were detected in 
different sizes (Fig. 4.8Ci), as was found for SCD RCDP. Detection of AV was also possible and 
round structures with a lipid bilayer were detected (Fig. 4.8Cii). Comparison of the morphology of 




Figure 4.8 TEM of enriched red cell-derived particles and autophagic vesicles. (A) Isolated 
RCDP from SCD PFP were stained using (i) immunogold labelled ex. GPA (R10) or (ii) & (iii) ex. 
Band 3 (BRIC200). Red scale bars indicate 50nm (i) or 100nm (ii and iii). (B) AV from SCD PFP 
either (i) cyt. Band 3 (BRIC155) positive were stained with gold cyt. Band 3 (BRAC66) or (ii) cyt. 
GPA (BRIC163) positive were stained using gold cyt. Band 3 (BRAC66). Red scale bars indicate 
100nm (i) or 50nm (ii). (C) Isolated RCDP were stained using gold ex. GPA (R10) (i) and AV stained 
with cyt. GPA (BRIC163) (ii) from healthy PFP. Scale bars indicate 100nm (i) & (ii). Yellow arrows 




4.3.2 Storage vesicles and storage effects 
Apart from RCDP and AV, the morphology of 3 SV preparations was examined. These SV were 
formed by RBC budding during storage (165, 352) and were isolated from outdated blood units (day 
35) by centrifugation (Chapter 2.2.3) then immunogold labelling followed. SV were found to form 
round and tubular structures surrounded by lipid membranes (Fig. 4.9A). Gold particles detecting ex. 
GPA were also observed (yellow arrows). In addition, old SV isolated 49 days after blood collection 
from one blood unit were also examined (Fig. 4.9B). Despite the presence of gold particles detecting 
ex. GPA on several SV, their shape had changed remarkably, probably because of biochemical 
alterations during storage, forming irregular structures. Generally, SV lost their round shape and less 
ex. GPA could be seen. 
 
Figure 4.9 TEM of storage vesicles. (A) SV were isolated on day 35 by centrifugation, then stained 
using immunogold labelling against ex. Band 3 (i) or ex. GPA (ii & iii). Red scale bars indicate 100nm 
(ii & iii) or 50nm (iii). (B) SV isolated on day 49 and stained for ex GPA. Red scale bars indicate 
100nm (ii & iii). Yellow arrows indicate immunogold particles. Images in (A) are representative of 3 




4.3.3 Imaging storage vesicles by super resolution microscopy 
So far, confocal microscopy could detect RCDP close to 1μm but it was not found sensitive enough 
to detect smaller RCDP, as they were close to instrument’s diffraction limit. For this, super resolution 
microscopy was carried out on SV preparations (day 35), as it was easier to enrich high numbers 
due to the isolation method used (Chapter 2.2.3). Then, SV were stained with anti-ex. GPA or anti-
ex. Band 3 (Fig. 4.10 left and right, respectively). For first time, it was possible to detect particles 
below 1μm, as observed above on a confocal microscope (see Fig. 4.3A). This indicated that 
visualisation of enriched RCDP and AV by confocal microscopy was possible. However, it was not 
carried out due to lack of time. 
 
Figure 4.10 Protein detection in storage vesicles. Images from 2 SV preparations were stained 
with anti-ex GPA-AF 647 (left) or anti-ex. Βand 3-AF 488 (right). White bars represent 5μm (left) or 
0.5μm (right). Image was captured using 1000X magnification.  
 
 
4.4  Size determination of enriched red cell particles, autophagic and storage vesicles by DLS 
The size of RCDP and AV from SCD and healthy PFP isolated using immunomagnetic beads, as 
well as SV (day 35) preparations was estimated using DLS. Since RCDP and AV contained magnetic 
beads (50nm), the instrument could have miscalculated the size by up to 100nm, in cases where 2 
beads were bonded on anti-diametric positions on the MP. As described in Chapter 3.7, DLS failed 
to read polydisperse samples and so enriched RCDP and AV from only 3/10 plasma samples, could 
be measured by the instrument. First peak (PK1 on the table) at 6-9nm corresponded to buffer 
particles and it was observed in all experiments. RCDP, readings from 1 SCD sample (P21) and 1 
healthy (H1) showed 2 peaks around 60 and 480nm, suggesting similar RCDP sizes between SCD 
and healthy individuals. However, a second sample from a healthy individual (H2), revealed one 
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peak at 193nm, demonstrating size variability between healthy samples. A small peak at approx. 
5.5μm was detected (Fig. 4.11A, not shown on the table), which probably corresponds to large 
membrane fragments. It should be considered that since all these particles are bonded with magnetic 
beads, the reading of 50nm probably corresponds to unbound beads and therefore RCDP detected 
ranged from 150-420nm.  
 
 
Figure 4.11 Size estimation of enriched plasma vesicles and storage vesicles by DLS. On the 
left: RCDP (A) and AV (B) were enriched from 1 SCD PFP sample (SCD1) and 2 healthy (H1, H2) 
PFP sample and their size, along with diluent buffer used (red for (A) and green for (B)), was 
estimated using DLS. (C) Size estimations from 2 SV (day 35) preparations in red and blue. Buffer 
is shown in green. In the table, the mean intensity of detected MP diameter (d. nm) and the area 
intensity (%) of each peak (PK) are presented. 
 
AV enriched using cyt. GPA from the same samples used above, were found to be less diverse in 
size, approx. 65nm for healthy AV and 142nm for AV from SCD plasma (Fig. 4.11B). Similar to the 
RCDP results, the peak detected at 4-4.6μm was probably composed of large membrane fragments. 
Considering that readings in healthy samples corresponded to unbound beads, it was estimated that 
larger AV from SCD samples could reach up to 100nm. On the other hand, results from 2 SV 
preparations were close to 200nm (Fig. 4.11C), which is the reported size for such SV (183).   
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4.5 Detection of red cell proteins, calcein AM and PS on enriched and storage vesicles  
Protein abundance was examined by imaging flow cytometry, as was previously shown to be a more 
sensitive method for protein detection than flow cytometry (Chapter 3.9-10). RCDP and AV were 
stained against RBC proteins (ex./cyt. GPA, ex./cyt. Band 3, cyt. GPC and GLUT1), along with 
calcein AM, an intact marker for MP (349). Calcein AM was only used along with anti-ex or cyt. GPA 
(dual staining) in order to detect intact RCDP or AV, respectively. RCDP from 6 SCD PFP showed 
that despite being enriched for ex. GPA, ex. Band 3 was the most abundant protein (7.72x106± 
1.01x107 RCDP/ml) (Fig. 4.12A and Table 4.2). Ex. GPA was detected in 2.57x106 ± 2.43x106 
RCDP/ml, whereas all cytoplasmic proteins tested (GPA, band 3 and GPC) as well calcein AM+/ ex. 
GPA+ RCDP were found at lower levels below 6.6x105 events/ml. Ex. Band 3 was significantly higher 
than cyt. Band 3 (P=0.02), as well as GLUT1 (P=0.04) (Table 4.2, indicated in bold). The higher 
levels detected for the extracellular protein domains confirmed that detected RCDP were indeed 
right-side out, exposing extracellular RBC protein domains as parts of RBC membrane. 
 
Figure 4.12 Protein abundance of enriched plasma and storage vesicles. Isolated RCDP (A) 
and AV (B) using immunomagnetic separation from 6 SCD PFP were stained against RBC proteins 
(ex./cyt. GPA, ex./cyt. Band 3, cyt. GPC and GLUT1) and calcein AM, then analysed by imaging flow 
cytometry. (C) SV (day 35) (n=3) were stained with the same antibody panel and annexin V. Lines 
represent mean ± SD.  
 
Interestingly, in AV isolated from 6 patients using an anti- cyt. GPA, ex. and cyt. Βand 3 were also 
the most prevalent proteins (2.18x106/ml ± 2.12x106 and 2.08x106/ml ± 1.76x106, respectively) (Fig. 
4.12B and Table 4.2). AV exposing ex GPA+ were found at concentrations of 1.89x106 ± 2.38x106/ml 
and GLUT1+at 1.08x106 ± 2.27x105/ml. Cyt. GPA, cyt GPC and calcein/cyt. GPA dual positive AV 
numbers were below 1x106 /ml (Table 4.2). There was no significant difference in the number of AV 
expressing these different proteins. Because of the similar levels of ex and cyt. Band 3 as well as 
ex. GPA (appr. 2x106) exposed on AV, despite the fact that the enrichment was based on cyt. GPA, 
it was hypothesised that presence of extracellular and cytoplasmic domains probably corresponds 
to membrane fragments rather than AV. Furthermore, increased levels of GLUT1 on AV compared 
109 
 
to RCDP (Table 4.2), suggest that the antibody detects a cytoplasmic epitope, which is in line with 
what was shown before in Chapter 3.9.2, where GLUT1 levels, as well as all cytoplasmic domains 
were found to be less exposed than extracellular domains in SCD PFP. Despite cyt. Βand 3 and 
GLUT1 positive events being higher in AV than RCDP, no statistical significance was revealed. 
Interestingly, Calcein AM/ ex. or cyt GPA dual positive events were similar (approx. 6x105 events/ml), 
which means that numbers of isolated intact RCDP and AV were the same in plasma. However, the 
total number of RCDP (1.2x107 /ml) was 9-fold higher than AV (9.2x106 /ml). 
Three SV preparations from outdated blood (day 35) were also examined for the presence of the 
above RBC proteins, as well as annexin V, an apoptotic marker that targets PS (Fig. 4.12C) (335, 
336). The number of annexin V+ events were higher (8.28x107 ± 1.16x108/ml) along with ex. Band 
(4.39x107± 2.54x107/ml). Slightly lower numbers of ex. GPA+ (1.32x107 ± 1.56x107/ml) were found, 
whereas rest of the proteins were present on low numbers of SV (< 5x105/ml) but the differences 
were not statistically significant. 
 

























- 6.19 25.71 3.10 77.17* 1.58 5.62 0.47 119.84 
RCDP 
SD 
- 3.93 24.31 5.34 101.20 3.55 5.90 0.58 - 
AV 
Mean 
- 6.57 18.95 6.98 21.80 20.83  6.38 10.77 92.28 




131.69 4.69 438.69 0 3.40 0.005 140.64 
SV SD 11.61 - 55.66 5.91 253.90 0 3.24 0.008 - 
Results of proteins detected in enriched RCDP, AV from SCD plasma (both n=6) and SV (n=2) were 
compared using a nonparametric ANOVA and Kruskal-Wallis test. * P≤0.04 compared to cyt. Band3 





4.6 Optimising a protein quantification protocol on enriched vesicles  
Further protein characterisation of RCDP and AV from SCD and healthy PFP was attempted by 
proteomic analysis using mass spectrometry, in order to identify any differences between these 
populations. For this type of analysis, protein concentrations tested should be the same for all sample 
types, so meaningful comparisons can be drawn. All the different methods and conditions tested are 
summarised in Table 4.3. 
 
i) Bradford assay and different red cell hypotonic lysis buffers 
Initially, protein quantification was attempted using the Bradford method, which was used 
successfully for ghost membrane and SV preparations. All results obtained for RCDP and AV by this 
method were either too low to be detected or did not provide reproducible results. A commercial 
hypotonic RBC lysis buffer was also used, as well RIPA buffer (Chapter 2.11.1), unsuccessfully. 
Despite concentrating the enriched population using centrifugal filters, protein levels were always 
undetectable. It was assumed that enriched RCDP and AV numbers were low, hence, higher PFP 
volumes for enrichment were used. RCDP and AV from SCD and healthy PFP were isolated from 
appr. 25ml, rather than 1ml, which was the usual PFP volume. 
 
Table 4.3 Protein assays and conditions tested for red cell ghosts, storage and enriched 
vesicles.  
 
Details of the BCA assay (encircled in blue) are presented on the right. Y-assay worked, N-assay 





ii) Assessment of protein dissociation in protein quantification 
Another reason for undetectable protein levels could be the incomplete lysis, due to inadequate 
mixing of the sample in lysis buffer and the formation of protein aggregates. The effects of 
dissociating protein by sonication, mechanical forcing by passing samples through a syringe, or just 
mixing thoroughly, were assessed. RIPA buffer was added to SV preparations at 1:1, 1:2 and 1:4 
volume ratios and samples were either mixed using a vortex, sonicated or forced through a syringe 
(Chapter 2.11.1). A centrifugation step followed, to pellet insoluble proteins and debris, then 
supernatants were collected and tested using a commercial BCA kit (Chapter 2.11.3). Results 
showed that both dissociation methods gave similar protein content compared to mixing, which 
always produced the lowest protein concentration. It was decided to use mechanical force, which 
was more gentle for the sample than sonication. However, when enriched RCDP and AV were 
tested, the protein concentrations were either too low to be detected, or readings were inconsistent. 
One thought was that protein levels in enriched RCDP and AV were undetectable because they were 
eluted in PBS buffer, just after the enrichment stage (see Chapter 2.5.2 and Fig. 2.1). Lysis buffers 
are usually added to a cell pellet, which was not the case here, as enriched RCDP and AV were in 
solution. Thus, RIPA buffer 10x was used at a final 1x concentration on enriched RCDP and AV. 
However, again, this did not work for RCDP and AV. 
 
iii) Protein precipitation 
Since a relatively large volume of sample was required for readings using a plate reader (20-100μl), 
the Nanodrop was used instead, which requires only a few microlitres of the sample. However, RIPA 
buffer was shown to interfere with the Nanodrop. Thus, protein precipitation using acetone was 
carried out, in order to remove the lysis buffer and precipitate the protein. The readings from the 
Nanodrop indicated that protein concentrations in enriched RCDP from both SCD and healthy PFP 
ranged from 67-85mg/ml, whereas AV from both sources ranged from 74-94mg/ml (Table 4.4). As 
controls, beads for each type were included and protein concentration was found to be 63mg/ml for 
the RCDP control and 73mg/ml for the AV. RBC ghosts and SV lysates, which had previously had 
protein concentration determined by Bradford assay (Chapter 2.11.2), were also quantified using the 
Nanodrop and same readings were obtained. The readings from the Nanodrop were used to 
examine protein presence in lysates and controls by immunoblotting. 
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Table 4.4 Protein detected in controls and lysates using Nanodrop. 
Prot - protein detected in RCDP or AV lysates. 
iv) Investigation of protein levels by immunoblotting 
Before lysates were sent for mass spectrometry, an additional validation was carried out. This was 
to confirm that proteins originated from RBC by immunoblotting against band 3 (Chapter 2.11.6). 
Initially, protein was loaded at 20μg/well and RBG ghost membranes were used as a positive control. 
Samples were probed for band 3, as well as stomatin, which is widely exposed by SV and RBC 
membranes (183, 216). Both proteins were detected in the positive controls but not in the samples 
(Fig. 4.13). Band 3 was detected as a smear at appr. 90-100kDa and apparent molecular weight of 
stomatin was appr. 30-32kDa. Blotting experiments were repeated several times, increasing the 
sample concentrations up to 150μg/well and no bands were detected for band 3.  
 
Figure 4.13 Investigation of band 3 and stomatin on SDS-PAGE gels and blots. Lysates of 
RCDP (left) and AV (right) from 3 healthy (H) and 4 SCD (P) PFP samples were analysed for band 
3 (BRIC170) and stomatin, using RBC ghosts as a positive control. Molecular weight marker (M) 
indicated in kDa. Representative result from 6 experiments. 
 
v) Protein identification using mass spectrometry 
Finally, a quick mass spectrometry test (Chapter 2.12.2) was carried out in 2 lysates, one from RCDP 
and one from AV, both enriched from SCD samples. Results revealed that samples were enriched 
in keratin and other contaminants but no RBC proteins were present. This was in line with the results 
from immunoblot analysis (see Fig. 4.13).  
Controls Protein (mg/ml) Lysates Prot RCDP (mg/ml) Prot AV (mg/ml) 
RCDP (anti-GPA 
beads) 
63.35 H3 72.00 74.39 
AV (anti-cyt GPA+ 
beads) 
72.87 H4 75.92 76.64 
RBC ghosts 5.66 H5 84.77 82.87 
SV 1.34 P21 77.71 74.74 
  P22 74.39 76.50 
  P23 69.82 93.88 




In SCD patients, destruction of abnormal cells as well as incomplete reticulocyte maturation, due to 
splenic sequestration, results in increased RCDP levels compared to healthy individuals (179, 180, 
255, 269). It is suggested that RCDP are formed by membrane blebbing, resulting in right side-out 
microvesicles which expose PS (267, 269, 337). Our colleagues have previously reported the 
presence of AV on maturing reticulocytes, as well as sickle cells. AV were found to expose PS, as 
well as the cytoplasmic domains of RBC membrane proteins, having therefore an inside-out 
orientation (127, 182). It was suggested that these AV are removed by splenic passage during 
reticulocyte maturation and phagocytosed by splenic macrophages. In SCD patients, a damaged 
spleen would cause AV to be released directly into plasma, resulting in elevated AV numbers in such 
patients (127). 
Some commonly reported methods for MP isolation are sequential or differential centrifugation and 
size exclusion chromatography, which can isolate small particle sizes (348). Since our interest was 
focused on RBC particles only, the above methods were not applicable, as MP from other types of 
blood cells would be collected. FACS was assessed for RCDP and AV isolation from non pelleted 
and pelleted SCD plasma, targeting ex. or cyt. GPA, respectively. However, FACS failed to detect 
small particles below 200nm in size. Furthermore, high velocity centrifugation used to pellet PFP 
could damage RCDP and AV, or even lead to formation of artificial MP (348, 353, 354). As RCDP 
would ideally be isolated from plasma without centrifugation (353), immunomagnetic separation 
using commercial beads that target either ex. GPA directly for RCDP isolation, or cyt. GPA, indirectly 
for AV identification, was a more gentle and efficient way of enrichment. This was the first 
demonstration of RCDP and AV enrichment from SCD and healthy plasma. From observations by 
collaborators using imaging flow cytometry, all RCDP and AV could be removed by using 4-10%(v/v) 
of these beads in plasma, as they could not be detected in the flow through before elution. However, 
TEM revealed that such concentrations were saturating the sample with beads and so lower bead 
concentrations were tested. Saturation with beads could potentially contribute to the total protein 
content, especially in AV where the anti-cyt. GPA was used. However, this was not found to be the 
case, when protein content was analysed. The optimum concentration was found to be 0.35%(v/v) 
for beads targeting RCDP and 0.12%(v/v) for AV.  
Due to the immunomagnetic beads bound to enriched RCDP and AV, DLS and nanotracking 
analysis, which are widely used for size estimation, could not be used to detect size (353). Both 
methods calculate size according to their Brownian motion and beads on MP would be considered 
to be a single particle. However, since RCDP and AV were analysed under the same protocol, DLS 
provided a rough size estimate for the most abundant large populations. RCDP from SCD and 
healthy plasma were approx. 150-420nm, whereas AV from SCD were approx. 100nm. Readings of 
AV from healthy plasma corresponded to unbound beads (~50nm), indicating that AV are cleared 
by the spleen in healthy individuals (127). As the above estimations were from 2 samples from 
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healthy individuals and 1 from SCD plasma, more samples need to be examined. However, this 
suggested that RCDP are larger than AV. This is in line with our findings from imaging flow cytometry, 
where detected AV were much smaller than RCDP and were far less abundant than them (Smith et. 
al, manuscript submitted). These findings were also confirmed by TEM, as RCDP were found to be 
larger and more abundant than AV. Additionally, sizes detected by DLS, as well as observations by 
TEM, are in the range suggested for microvesicles (up to 1μm) and exosomes (up to 150nm) (155), 
which further supports the categorisation of RCDP and AV as microvesicles and exosomes, 
respectively.  
Recently, we demonstrated that RCDP and AV from SCD PFP can be visualised using imaging flow 
cytometry (Smith et. al, manuscript submitted). However, it was assumed that small membrane 
aggregates and tiny membrane fragments could be regarded as small, round particles by the 
instrument. TEM allowed us to distinguish intact round RCDP and AV from membrane structures 
and prove that the morphology of isolated RCDP and AV from SCD and healthy PFP corresponded 
to true microvesicles, rather than membrane fragments. The morphology of RCDP and MaV is in 
agreement to what was first observed in healthy individuals, by cryo-electron microscopy (355). 
However, this is the first demonstration of RCDP in SCD plasma, as well as AV in both plasma 
sources. 
Imaging flow cytometry showed that RCDP from healthy and SCD plasma expose the extracellular 
domains of GPA and band 3, which further supports the concept that RCDP are formed by 
membrane budding. On the other hand, similar levels of extracellular and cytoplasmic protein 
domains on AV indicated the existence of inside-out AV, along with unsealed membrane blebs. 
GLUT1 expression was 10-fold higher on AV than RCDP. This supported the manufacturer’s (PDPU) 
assumption that the antibody recognises an intracellular epitope, as well as our hypothesis about AV 
formation through autophagy. Recently we showed that numbers of RCDP and AV were 5-fold and 
3-fold higher in SCD plasma than in healthy individuals respectively, while RCDP were significantly 
increased in crisis patients than in healthy plasma (Smith et. al, manuscript submitted), suggesting 
they may play a role in vaso-occlusion in these patients. More research in this field may reveal useful 
biomarkers for vaso-occlusive crisis in SCD. While significantly higher RCDP numbers in SCD 
patients than healthy individuals have been previously reported by others using flow cytometry (333, 
346), here we confirm that previous findings corresponded to RBC ghosts and MaV rather than 
microvesicles. 
Intact RCDP and AV were identified by staining with calcein AM, along with ex. GPA or cyt. GPA, 
respectively. Calcein AM can easily permeate intact cells and is hydrolysed by intracellular 
esterases, producing a fluorescent product (356, 357). RCDP and AV, which expressed calcein AM, 
were found to be similar but relatively low compared to other proteins examined, such as GPA and 
band 3. This might indicate that due to their small size, some RCDP and AV may lack esterases. It 
could also be that calcein AM binding to small RCDP and AV is prevented by their high curvature. 
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However, as only GPA was used along with calcein AM in order to identify intact vesicles from RBC, 
it would be interesting to repeat this experiment replacing GPA with band 3, which was found in 
higher levels than GPA. Analysis of SV by imaging flow cytometry revealed mainly ex. Band 3 and 
PS exposure. The last finding is not surprising due to increasing PS levels on senescent RBC during 
RBC aging (191, 217, 358). Band 3 is one of the most abundant proteins on RBC, along with GPA 
(90). Despite the fact that it undergoes aggregation or degradation during storage, band 3 remains 
abundant in stored RBC (day 42) and SV (218), which is in line with our findings. Our findings that 
SV change shape to less round particles during storage, can be attributed to storage conditions and 
band 3 clustering, as irregular RBC morphology have also been reported for stored RBC (358, 359). 
Our finding that RCDP levels were higher in SCD patients in crisis than in steady state lead us to 
hypothesise that removal of large RCDP and MaV may alleviate vaso-occlusive episodes in SCD 
(Smith et. al, manuscript submitted). Exploring the differences in proteome between RCDP and AV 
in healthy individuals and SCD patients could potentially reveal useful biomarkers of vaso-occlusion, 
as well as the severity of the disease. A considerable amount of time was devoted to optimisation of 
a protocol that could quantify proteins in enriched RCDP and AV. Initially, it was attempted to 
minimise manipulation of RCDP and AV samples. However, difficulties in protein quantification led 
to the addition of multiple steps in the protocol, such as protein dissociation and precipitation. 
Although the initial experiments by Coomassie stained SDS-PAGE gels revealed that protein could 
be identified in RCDP and AV samples, the updated protocol used for lysate preparation did not 
allow us to identify the major RBC membrane proteins like band 3, probably due to denaturation. 
Taking this work forward, protein loading of enriched RCDP and AV could be calibrated by matching 
the sample loading using immunoblotting (360). Despite the fact that protein quantification would be 
only semi-quantitated, sample manipulation and protein denaturation will be prevented. Furthermore, 
this would provide an estimation of relative protein abundance amongst samples, allowing protein 
examination by comparative proteomics analysis.  
In β-thalassaemia, the proteome of RCDP has been explored in patients and compared with that in 
healthy individuals by Kittivorapart et. al, 2018. Protein exposure for antioxidants, iron sequestering 
proteins and chaperones was higher in patients than controls, whereas haptoglobin and hemopexin, 
which remove free haemoglobin and heme respectively, were found to be significantly reduced, 7.1- 
to 20-fold for haptoglobin and 12.5-to 25-fold for hemopexin (361). Similar reductions in the last two 
proteins was also reported in paediatric SCD patients, which suggested that these proteins could be 
used as biomarkers for the severity of both diseases (362). However, in that study, RCDP were 
isolated by ultra-centrifugation and sedimented particles could originate not only from RBC but from 
any cell type. Presumably, this is the reason that pelleted protein from 1ml plasma was more than 




In another study examining the proteome of band 3 complexes in RBC and SV during ageing, 
analysed protein gel bands were used. The findings suggested adenylosuccinate lyase, α-adducin 
and flotillin-2 as potential markers for RBC ageing during storage (218). Despite the efficiency of this 
method, in our study it was attempted to identify the whole proteome of RCDP and AV, including the 
low protein levels which would not be picked up by a Coomassie-based stain on a gel.  
In conclusion, immunomagnetic separation proved to be a better method for RCDP and AV isolation 
of all sizes, without damaging the plasma. This is the first demonstration of small RCDP and AV in 
SCD and healthy samples. AV from both sources were found to expose the cytoplasmic domains of 
GPA, band 3, GPC, GLUT1 and PS, whereas RCDP exhibited the extracellular domains along with 
PS. RCDP were found to be larger and more abundant than AV. Further research on their proteome 





  Inducing tolerance to red cell antigens in a murine model 
5.1 Introduction 
SCD patients undergoing frequent blood transfusions in order to increase the numbers of healthy 
RBC, can develop alloimmunisation, which is a major complication as it can lead to life-threatening 
haemolytic reactions and haemolysis (310, 311). This is caused by genetical and racial differences 
between patients with African ethnicity and white donors (363, 364). Alloimmunisation has been 
found to depend on the patient’s immune system, as well as the age of first transfusion. It has been 
shown that children who received their first transfusion before age 3 had significantly lower 
alloimmunisation levels compared to those transfused later, probably due to their undeveloped 
immune system (322-326). 
Different mechanisms have been suggested to explain alloimmunisation but the exact mechanism 
is yet unknown (120). A proposed model described decreased levels of immune suppressive IL-10, 
which enable APC to recognise the antigen on the transfused RBC and proceed to antigen 
presentation and alloantibody production (365). A study in alloimmunised and non alloimmunised 
chronically transfused 22 SCD and 8 β-thalassemia major patients showed suppressed peripheral 
Tregs and increased Th1 responses to Th2 along with higher levels of circulating IFN-γ and lower 
IL-10 levels in alloimmunised patients compared to those without alloantibody present (317). 
Furthermore, B regulatory cells (Bregs), that were previously shown to control Treg and Th 
differentiation (366, 367), were also found to produce lower levels of IL-10 in alloimmunised patients 
and failed to inhibit TNF-α production by monocytes efficiently, suggesting implication of IL-10, IFN-
γ and TNF-α in alloimmunisation (368). 
Since 1911, it is known that the regular exposure to an antigen can enable the immune system to 
become tolerant to it (369). In some cases of allergic diseases, it has been shown that tolerance can 
be achieved by specific allergen immunotherapy, via antigen delivery in increased doses in order to 
cause desensitisation (370). For example, immunotherapy against house dust mites and pollen in 
allergic rhinitis can result in remission in up to 80% of cases (371). Billingham et. al, in 1953 were 
the first to induce tolerance to transplanted tissue by administration of allogeneic BM and 
splenocytes into neonatal mice. Once the animals had reached adulthood, they were successfully 
given skin allografts from the same source as the BM and splenocytes without immunosuppression 
(372). Later in 1969 induced tolerance to sheep RBC was demonstrated in mice by inoculating the 
sensitiser once or twice (373). In some other studies, patients received a blood transfusion before 
kidney transplantation from the donor and revealed less rejection than patients who haven’t been 
previously transfused (374-376). Conjugation of the antigen to cellular components is known to 
promote antigen uptake by dendritic cells (377, 378). This can trigger the differentiation of IL-10 
producing Tregs and further promote tolerance (379, 380). RCDP and SV are recognised by immune 
cells (179, 180). Here, we explored the possibility of inducing tolerance to different blood groups, by 
exposing immune competent mice to low levels of RBC antigens exposed on RBC ghost 
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preparations and SV. The immunogenicity of ghost from SCD and healthy donor samples, 22 days 
after blood collection, was also examined. Responses were assessed using serology, as well as a 
commercial cytokine assay. 
 
RESULTS 
5.2 Experimental design 
5.2.1 Developing an appropriate haemagglutination test for mouse plasma  
To investigate whether inducing tolerance to RBC antigens is possible, ghosts preparations (Chapter 
2.2.2) were used as natural RBC antigen carriers (381). To assess the immune responses in vivo 
after inoculations (Chapter 2.13.1), a respective test had to be developed. Serology is commonly 
used to assess RBC compatibility prior to blood transfusion (338, 339). Here, we modified a 
commercial haemagglutination assay used for detection of paroxysmal nocturnal haemoglobinuria. 
This assay was selected because the microtubes used for the test contain rabbit anti-mouse antibody 
within the gel matrix, which means that it can bind mouse antibodies in the plasma (Fig. 5.1Ai). Our 
hypothesis was that if the mouse plasma contains antibodies against human RBC, then those 
antibodies will bind to the cells during incubation (Fig. 5.1Aii) and haemagglutination will occur. Next, 
anti-mouse secondary antibodies in the gel will bind the heavy chain of mouse antibodies linked to 
agglutinated RBC, retaining the cell clump on the top of the tube and indicating a positive result (Fig. 
5.1Aiii and 5.1B left). If no anti-human antibodies are generated by the mouse, then RBC would 
sediment in the bottom of the microtube (negative, Fig. 5.1Aiv and 5.1B right).  
 
Figure 5.1 Assessment of mouse anti-human antibody production using a gel card. (A) 
Schematic of the experimental process. Mouse plasma was mixed with human or mouse RBC on 
the top of the tube (i), then incubated and centrifuged (ii). In a positive reaction, anti-human antibody 
in mouse plasma coated RBC and caused haemagglutination. Coated RBC were retained by anti-
mouse antibody in gel (iii). In absence of mouse anti-human antibody, RBC sank to the bottom of 
the tube (iv). (B) Actual positive (left) and negative results (right) observed on a gel card at the end 
of the experiment. 
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Apart from the actual test, which was intact human RBC from the same donor that the ghosts were 
prepared from (Fig. 5.2A 4th tube), both positive and negative controls were included. Murine RBC 
(m-RBC) and plasma from the same mouse were used as a negative control, as the plasma would 
not contain antibodies against its own RBC (Fig. 5.2A 5th tube). As a positive control, a mouse anti-
human Lutheran (Lu) antibody was used (see Table 2.1) which caused haemagglutination when 
mixed with human reference RBC of known phenotype, exposing Lu (Chapter 2.13.4) (Fig. 5.2A 6th 
tube). Three separate human reference RBC were incubated with mouse plasma (Fig. 5.2A tubes 
1-3) and served as alternative positive controls. Initial tests showed that our hypothesis was correct. 
Apart from the negative and positive results for all the controls (Fig 5.2A and B), in some cases the 
antibody was specific to the donor cells (Fig 5.2C). A mixed result was obtained sometimes, 
indicating that the anti-human antibody concentration in mouse plasma was too low to cause 
haemagglutination of RBC (Fig 5.2D and E). In these cases, the test was repeated a week later and 
usually by this time the antibody concentration had increased enough to cause haemagglutination.  
 
Figure 5.2 Detected results on a gel card. Human reference cells (tubes 1-3 and 6, alternative and 
positive controls, respectively), donor RBC (4th tube in yellow box, actual test) and m-RBC (5th tube, 
negative control) (all 0.8%) were mixed with mouse plasma (tubes 1-5) or mouse-anti human Lu (6th 
tube). (A) Negative and (B) positive reactions. (C) Positive reaction specific to the donor. (D) Mixed 




5.2.2 Setting up an appropriate experimental model  
This study had to be designed, validated and optimised from the beginning. Immune competent 
BALB/c mice were used, since this strain is widely used for assessing immune responses (373, 382). 
In the early phase of the experiments, the immunogenicity of ghost preparations was examined, due 
to the fact that Hb remnants during their preparation from RBC could potentially trigger haemolysis, 
as well as the fact that they carry RBC antigens, such as Kell (381). Ghosts are larger than SV (7μm 
to 200nm, see Chapters 3.8 and 4.4, respectively) meaning they could contain more antigens on 
their membrane than smaller SV. Hence, induction of an immune response using ghosts could 
potentially be stronger. Also, ghosts were chosen for the first experiments as a more accessible 
source than SV, since they can be counted on a conventional flow cytometer. Use of SV on the other 
hand, required accurate readings that could be taken by an imaging flow cytometer outside of Bristol 
(Chapter 2.7), as their size was previously found to be below the detection limit of the flow cytometer 
(Chapter 3.3.3.1). In order to reproduce biochemical changes on transfused RBC caused by storage, 
such as PS exposure (221), ghosts were prepared from RBC 22 days after blood collection (Chapter 
2.2.2). PS exposure is of great importance as it is a well-known “eat me” signal for phagocytic cells 
(94), it would therefore stimulate these cells leading to an immune response. The quality of ghost 
preparations was examined by GPA and band 3 levels, as well as PS by flow cytometry (Chapter 
2.6), in order to ensure that these proteins remained intact after preparation. Additionally, ghost 
preparations from 2 blood units were examined for the presence of calcein AM, in order to identify 
how well sealed they were. Both preparations found positive for calcein AM (65.6 and 71.4% 
respectively), which indicates that they were well resealed after RBC lysis (Fig. 5.3). This showed 
that the protocol selected for ghost preparation, generated resealed ghosts, representing a sealed 
population like cells or MP, rather than large membrane fragments. 
 
Figure 5.3 Examination of red cell ghost preparations. Ghosts were prepared from RBC using 
hypotonic lysis, from 2 blood units 22 days after collection. Ghosts were stained with calcein AM to 




One limiting factor was the volume of blood obtained after bleeding the mice: each 
haemagglutination test required 125μl of plasma (5 tubes x25μl), which corresponded to approx. 
250μl blood. However, the test was validated to work with half the volume of plasma/ RBC by our 
colleagues at NHSBT. This means that at least 125μl of blood needed to be aspirated, which is a 
relatively large volume for venepunctures, requiring time to collect. Use of serum instead of plasma 
by leaving blood to clot was not an option, as RBC were needed for serology. Instead, blood was 
collected in Alsever’s whereby both RBC and plasma could be used.  
In order to examine the sensitivity of the haemagglutination test on a gel card in diluted plasma, half 
serial dilutions were carried out using plasma samples from 3 mice which previously showed 
haemagglutination on termination. The detection limit of the gel card was shown to be very low. 
Mixed positive results indicating semi-haemagglutination and a reduction in antibody levels, was 
detected even when plasma was diluted more than 1,280 times (Fig 5.4). Thus, it was decided that 
it was only necessary to aspirate 5-10μl of blood, corresponding to 2.5-5μl plasma for these tests 
and dilute in 100μl Alsever’s. The dilution factor (DF) was calculated as a ratio of final volume to the 
initial volume and ranged from 22-42 (110-105μl total volume of blood in Alsever’s / 5-2.5μl plasma). 
For this reason, capillaries used to aspirate the venepunctures were marked to indicate 2.5, 5 and 
10μl of volume. 
 
Figure 5.4 Assessing the gel card sensitivity by antibody titres. Three mice (A-C) were injected 
with 5x105 ghosts (day 0), challenged with RBC from the same donor 22 days later and 
exsanguinated on day 36. Half dilutions from murine plasma diluted in Alsever’s. Green boxes 
indicate mixed haemagglutination. In sample C a mixed reaction was not observed using the dilution 
factors indicated. DF - dilution factor.  
Another restrictive factor was the method of cardiac blood collection on termination. During the first 
experiments, blood was collected by inserting the needle from the top of the mouse heart (Fig. 5.5i). 
While competent users applying the procedure can collect up to 1ml, here, blood collections ranged 
from few microlitres up to 700μl. In later experiments, cardiac puncture was performed from the 




Figure 5.5 Syringe position for cardiac puncture. Mice were anaesthetised with isoflurane and 
cardiac puncture was performed either from the top (i) or the bottom (ii) of the sternum. In both cases, 
needles were positioned horizontally, as the arrows indicated. Image was reproduced from (383).  
 
5.3 Investigating immune responses induced by ghost preparations 
Choosing the dose to induce tolerance was the most challenging part of the experimental design. It 
was decided to start with 1x105 ghosts, as such doses were reported to enhance T-cell differentiation 
to Th1, rather than Th2, in mice, when using sheep RBC (384). Ghosts were emulsified with CFA, a 
suspension of inactive mycobacteria in oil that induces immune responses (385), then injected 
subcutaneously. The early experiments lasted 9-15 days and aimed to assess immune responses 
and differences in cytokine levels between mice receiving HBSS in CFA (controls) and mice 
inoculated with ghosts/CFA (Fig. 5.6A). Immune responses were further assessed by serology and 
a commercial cytokine assay that can test up to 40 different cytokines (Chapter 2.13.5).  
In the first experiment, 3 mice were inoculated with 1x105 ghosts from an A+ blood donor, which was 
the lowest dose reported to induce Th1 responses (384) and 3 mice were given HBSS (controls). It 
was not known whether ghosts may induce a rapid and severe immune response, so mice were 
culled after 9 days, without being exposed to RBC (Fig. 5.6A). Serology tests showed positive 
immune reactions to ghosts (Fig. 5.6B). Proinflammatory cytokines and chemoattractants, such as 
B lymphocyte chemoattractant (BLC) (386), tissue inhibitor of metalloproteinase-1 (TIMP-1) (387, 
388), soluble intercellular adhesion molecule (sICAM-1) (389), complement component 5a (C5/C5a) 
(390), stromal cell-derived factor 1 (SDF-1 or CXCL12) (391) and macrophage colony-stimulating 
factor (M-CSF) (392) were the most abundant detected by the cytokine assay, although most of them 
were at very low levels. However, this assay does not provide quantitative information, instead it 
allows comparisons of different cytokines (Fig. 5.6C). To determine the predominant cytokines 
detected, pixel values obtained from primed and control mice were transformed to log10 (Fig. 5.6D). 
Then, the mean pixel densities of pro-inflammatory cytokines expressed at higher levels (>1.4 in D) 
are shown (Fig. 5.6E). Log>1.4 was chosen to present overexpressed cytokines by excluding 
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corresponding pixel intensities which were detected in very low levels. Anti-inflammatory IL-1ra and 
pro-inflammatory TNF-α are also presented, as molecules of interest. IL-1ra has been reported to 
control inflammation (393), while TNF-α is implicated in inflammation (394) and has also has been 
reported in alloimmunised patients (368). IL-1ra and TNF-α were detected at low levels in the 
controls but were absent in mice inoculated with ghosts. 
 
Figure 5.6 Responses following inoculation of ghosts. Mice were given HBSS (controls, n=3) or 
1x105 RBC ghosts in CFA (n=3) and left for 15 days. Peripheral blood was collected from 2 mice per 
group and plasma was used for analysis. (A) Schematic of the experimental process. (B) 
Haemagglutination results of the controls (negative result) and mice given ghosts (positive). 
Alternative haemagglutination controls (3 human reference RBC incubated with mouse plasma), 
actual test (donor’s cells with mouse plasma) and positive controls (1 human reference RBC with 
mouse-anti human antibody) are indicated. CT -control. (C) Blot from commercial cytokine assay 
from one mouse given ghosts. Reference spots (blue) showed that the membrane was incubated 
with the secondary antibody before exposure. Duplicates of detected cytokines are boxed in green. 
(D) Log10 transformation of mean pixel intensity of all cytokines detected in blots, after background 
was subtracted from control (n=2) and mice exposed to ghosts (n=2). Undetectable cytokines are 
indicated with a crossed box. (E) Mean pixel intensity of cytokines in (C) with expression >1.4 and 
cytokines of interest. Data shown as mean ± SD. 
 
 
BLC as well as TIMP-1 were expressed at higher levels in the controls than the primed mice. Similar 
levels of sICAM-1, indicating inflammation (389), C5/C5a, a chemoattractant for macrophages and 
neutrophils (390) and CXCL12, which induces chemotaxis for lymphocytes and macrophages, were 
found in controls and ghost primed animals (391). M-CSF that activates macrophages during 
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inflammation (392) and chemokine CXCL1 which activates neutrophils at the inflammatory site (395) 
were detected in lower levels among the dominant cytokines. Cytokine levels between both groups 
could not be statistically examined due to the limited number of replicates (n=2). The same results 
were obtained when the experiment was repeated using higher ghost inocula of 5x105. The results 
from these 2 experiments showed that the chosen concentrations of ghosts were capable of inducing 
an immune response. In addition, ghosts may dampen immune responses, as most of the cytokines 
were decreased or undetectable when compared to the controls. 
In subsequent experiments the dose of RBC ghosts was increased to 1x106. Haemagglutination was 
detected in all six primed mice (ghosts x1) 15 days after inoculation (Fig. 5.7A). In order to investigate 
whether cytokine production could be further induced, a boost of the same dose of ghosts as the 
initial inoculum (ghosts x2) was given to 3/6 primed mice. The experiment was terminated on day 24 
and haemagglutination was detected in all tested mice.  
   
Figure 5.7 Assessing immune responses after a boost of red cell ghosts. Mice were given 
HBSS (control, n=3) or 106 RBC ghosts in CFA (n=6). (A) Haemagglutination assessment of all mice 
on day 15, before the boost. Tests, as well as alternative, negative (NEG) and positive (POS) controls 
(CT) are indicated. (B) Log10 transformation of mean pixel intensity of all cytokines detected in 
control, primed mice (ghosts x1, n=2) or boosted (ghosts x2, n=2), to show cytokine expression. 
Undetectable cytokines are indicated with a crossed box. (C) Mean pixel intensity of higher detected 
cytokines in (B) (log10>1.4) and cytokines of interest. Data shown as mean ± SD. 
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Anti-inflammatory IL-1ra was absent and only pro-inflammatory cytokines were detected (Fig. 5.7B), 
although TNF-α was only found in primed mice, at very low levels. The dominant cytokines detected 
from highest to lowest were sICAM-1, CXCL12, C5/C5a, M-CSF and BLC (Fig. 5.7C), as was shown 
in previous experiments. There were no differences in CXCL12 and sICAM-1 levels among the three 
groups, whereas BLC was absent in control and slightly higher in primed mice. Increased levels of 
M-CSF were also detected in both ghost groups (Fig. 5.7 and C). It was also the first time that TREM-
1, which is expressed on neutrophils, some monocytes and macrophages (396) was found at higher 
levels in primed mice. However, statistical analysis could not be performed between groups due to 
the small number of replicates (n=2). Levels of M-CSF, BLC and TREM-1 were found to be higher 
in primed mice than in controls. This suggested that higher doses of ghosts can induce different 
cytokine levels. 
 
5.4 Assessing effects of exposure to red cell antigens 
Next, it was investigated whether tolerance could be induced after challenging mice with human 
RBC. For the following experiments, ghosts and RBC from the same donor with A+ blood were used, 
in order to avoid antibody generation against RBC antigens from different donors. To prevent 
potential detrimental effects on the mice, the dose used was lower (5x105) (Fig. 5.8A). 
Haemagglutination was showed for 6/6 tested mice on day 14 (Fig. 5.8B) and they were split into 3 
groups (n=2 per group) to be challenged with different RBC doses: 2.5x105 RBC, 5x105 or no RBC. 
Control mice, which were not primed with ghosts, were given 2.5x106 RBC. The final groups were 
formed as stated below: 
1. 2.5x105 RBC (controls, n=3), referred to as RBC (1) 
2. 5x105 ghosts, 2.5x105 RBC (n=2), referred to as ghosts +RBC (2) 
3. 5x105 ghosts, 5x105 RBC (n=2), referred to as ghosts +RBC (3) 
4. 5x105 ghosts, no RBC (n=2), referred to as ghosts 
Mice were left for 2 weeks and then culled (day 35 from start of experiment). Haemagglutination was 
observed in all mice but all controls showed positive reactions only to the donor and not for the 
reference cells, suggesting that the antibody response is specific (Fig 5.8C). This also implied that 
ghosts are more immunogenic than RBC, as positive reactions were observed with the reference 
cells. Ghost immunogenicity may be attributed to potentially more exposed antigens resulting from 
hypotonic lysis of RBC during their preparation. Since the donor had blood group A+ and the 
reference cells were always O+, it was questioned whether the generated immune response was an 
anti-A antibody. Cytokine assessment revealed the presence of pro-inflammatory cytokines only (Fig 
5.8D and E), while prevalent cytokines found were sICAM-1, CXCL12, C5/C5a, M-CSF and BLC, 
which is similar to what was found in the previous experiments above. Although sICAM-1 levels were 
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similar for all groups, levels of C5/C5a, M-CSF and CXCL12 were found to be lower in mice primed 
with ghosts and challenged with RBC (3).  
 
 
Figure 5.8 Examination of immune responses post red cell challenge. Mice were given HBSS 
(n=3) or 5x105 RBC ghosts (n=6) and left for 20 days. Then, all mice apart from 2 mice primed with 
ghosts, were challenged with 2.5x105 RBC (1) or 5x105 RBC (2). (A) Schematic of the experiment. 
(B) Haemagglutination examination of all mice on day 15. Tests, as well as alternative, negative 
(NEG) and positive (POS) controls (CT) are indicated. (C) Positive results and antigen specificity 
(haemagglutination against donor RBC only) were observed in controls after termination (day 35). 
(D) Log10 transformation of mean pixel intensity of all cytokines detected in mice to show log-fold 
cytokine expression. Undetectable cytokines were indicated with crossed box. (E) Mean pixel 





The most abundant cytokines detected were C5/C5a, sICAM, M-CSF and CXCL12. Their levels 
were similar in controls -RBC (1) and ghost groups, although slightly reduced in mice challenged 
with higher number of RBC (group 3). BLC levels were higher in group 3, while mice challenged with 
the lower RBC dose (group 2) had lower BLC than other groups and the lowest M-CSF levels. 
Additionally, IFN-γ and TNF-α, which were previously reported in alloimmunised SCD patients (368), 
as well as chemokine ligand 9 (CXCL9), which was found to be overexpressed in β-thalassemia 
major patients (397) were found at low levels in control and ghost groups but were reduced or 
undetectable in primed mice challenged with RBC. Anti-inflammatory IL-1ra was not detected. Again, 
limited replicates for all groups of primed mice (n=2) did not allow statistical analyses.  
 
 
5.5 Comparisons of responses to O and A blood groups 
In order to investigate whether the response observed above was to anti-A antigens, ABO O+ blood 
was examined as a source of ghosts and RBC. Furthermore, ghosts were replaced with SV from 
outdated ABO O+ and A+ blood (day 35), in order to investigate and compare their immunogenicity 
with what was observed above using ghosts. These SV naturally originate from the RBC membrane, 
exposing membrane antigens (218). Groups of 3 mice were primed with 5x105 A+ SV per mouse, or 
with O+ SV at 3 different doses: 1x105, 5x105 and 1x106 (Fig 5.9A). Most of the mice did not show an 
immune response 15 days after inoculation. Thus, a boost of the same initial inoculum, was given to 
all mice. Ten days later, all mice given O+ SV showed positive haemagglutination results, whereas 
1/3 of mice given A+ SV was positive and one showed mixed results. Therefore, control and O+ SV 
mice were challenged with 5x105 O+ RBC on day 32. Mice given A+ SV delayed in showing 
haemagglutination reactions and were challenged with 5x105 A+ RBC on day 49. In order to 
investigate if some cytokines need more time to be produced, only 2/3 mice in each group exposed 
to O+ RBC, along with 2/3 controls, were terminated 2 weeks after being challenged, on day 47. The 
remaining O+ mice were terminated with A+ RBC challenged mice 2 weeks post A+ RBC challenge 
(day 67), in order to compare findings (Fig 5.9A). The groups examined are stated as below: 
1. 5x105 O+ RBC only on day 32 (control)  
2. 5x105 A+ SV + 5x105 A+ RBC on day 49, referred to as A+  
3. 1x105 O+ SV x2 + 5x105 O+ RBC on day 32, referred to as O+ (1) 
4. 5x105 O+ SV x2 + 5x105 O+ RBC on day 32, referred to as O+ (2) 
5. 1x106 O+ SV x2 + 5x105 O+ RBC on day 32, referred to as O+ (3) 
Post termination of the experiment, revealed positive haemagglutination for all mice, showing that 1-
5x105 SV from both ABO groups were capable of inducing an immune response. Data on cytokine 
levels in SV primed mice were normalised to controls from the same time interval, in order to 




Figure 5.9 Comparison of immune responses post A+ and O+ red cell challenge. Fifteen mice 
were given HBSS (n=3) or 5x105 A+ SV (A+, n=3) or three different doses of O+ SV: 1x105 (O+ (1), 
n=3), 5x105 (O+ (2), n=3) and 1x106 (O+ (3), n=3). A boost same as the initial inoculum was given on 
day 15. All mice given O+ SV had a positive immune reaction on day 32 and were challenged with 
O+ RBC from the same donor, along with controls. Two weeks later, 2/3 mice given O+ SV along with 
2/3 controls were culled. A+ SV mice were challenged with A+ SV from the same donor on day 49. 
All remaining mice were culled 2 weeks later. (A) Schematic of the experimental procedure. (B) 
Cytokine levels were normalised to respective controls (day 47 or 67) and log10 transformed to show 
log-fold difference of mean pixel intensity of all cytokines detected in the different experimental 
groups. Undetectable cytokines are indicated with a crossed box. (C) Mean pixel intensity of log-fold 
difference (>4) detected cytokines and cytokines of interest in mice inoculated with O+ blood, culled 
on day 47 and (D) in mice inoculated with A+ and O+ blood terminated on day 47. Data shown as 
mean ± SD. (E) Blots from 1 control (HBSS) and 1 mouse that was primed with SV and boosted (day 




Cytokines with high log-fold difference (>4 in B) for most samples like CXCL11, CXCL1 and TIMP 1 
are presented for both timepoints (Fig. 5.9C for day 47 and Fig.5.9D for day 67, respectively). IL-
1ra, TNF-α, and CXCL9 were also included as cytokines of interest. An increase in the levels of TNF-
α, CXCL1 and CXCL11 were also observed at day 67 compared to day 47 in all groups, although 
again their levels were very low compared other cytokines detected. Anti-inflammatory IL-1ra was 
detected only in O+ (2) mice on day 47. The levels of the inflammation attenuator TIMP-1 were 
elevated compared to controls, particularly at day 67, albeit at low levels. Also, M-CSF and C5/C5a 
levels were found to be lower for all samples on day 47 than day 67. However, cytokine pixel values 
for each interval showed that both TIMP-1 and IL-1ra were particularly low, compared to the elevated 
levels of sICAM-1, CXCL12, C5/C5a, M-CSF and BLC for both time points. 
As differences in cytokine levels did not differ substantially from the pattern observed previously, 
meaning that dominant cytokines were always the same in every experiment performed, a final 
investigation into cytokine expression took place. One mouse was given HBSS (control) and another 
SV, then the primed mouse was given a boost on day 15 and challenged with RBC 15 days later, on 
day 30. Both mice were culled 2 weeks later (day 44 from start of the experiment) and tested for 
cytokine expression. As blots showed no differences in cytokine levels between control and test (Fig. 
5.9E), it was decided that the commercial cytokine assay was not sensitive enough and was not 
used further. The above experiments demonstrated that SV from ABO O+ and A+ were capable of 
inducing tolerance in this model. Therefore, in an attempt to imitate the frequent blood transfusions 
SCD patients receive, a second RBC challenge was introduced in subsequent experiments. 
 
 
5.6 Sequential challenge with red cells 
Alloimmunisation is developed due to exposure to antigens after multiple blood transfusions (363, 
364). Therefore, immune responses after a second RBC challenge along with a higher SV dose were 
examined. Mice were given HBSS or 1x106 O+ SV. Since primed mice produced an immune response 
at different time points in all previous experiments, it was decided that mice would be grouped 
according to the time of their response. Haemagglutination was examined after 15 days and only 3/8 
primed mice showed positive or mixed reactions. Thus, 5 mice were given a boost of the same initial 
inoculum. Two weeks later 5/8 mice showed haemagglutination and were challenged with 1x106 O+ 
RBC along with 4 controls, on day 30. All responders received a second RBC challenge, 29 days 
after the first and were left for 2 weeks, before they were terminated. At the end of the experiment, 
there were 7 groups of mice: 
1. No SV, RBC x2 (controls, n=4) 
2. SV x1, RBC x1 (n=1) 
3. SV x1, RBC x2 (n=2) 
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4. SV x2, no RBC (n=3) 
5. SV x2, RBC x1 (n=1) 
6. SV x2, RBC x2 (n=1) 
7. no SV or RBC (n=3) 
In order to examine how strong the immune response was, mouse antibody levels were examined 
by serology, through antibody titres in serial dilutions of plasma. Low dilution factors would mean 
that the antibody levels were low, whereas high dilution factors would indicate high levels of the 
antibody, suggesting strong responses. Results indicated that mice that were primed before being 
challenged with RBC had lower immune responses (dilution factors 808), whereas mice that were 
given RBC without priming (RBC x2 only), showed stronger immune responses and higher antibody 
levels (1,464.5 ± 1,313 Table 5.1). This was over 10-fold higher than in mice primed with SV but not 
challenged (134.7 ± 58.3). Mice, which were not exposed to SV nor RBC, did not agglutinate. This 
was a first indication that tolerance to foreign blood antigens can be induced when using SV. 
 


















1 0 808 101 808 202 808 808 
2 0 3,232  - 808 101 - - 
3 0 1,616  -  - 101 - - 
4 - 202  -  -  - - - 
Mean 0 1,464.5 101  808 134.7 808 808 
SD 0 1,313.0  - 0  58.3  -  - 
Serial half dilutions of murine plasma to detect antibodies using serology. Dilution factors that 
showed mixed haemagglutination responses were determined. 
 
The same experiment was repeated using a larger number of mice. Six mice were used as controls 
receiving HBSS and 12 mice were given 1x106 O+ SV, from a different donor than the previous study. 
Here, 3 categories were examined:  
1. RBC x2 only (controls, n=6) 
2. SV x1, no RBC (n=6) 
3. SV x 1, RBC x2 (n=6) 
On day 20, 6/12 mice tested positive for haemagglutination, 1 showed a mixed result and 5 were 
negative. However, due to time restraints with potential forthcoming building closures, all mice along 
with controls were not boosted but challenged with RBC on day 21. A second challenge took place 
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28 days later, on day 49 and the experiment was terminated 15 days later. Statistical analyses of 
data, using a nonparametric ANOVA and Kruskal-Wallis, showed that primed and not boosted mice 
which were challenged twice (SV x1, RBC x2) were found to have significantly higher levels (912.9 
± 441.8) than controls which did not receive SV (RBC x2 only, 376.00 ± 244.3) and mice primed with 
SV but not challenged (SV x1, no RBC, 300± 285.7, P≤0.02, Table 5.2).  
 
Table 5.2 Plasma dilution factors detecting mixed agglutination. 
Mouse 
Dilution Factors 
RBC x2 only SV x1, no RBC SV x1, RBC x2 
1 600 80 720 
2 240 720 800 
3 200 200 350 
4 160 700 1800 
5 680 200 800 
6 - - 960 
7  - - 960 
Mean 376.0 300.0 912.9* 
SD 244.3 285.7 441.8 
Antibody titres were determined in murine plasma post termination, using serology. Results among 
tested groups were compared using a nonparametric ANOVA and Kruskal-Wallis test. *Significantly 
higher compared to RBC x2 only and SV x1, no RBC (P≤0.02).   
 
 
Taking results from the two latest experiments together, it was shown that mice, that had been 
primed, boosted and challenged twice (Fig. 5.10A), showed similar antibody titres to non-primed 
controls (SV x1, RBC x2 and RBC only), which were 889.6 ± 385.4 and 859.8 ± 1,003, respectively 
(Fig. 5.10B). However, there was a large variation in antibody titres detected in mice that had not 
been primed with SV. The antibody levels of primed and twice challenged mice (SVx1, RBC x2) were 
higher than primed, non-challenged mice, particularly the group that were primed, then boosted 
(P=0.03). Non-challenged mice primed and boosted (SV x2, no RBC) showed lower dilution factors 




Figure 5.10 Investigation of tolerance induction. (A) Schematic of the experimental design. Mice 
were given HBSS (controls, n=9) or 106 RBC SV ABO O+ (SV x1, n=17). On day 15, 3 tested mice 
that did not show immune response by serology were given a boost (SVx2, no RBC). On day 21, the 
controls and primed mice that showed immune reaction but were not given a boost previously, were 
challenged with 106 O+ RBC (n=9). On day 49, the same mice were challenged for second time 
(SVx1, RBC x2). The remaining five mice with a negative haemagglutination result at day 15 were 
not challenged (SVx1, no RBC). The experiment was terminated at day 64. (B) Antibody titres in the 
combined studies. Data shown as mean ± SD. 
 
 
5.7 Examination of sickle cell ghost immunogenicity 
It was questioned whether SCD ghosts, which are known to expose PS (123, 127, 334), were more 
immunogenic than ghosts prepared from normal healthy blood. Separate groups of mice were 
inoculated with 1.7x105 A+ ghosts either sorted from SCD PFP using anti ex. GPA- AF 647 or with 
ghosts prepared from a day 22 A+ blood unit. PS expression was estimated by flow cytometry to be 
63.7% for SCD ghosts and 78.7% for A+ healthy ghosts (Fig. 5.11A). Both groups of mice did not 
show haemagglutination throughout this period, upon examination in plasma diluted 100 times. At 
the end of the experiment (day 36), serology was performed in pure plasma and haemagglutination 
was detected in all tests, revealing that plasma examined at several time points during the 
experiment was too dilute. Subsequently, antibody titres in half serial dilutions were calculated and 
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they were found to be similar for both ghost groups: 23.8 ± 2.5 detected in SCD ghosts and 25 ± 4.1 
for healthy ghosts (Fig. 5.11B), which were not statistically different when examined by an unpaired 
non parametric t-test (P>0.99). The results showed that ghosts from SCD PFP or from healthy 
donors, exposing similar PS levels, induce similar antibody production in mice. 
 
 
Figure 5.11 Comparison of ghosts from sickle cell patients and healthy donors. Mice were 
given 1.7x105 A+ ghosts from SCD plasma or day 22 A+ healthy blood. On termination (day 36), the 
immune response was determined by serology and antibody titres determined. (A) PS levels 
determined by flow cytometry before the inoculations, using annexin V (FITC) and anti- ex. Band 3-





Alloimmunisation in frequently transfused SCD patients can lead to dangerous haemolytic reactions 
and haemolysis (310, 311). It has been shown to depend on the patient’s immune state, as well as 
the age of first transfusion (322-326). The most common highly immunogenic antigens that have 
been found are RhC, RhD and RhE, K in the Kell system, Jkb in Kidd system, S in the MNS system 
and Fya and Fyb in Duffy system (120, 312). Alloimmunisation cannot be prevented by using 
phenotypically matched blood because of the great diversity of the RH gene in individuals of African 
origin (314) and because RhC, Fya, Fyb, Jkb and S are rare in most SCD patients unlike in prevalent 
white donors (315). 
Generally, induction of tolerance depends on various factors, such as the dose, the delivery method 
and the type of APC targeted (398). While CD4+ Th1 subset is mainly responsible for cell-mediated 
responses, usually through cytokine secretions such as IFN-γ, humoral immune responses (Th2) 
usually produce IL-4 and IL-5 to activate B cells and trigger antibody production (399, 400). Antigen 
affinity with MHCII has also been found to enhance Th1 or Th2 responses, as strong MHC affinity 
favours Th1 and low affinity promotes Th2 (401). In tolerance studies, prevention of antibody 
production and B-cell stimulation is desired, thus, experimental design targets enhanced Th1 
production rather than Th2 and induction of anti-inflammatory humoral responses (384, 402). 
Protein replacement therapies are used to elevate levels in patients with protein deficiency, such as 
haemophilia (403). To reduce immune responses to the protein, drug administration usually takes 
place either with soluble proteins and peptides or through their conjugation to apoptotic cells or MP 
and this was reported to induce immunological tolerance (378, 404, 405). RBC have been 
investigated as delivery vehicles for therapeutic peptides and erythrocyte-binding antigens (398, 
406, 407). They were shown to induce tolerance to proteins in a model of autoimmune type 1 
diabetes (408, 409). Another study explored the potential of a K peptide from the Kell blood group 
to be used for specific immunotherapy for K negative mothers after incompatible pregnancy with a 
K-positive foetus. K is known to cause haemolytic disease of the newborn when delivered from a K 
positive mother during pregnancy (410, 411). The K peptide was found to induce tolerance in vitro 
in Th-cells isolated by alloimmunised K-negative individuals, when compared to those without anti-
K alloantibody presence. Also, the peptide induced immune suppression in HLA-transgenic mice, 
suggesting its beneficial use in specific immunotherapy (139). More recently the dose of RBC used 
was shown to affect the immune response. Priming mice with a low (1x105) or high (1x109) dose of 
sheep RBC intravenously, has been reported to induce Th1 cells and Th2 cells, respectively, when 
examined by cytokine mRNA expression (384). Inflammation status has also been reported to affect 
alloantibody production in murine models after transfusion. It was shown to increase 
alloimmunisation magnitude in mice with inflammation, than those transfused in the absence of 
inflammation (412-415). Additionally, tolerance after transfusion to RBC expressing transgenic 
human GPA or membrane-bound hen egg lysozyme antigen, was reported in mice in the absence 
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of inflammation in another study. These mice produced undetectable antibody levels in contrast to 
transfused mice that had inflammation (416). However, as far as we are aware the potential of using 
ghosts or SV to induce tolerance to human RBC antigens in immune competent mice and particularly 
the highly immunogenic antigens in alloimmunisation has not been investigated. 
Due to the novelty of this project, the experimental procedures needed to be designed from the 
beginning. Additionally, the tests to examine the immune reactions had to be developed. Serology 
is commonly used to assess RBC compatibility prior to blood transfusion through RBC 
haemagglutination (338, 339). However, despite such tests being relatively easy to set up and 
perform, in this case it would be laborious and time-consuming to establish due to the novelty of this 
work. As a base, commercial gel cards containing anti-mouse antibody were used along with human 
reference RBC of known phenotype. As a positive control, a mouse anti-human Lu antibody was 
used that caused haemagglutination when mixed with cells known to expose this antigen. Mouse 
RBC with plasma from the same mouse, which were not expected to agglutinate, were used as 
negative controls. The assay was found to be very sensitive, as it could detect immune reactions 
upon dilution up to 8,000-fold in some cases. In terms of the delivery method, intravenous inoculation 
of low (1x105) and high (1x109) doses of sheep RBC was suggested to induce tolerance to the 
inoculum (373, 384). Subcutaneous administration of the sensitiser in pollen allergies was also 
shown to decrease sensitivity to the allergen either by Th2 downregulation, or Th1 upregulation (417, 
418). Here, we used subcutaneous delivery of the inocula, as it is a common delivery method for 
adjuvants, in order to induce inflammation by CFA (385).  
Human RBC ghost preparations, as well as SV were investigated for their ability to induce tolerance 
to human RBC antigens in mice. Ghosts preparations and SV have been shown to be natural RBC 
antigen carriers (218, 381), hence, they could be used to expose the immune cells to these antigens. 
A range of doses, previously showed to induce tolerance were tested, starting from the lowest 
reported one (1x105) and reaching up to 1x106 were tested. All doses within that range showed 
haemagglutination. However, immune responses between ghosts and SV were developed at 
different timepoints, ranging from 1-6 weeks, regardless the dose used. RBC ghosts were shown to 
be more immunogenic than the same dose of SV, as immune reactions in mice, detected by 
serology, were always achieved by day 15. This may be explained from differences in size and 
consequently length of membrane surface exposing antigens, as ghosts were previously found to 
be close to 7μm and SV 200nm. For the latest experiments 1x106 SV per mouse was used. The 
optimum dose would be one which induced an immune response, decrease inflammatory cytokines 
in challenged mice and increase anti-inflammatory ones. However, this needs to be further 
investigated. 
The immune reactions detected were not found to be dependent on ABO groups, as ghosts and SV 
from both A+ and O+ units were found to be capable of inducing haemagglutination. Serology results 
showed that mouse antibody developed against the human inocula was specific to donor RBC ghost 
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preparations in a few cases and not to human alternative controls used, as haemagglutination in 
those controls was not observed. Knowing that PS, an “eat me” signal for phagocytes (94) is 
increased in RBC during storage (106, 107) it was questioned whether SCD ghosts, which expose 
PS (123, 127, 334) were more immunogenic than ghosts from blood units. These ghosts were 
prepared 22 days after blood collection, in order to increase PS levels and imitate PS exposure on 
stored RBC. The same doses for both ghosts were inoculated, and antibody titres were similar on 
termination, indicating comparable immunogenicity. This may be explained by the similar PS levels 
both ghost groups showed. 
A study in alloimmunised and non alloimmunised chronically transfused SCD (n=22) and β-
thalassemia major patients (n=8), revealed suppressed peripheral Tregs and decreased Th1 along 
with higher levels of IFN-γ and lower IL-10 levels in alloimmunised patients than patients without 
alloantibody present. Half of the alloimmunised patients had higher levels of intracellular IL-4 in their 
CD4+ than non alloimmunised patients, suggesting an increased Th2 humoral immune response in 
the alloantibody responders. All patients exhibited increased levels of Th17, indicating inflammation 
(317). Furthermore, Bregs in alloimmunised patients were also found to produce lower levels of IL-
10 and they failed to inhibit TNF-α production by monocytes efficiently implying participation of IL-
10, IFN-γ and TNF-α in alloimmunisation (368). Our results showed undetectable levels of circulating 
IL-10 in all mice. Reduced levels in challenged mice were found for IFN-γ and TNF-α, which were 
previously reported in alloimmunised SCD patients (368), as well as for CXCL9, which was found to 
be overexpressed in β-thalassemia major patients (397) and decreased in maternal RhD 
alloimmunisation (419). Decreased levels of the above inflammatory molecules in challenged mice 
indicate a reduction in inflammatory response. On the other hand, anti-inflammatory IL-1ra, which 
inhibits pro-inflammatory IL-1 controlling inflammatory response (393), was elevated in challenged 
groups in a few cases but was found to be decreased in other. However, it should be mentioned that 
detected levels of IFN-γ, TNF-α, IL-1ra and CXCL9 were particularly low.  
The majority of the circulating cytokines detected across all the experiments were pro-inflammatory 
and chemoattractants, such as BLC, sICAM-1, C5/C5a, CXCL12 and in some cases, M-CSF and 
TIMP-1, as a response to foreign RBC antigens. Anaphylatoxin C5a is produced after activation of 
complement (420). In a study comparing responses after transfusion of RBC from a donor or from 
the same patient collected several weeks before operation, C5a was found significantly decreased 
1 day after operation in both groups and reached the pre transfusion levels 4-5 days later (421). 
ICAM has been found at increased levels 48 hours after a blood transfusion in preterm infants, along 
with IL-1β, IL‐6, IL‐8, IFN-γ, TNF-α, IL‐17 and monocyte chemoattractant protein‐1 (422). 
Additionally, exposure of stored RBC to isolated T-cells in vitro led to decreased T-cell proliferation, 
as well as reduced levels of IL-10, IL-17α, IFN-γ, TNF-α and GM-CSF, suggesting RBC involvement 
in immunosuppression observed post transfusion (423). The presence of BLC, CXCL12 and M-CSF 
indicated chemotaxis and activation of lymphocytes (BLC, CXCL12) and macrophages (CXCL12, 
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M-CSF), as a response to inflammation caused by human RBC antigens (386, 391, 392). Here, 
differences in prevalent molecules between samples and controls were subtle and furthermore, 
many cytokines are produced in very low amounts in vivo (384). Thus, it was decided that the 
particular cytokine assay is not sensitive enough for such analyses.  
Antibody titres were subsequently used to compare murine anti-human antibody levels in plasma 
among tested animals. Low titre values indicated low antibody levels, which means lower immune 
responses that may imply induction of tolerance. On the other hand, high titres suggested higher 
antibody levels and stronger immune responses that could lead to inflammation and haemolysis of 
donor RBC. The first attempt to induce tolerance to sequential RBC challenges showed promising 
results, in which mice primed with SV or primed and boosted, exhibited lower antibody levels than 
non-primed animals, although the number of mice were limiting. Combining these data with results 
from a second experiment revealed similar titres for primed and non-primed mice, although there 
was greater variation in control (non primed) animals. Primed mice, as well as primed and boosted 
that had not been challenged, showed the lower antibody titres. In particular, antibody levels in 
primed and boosted mice were significantly decreased compared to mice primed once and 
challenged twice. This finding could indicate that double exposure of the animals to the antigen may 
be a better approach. However, due to the developing situation with SARS CoV2 it was not possible 
to transfuse the mice that had been primed and boosted to investigate whether or not this would be 
the case. Studies using synthetic peptides have shown that multiple doses were required to induce 
tolerance, whilst a single dose favoured priming for potential vaccination (424). 
In conclusion, we developed an experimental in vivo model to investigate responses to RBC antigens 
together with a reliable, sensitive haemagglutination assay for assessing immune responses. Further 
research would have included functional comparison of T cell proliferation responses between 
treated mice and controls. However, this was not possible in the time frame and the cessation of all 





In normal physiology, RCDP are thought to be produced during the maturation of the RBC and along 
with senescent cells are cleared by the spleen. However, deformed SC frequently damage the 
spleen and this results in significantly higher numbers of RCDP in the plasma of SCD patients than 
healthy individuals (179, 180, 255, 269). RCDP are thought to have a right side-out orientation due 
to their formation by membrane shedding, exposing extracellular domains of RBC membrane 
proteins. On the other hand, AV, a type of autophagic exosome, are thought to have an inside-out 
orientation, exposing cytoplasmic protein domains. It was suggested that these AV are removed by 
splenic passage in healthy individuals. In SCD patients however, a damaged spleen would cause 
AV to be released directly into plasma, exhibiting elevated numbers of both AV and RCDP in these 
cases (127). This project aimed to characterise RCDP and AV in SCD patients, healthy individuals 
and in cultured reticulocyte (CR) media and compare the findings with SV from out of date blood 
units. 
6.1 Summary of the key findings in the thesis and suggestions to take the project forward. 
Chapter 3 Chapter 4 Chapter 5 
Presence of RBC ghosts and 
large MaV along with small 
RCDP in plasma from healthy 
individuals and SCD patients.  
 
Demonstrated that previous 
reports on RCDP probably 
correspond to ghosts: 
Imaging flow cytometry was an 
accurate method for small 
RCDP and AV analysis. 
Intact, enriched RCDP and AV were 
isolated and characterised for first 
time. 
 
RCDP expose extracellular RBC 
membrane protein domains and AV 
cytoplasmic. Both expose PS. 
 
SV expose extracellular RBC 
proteins and PS. 
 
RCDP are larger and more 
abundant than AV in healthy and 
SCD plasma. 
Tolerance induction to RBC 
antigens using RBC ghosts 
and SV: a suitable 
experimental model was 
developed and a robust 
serology assay to assess 
immune responses was set 
up. 
Serial antibody dilutions 
indicated that tolerance may 
be induced in some cases. 
SCD ghosts and ghosts from 
normal blood expose similar 
PS levels and showed similar 
immunogenicity.  
Future work Future work Future work 
Continuation of this work was 
carried out in Chapter 4. 
Examination of RCDP and AV 
presence in CR media using TEM 
and imaging flow cytometry. 
 
Proteomic profiling to explore 
differences in RCDP and AV from 
SCD and healthy plasma. 
Biomarkers for vaso-occlusive crisis 
in SCD may be revealed. 
Development of a removal device 
for MaV and ghosts to reduce vaso-
occlusion in SCD. 
Investigation of RCDP, AV and SV 
as vehicles for therapeutic drugs or 
peptides. 
Examine whether tolerance 
can be achieved by increased 
exposure to antigens. 
Assessment of T-cell 
proliferation between control 
and treated mice. 
If successful, use of a 
humanised mouse model to 
investigate if tolerance can be 




Until now, identification and characterisation of RCDP in the plasma of SCD patients have generally 
taken place using conventional flow cytometry, targeting extracellular RBC protein domains (267-
269, 337). Here, we aimed to characterise RCDP and AV from SCD plasma, as well as from CR 
media. The cultured reticulocytes were generated using a well-established protocol (123, 334). Flow 
cytometry performed on SCD PFP and CR media revealed the presence of the extracellular domains 
of abundant RBC proteins, like GPA and band 3. The presence of PS, an apoptotic marker previously 
reported on senescent RBC (106, 107) and RCDP (179, 180, 255, 269), was also confirmed, as was 
previously shown in SCD PFP by others, using flow cytometry. Cytoplasmic domains of GPA, band 
3, GPC and GLUT1 were also detected at lower levels, suggesting AV were also present in SCD 
plasma and CR media. When particles from SCD and healthy plasma, exposing extracellular GPA, 
were isolated using FACS, different microscopy methods, such as TEM and spinning-disc confocal, 
showed that the particles detected by flow cytometry were too large to be considered small MP. 
Furthermore, imaging flow cytometry along with TEM revealed that SCD and healthy plasma 
consisted of heterogenous populations composed of microvesicles (0.05-1μm diameter), large RBC 
ghosts (approx.6-7μm) and MaV (1-6μm). This suggested that previous reports on RCDP (267-269, 
337), using size beads, had probably detected ghost membranes rather than small RCDP. This may 
be attributed to differences in the light scattering intensity between biological samples and size beads 
(232). Structures positive for both extracellular and cytoplasmic domains of GPA and band 3 or PS, 
detected by flow cytometry, were shown to correspond to RBC ghosts and MaV when analysed on 
an imaging flow cytometer. Smaller structures positive for both domains of GPA and band 3 were 
also revealed. It is possible that these small and large double positive structures in SCD were caused 
by repeated polymerisation, as well as sealing of the membrane after RBC haemolysis, which is 
characteristic of SCD (178, 255, 332). Ghost numbers varied among different SCD patients, probably 
due to the level of haemolysis and RBC fragility. Due to lack of time, it was not possible to examine 
CR media for the presence of RCDP and AV by TEM or imaging flow cytometry.  
Imaging flow cytometry and TEM revealed the presence of RCDP, ghosts and MaV, as well as AV, 
in SCD and healthy plasma. Most importantly, these data suggest that previously reported RCDP in 
SCD plasma using flow cytometry (267-269, 337) corresponded to large ghosts rather than small 
RCDP. Imaging flow cytometry was proven to be an accurate method for imaging and protein 
characterisation of small MP. It also revealed that RCDP were more abundant than AV in SCD and 
healthy plasma. Both MP types were found in increased levels in SCD plasma compared to that from 
healthy donors.  
In Chapter 4, isolation of RCDP and AV from SCD plasma for further analysis was investigated using 
various methods: FACS failed to detect particles smaller than 200nm and pelleting samples by ultra- 
or high-speed centrifugation (100,000g and 20,000g, respectively) was found to generate artificial 
MP by destroying cells, or even damaging existing RCDP and AV, as observed by examination using 
TEM. Size exclusion chromatography or differential centrifugation, both widely used for MP isolation, 
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could not be used, as isolation by these methods is based on particle size (348). This is to say that 
MP from all blood cell types would be enriched rather than just RCDP. Eventually, immunomagnetic 
separation was chosen in order to gently isolate RCDP and AV of all sizes from SCD and healthy 
plasma. RCDP were targeted by immunomagnetic beads against extracellular GPA directly, 
whereas an indirect approach was applied for AV, as no commercial beads detecting cytoplasmic 
GPA were available. This took place by targeting the AlexaFluor 647 fluorochrome the antibody used 
against cytoplasmic GPA was conjugated to. TEM and immunogold staining confirmed that enriched 
populations were intact, round RCDP and AV, enclosed by an external lipid bilayer, similar to what 
has been previously shown for RCDP in healthy individuals, using cryo-electron microscopy (355). 
SV from of out of date blood units were used as a comparison, since they are formed RBC by 
membrane budding. Both tubular and round RCDP were detected in healthy and SCD plasma, 
whereas only round AV were found in each source. Round SV were also detected and found to lose 
their membrane integrity and circular shape in aged blood units probably due to storage lesions 
(191). This is the first visual evidence of RCDP in SCD plasma, as well as AV in both plasma sources. 
CR media was not examined by imaging flow cytometry and TEM due to lack of time. 
Analyses using imaging flow cytometry revealed the prevalence of extracellular domains on RCDP 
from healthy and SCD plasma, as well as SV, confirming that they were right-side out and they were 
probably formed by membrane budding. AV exhibited similar levels of extracellular and cytoplasmic 
domains, indicating that membrane blebs, exposing extracellular and cytoplasmic domains, were 
also isolated. This revealed limitations in the isolation method, which enriched not only AV but also 
membrane fragments. This was also confirmed by TEM. Furthermore, the presence of intact RCDP 
and AV was confirmed by staining, using calcein AM, which is a widely used marker for intact cells. 
Calcein AM can permeate the membrane, then become hydrolysed by intracellular esterases and 
produce fluorescence in intact cells (356, 357). RCDP were found to be larger and more abundant 
than AV in both SCD and healthy PFP, on bright field of imaging flow cytometry, as well as TEM and 
DLS. Altogether these findings indicate the presence of right-side out RCDP and inside-out AV in 
healthy and SCD plasma for first time. In addition, the use of imaging flow cytometry and TEM 
suggested that RCDP detected by flow cytometry in previous studies (179, 180, 255, 269), were 
probably RBC ghosts and MaV. Knowing that MP transfer cellular material from parental cells (152), 
further investigation of their composition may reveal information on their relevance in normal healthy 
individuals and those with SCD.  
We have recently shown that the numbers of RCDP and AV were 5-fold and 3-fold higher in SCD 
plasma than in healthy individuals, respectively, using imaging flow cytometry. Also, RCDP were 
significantly increased in SCD patients with acute pain (crisis) compared to those in steady state and 
healthy individuals. This is probably due to impaired splenic function. Furthermore, removal of MaV 
and RBC ghosts from SCD plasma was shown to decrease the blood clotting times. Therefore, it 
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may be possible to diminish vaso-occlusion in SCD cases by removing MaV and ghosts by 
developing a removal device (Smith et. al, manuscript submitted).  
Alloimmunisation is another complication in SCD patients, caused by frequent blood transfusions 
between genetical and racial differences in patients with African origin and white donors. Auto-and 
alloantibody development can cause life-threatening haemolytic reactions and haemolysis (363, 
364). Alloimmunisation has been found to depend on the patient’s immune system and the age of 
first transfusion (322-326). The most common immunogenic antigens in alloimmunised SCD patients 
have been reported to be RhC, RhD and RhE, K in the Kell system, Jkb in Kidd system, S in the MNS 
system and Fya and Fyb in Duffy system (120, 312). Although the exact mechanism of 
alloimmunisation is unknown (425), in Chapter 5 we investigated a potential approach to alleviate 
alloimmunisation. Knowing that the regular exposure to an antigen can tolerise the immune system 
to it (378, 380, 426), we thought that RBC ghosts and SV from blood units may be used as natural 
carriers to induce tolerance to immunogenic antigens in a murine model. Our data had shown that 
ghost and SV expose RBC antigens by imaging flow cytometry (discussed above) confirming 
proteomic analyses of SV (218). Prior to in vivo inoculation, RBC ghosts and SV were examined by 
flow cytometry and imaging flow cytometry, respectively, and were shown to expose the extracellular 
domains of RBC membrane proteins, like GPA and band 3. They were are also found to expose PS, 
which has been found on senescent RBC in blood units prior to transfusion (123, 127, 334). In 
addition, PS is a known signal for phagocytosis by professional cells (94) which would enhance 
immune responses. Ghosts and SV were both found intact after staining with calcein AM (349), 
showing that particularly ghosts were well re-sealed after RBC lysis. 
Tolerance was previously shown to be induced against sheep RBC in mice by inoculating the cells 
once or twice (373). Additionally, inoculation with a low or high dose of sheep RBC has been reported 
to increase Th1 responses compared to Th2 in mice, thereby preventing B cell stimulation as well 
as antibody production and potentially promoting tolerance (384). Due to the novelty of this project 
using human red-cell-derived components, the animal model and experimental process had to be 
set up from the beginning. Initially, RBC ghost preparations from day 22 blood bags were used, as 
natural carriers of RBC antigens (218). It was hypothesised that they would be a better source to 
induce tolerance to these antigens than RBC, as they have lost Hb during preparation, which could 
exaggerate potential haemolysis. The administered dose (1x105) was based on the lowest sheep 
RBC dose reported to increase Th1 response compared to Th2 (384). This was shown to induce an 
immune response, indicated by haemagglutination when assessed by serology. Importantly, there 
were no adverse effects on the mice which meant that increased doses could be tested in 
subsequent experiments. At all doses of ghosts from healthy donors investigated (max 1x106), 




Subsequently, ghost preparations from healthy donors were compared to sorted ghosts from SCD 
plasma in this model. Ghost from both sources exposed similar levels of PS that should induce 
recruitment of phagocytic cells. On termination the antibody levels were similar in mice exposed to 
both sources, indicating that SCD ghosts were as effective as ghost from healthy donors, potentially 
because of the comparable PS levels which might induce similar B cell activity.  
When SV were investigated for their ability to induce an immune reaction, a longer response time 
(1-4 weeks more) than ghosts was observed. In many cases a boost of SV was required before a 
positive haemagglutination reaction was observed. Therefore, SV are potentially less immunogenic 
than healthy ghost membrane preparations. Immune responses were found to be ABO unrelated, 
as both O+ and A+ samples induced an immune response. While an early experiment suggested that 
priming with SV may induce tolerance, as assessed by serology, this was not confirmed in 
subsequent experiments. On the other hand, mice that had been primed and boosted exhibited lower 
antibody levels, indicating that multiple exposure to SV may be a better approach. However, it was 
not possible to investigate this further due to closure of the University facilities in response to the 
SARS-Cov-2 outbreak. 
Our approach using intact biological material, such as SV, was different to other studies exploring 
specific immunotherapy to RBC antigens, using peptides to induce tolerance to Kell blood group. K 
is the most immunogenic antigen of the Kell system and in cases of a K-negative mother and a K-
positive foetus in pregnancy, it can lead to haemolytic disease of the newborn. A K peptide (1M) 
exhibiting K polymorphism at the C terminus was shown to induce tolerance to a carrier conjugated 
to synthetic Kell protein residues in a humanised mouse model (139). In other studies, the presence 
of inflammation was reported to increase alloantibody production in murine models after transfusion 
(412-415). However, a separate study demonstrated that tolerance to RBC expressing transgenic 
human GPA or membrane-bound hen egg lysozyme antigen could be achieved in the absence of 
inflammation (416). The above underlie the importance of inflammatory status and indicate that 
despite the fact that immune responses were induced in the work described here using an 
inflammatory adjuvant as a vehicle (CFA), it may be worth exploring immune responses excluding 
its use. Cytokine assessment using a commercial cytokine assay panel did not reveal differences in 
cytokines between controls and challenged mice. This may be due to lack of sensitivity in the assay 





6.2 Further Work 
Taking this project forward, it would be worth examining in CR media for the presence of RCDP and 
AV. Potential differences amongst RCDP and AV from healthy individuals, SCD patients, CR media 
as well as differences with SV, could be determined by proteomic analysis. CR media may be a more 
accessible source of RCDP, as it is a by-product from reticulocyte cultures and may be donated from 
colleagues growing these cells. In this case, a simple centrifugation step to remove cultured 
reticulocytes will be performed, rather than expensive and time-consuming immunomagnetic 
separation for large plasma volumes. Also, comparison of the proteome of RCDP, AV and RBC 
ghosts between healthy individuals and SCD patients and CR media, may reveal receptors for cell 
communication, biomarkers for vaso-occlusive crisis and severity of the disease, as could lead to 
further investigation of their role in health and pathology. Knowing the thrombotic properties of RBC 
ghosts and MaV, the development of a removal device targeting extracellular GPA or band 3 from 
SCD patient plasma may be beneficial in preventing vaso-occlusion in SCD. 
From a different angle, the role of RCDP in normal physiological conditions could be further explored. 
While it has been suggested that RCDP are phagocytosed by splenic and liver macrophages, 
communication with other cell types is yet unknown. Knowing that MP transfer cellular cargo during 
cell communication (152), RCDP from a mouse could be isolated and labelled using a fluorescent 
dye, such as PKH26. This dye has been successfully used to label induced red-cell vesicles using 
in vivo imaging systems (427). Labelled RCDP could be then re-introduced back to the donor mouse. 
Tracking may help us explore and understand the interactions of RCDP with other cells. There may 
be potential to use therapeutic peptide or drug loaded RCDP to target pathological conditions like 
cancer. Although SV can be easily obtained from blood units, RCDP may be a better source of MP, 
as they expose lower levels of the apoptotic marker PS and they can avoid phagocytosis. Also, 
loaded RCDP from the same donor are likely to be less immunogenic than foreign vehicles like SV.  
In terms of the immunological part of the project, more experiments including sequential challenge 
of primed, boosted and non primed mice are required, to determine the optimal conditions to induce 
tolerance. With regards to the inoculum, a direct comparison of SV and ghost from the same donors 
could determine if ghosts are better than SV in stimulation of immune responses, when examined 
by serology. Also, other experiments could determine immune responses with or without the 
inflammatory adjuvant (CFA) by serology, exploring its contribution to inflammation. For this, 
incomplete Freund’s adjuvant could be used, or even pure ghosts/SV in HBSS. For consistency, 
inoculate will be given subcutaneously in the early experiments. However, intravenous injections 
would be investigated later, since this is a simple delivery method of therapeutic material, such as 
vaccines, to animals and humans.  
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Apart from serology, T-cell proliferation assays using splenocytes from primed and non primed, 
challenged mice groups, will provide an indication of T cell activation. Use of CD3, CD4, CD8, CD25, 
CD27 and CD45RA markers along with cell trace violet by flow cytometry, will indicate the 
proliferation of different T cell subsets including naïve T cells, Tregs, effector and memory T cells. 
Proliferation upon stimulation with RBC will indicate response to the inoculum, whereas 
unresponsive cells will imply anergy and potential tolerance. Cytokine detection could be performed 
using different available commercial assays than the one used previously, to investigate whether 
there is a more sensitive assay for this work.  
Finally, if tolerance is induced, experiments in a humanised mouse model would be essential to 
investigate responses in a system imitating the human system. This would involve exposing neonatal 
humanised mice to SV or ghosts then challenging them with RBC as a proof of principle of inducing 
tolerance in young (<3 years) SCD patients. Hence, it may be easier to decrease alloimmunisation 
in adult patients, by exposure to RBC antigens in early childhood.  
 
6.3 Conclusion 
While RCDP in healthy individuals have been visualised previously, we managed to demonstrate for 
first time the morphological characteristics and protein content of RCDP in SCD patients. The 
imaging flow cytometry and TEM data suggests that previous reports of RCDP in SCD actually 
correspond to RBC ghosts. Also, this study is the first demonstration of AV in SCD patients and 
healthy individuals. RCDP and AV numbers were significantly higher in SCD than in healthy plasma 
suggesting they may be indicators of disease severity. Furthermore, SV and RBC ghosts could be 
used to induce tolerance to RBC antigens and revealed a potential approach to alleviate 
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